Document:

<PAGE>   1

                                                                    EXHIBIT 10.1

                                                                  EXECUTION COPY

================================================================================

                            STOCK PURCHASE AGREEMENT

                                      among

                               TICKETS.COM, INC.,

                       GENERAL ATLANTIC PARTNERS 74, L.P.,

                       GAP COINVESTMENT PARTNERS II, L.P.,

                                  GAPSTAR, LLC,

                                       AND

           INTERNATIONAL CAPITAL PARTNERS, INC., PROFIT SHARING TRUST

                  -------------------------------------------
                               Dated: May 1, 2001
                  -------------------------------------------

================================================================================

<PAGE>   2

                                Table of Contents
================================================================================

<TABLE>
<CAPTION>
                                                                              Page
                                                                              ----
<S>                                                                           <C>
ARTICLE I     DEFINITIONS......................................................1
   1.1        Definitions......................................................1

ARTICLE II    PURCHASE AND SALE OF PREFERRED STOCK.............................8
   2.1        Purchase and Sale of Preferred Stock at the First Closing........8
   2.2        First Closing....................................................8
   2.3        Purchase and Sale of Preferred Stock at the Second Closing.......8
   2.4        Second Closing...................................................8
   2.5        Certificates of Designations.....................................9
   2.6        Use of Proceeds..................................................9

ARTICLE III   REPRESENTATIONS AND WARRANTIES OF THE COMPANY....................9
   3.1        Corporate Existence and Power....................................9
   3.2        Authorization; No Contravention..................................10
   3.3        Governmental Authorization; Third Party Consents.................10
   3.4        Binding Effect...................................................10
   3.5        Litigation.......................................................10
   3.6        Compliance with Laws.............................................11
   3.7        Capitalization...................................................11
   3.8        No Default or Breach; Contractual Obligations....................12
   3.9        SEC Documents; Financial Statements. ............................13
   3.10       No Material Adverse Change; Ordinary Course of Business..........13
   3.11       Taxes............................................................14
   3.12       Private Offering.................................................14
   3.13       Employee Benefit Plans...........................................14
   3.14       Liabilities......................................................15
   3.15       Intellectual Property............................................15
   3.16       Privacy of Customer Information..................................17
   3.17       Environmental Matters............................................17
   3.18       Broker's, Finder's or Similar Fees...............................18

ARTICLE IV    REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS.................18
   4.1        Existence and Power..............................................18
   4.2        Authorization; No Contravention..................................18
   4.3        Governmental Authorization; Third Party Consents.................18
   4.4        Binding Effect...................................................18
   4.5        Purchase for Own Account.........................................19
   4.6        Restricted Securities............................................19
   4.7        Broker's, Finder's or Similar Fees...............................19
   4.8        Accredited Investor.  ...........................................19
</TABLE>

<PAGE>   3

<TABLE>
<CAPTION>
                                                                              Page
                                                                              ----
<S>                                                                           <C>
ARTICLE V     CONDITIONS OF THE PURCHASERS TO FIRST CLOSING....................20
   5.1        Representations and Warranties...................................20
   5.2        Compliance with this Agreement...................................20
   5.3        Officer's Certificate............................................20
   5.4        Secretary's Certificate..........................................20
   5.5        Filing of Certificate of Designations............................20
   5.6        Initial Purchased Shares.........................................21
   5.7        Registration Rights Agreement....................................21
   5.8        Opinion of Counsel...............................................21
   5.9        Nasdaq Waiver....................................................21
   5.10       Good Standing Certificates.......................................21
   5.11       No Material Adverse Change.......................................21
   5.12       Consents and Approvals...........................................21
   5.13       No Material Judgment or Order....................................21
   5.14       No Litigation....................................................22
   5.15       Board of Directors...............................................22

ARTICLE VI    CONDITIONS OF THE COMPANY TO FIRST CLOSING.......................22
   6.1        Payment of Purchase Price........................................22
   6.2        Registration Rights Agreement....................................22
   6.3        No Injunctions or Regulatory Restraints; Illegality..............22

ARTICLE VII   CONDITIONS OF THE PURCHASERS TO SECOND CLOSING...................22
   7.1        Representations and Warranties...................................23
   7.2        Compliance with this Agreement...................................23
   7.3        Officer's Certificate............................................23
   7.4        Secretary's Certificate..........................................23
   7.5        Additional Purchased Shares......................................23
   7.6        Opinion of Counsel...............................................23
   7.7        Stockholder Approval.............................................23
   7.8        Good Standing Certificates.......................................24
   7.9        No Material Adverse Change.......................................24
   7.10       Consents and Approvals...........................................24
   7.11       No Material Judgment or Order....................................24
   7.12       No Litigation....................................................24
   7.13       Amendment of Certificate of Incorporation.  .....................24

ARTICLE VIII  CONDITIONS OF THE COMPANY TO SECOND CLOSING......................24
   8.1        Payment of Purchase Price........................................25
   8.2        Stockholder Approval.............................................25

ARTICLE IX    INDEMNIFICATION..................................................25
   9.1        Indemnification..................................................25
   9.2        Notification.....................................................26
   9.3        Contribution.....................................................26
</TABLE>

                                      -ii-
<PAGE>   4

<TABLE>
<CAPTION>
                                                                              Page
                                                                              ----
<S>                                                                           <C>
ARTICLE X     COVENANTS........................................................27
   10.1       Conduct of Business of the Company.  ............................27
   10.2       Satisfaction of Conditions.......................................27
   10.3       Preparation of the Proxy Statement; Stockholders Meeting.........28
   10.4       Reservation of Common Stock......................................29
   10.5       NASDAQ Listing...................................................29
   10.6       Approval by the Company's Stockholders...........................29
   10.7       Insurance........................................................30
   10.8       Books and Records................................................30
   10.9       Back-ups of Computer Software....................................30
   10.10      Inspection. .....................................................30
   10.11      Board of Directors...............................................30

ARTICLE XI    TERMINATION OF AGREEMENT.........................................30
   11.1       Termination......................................................30
   11.2       Survival.  ......................................................31

ARTICLE XII   MISCELLANEOUS....................................................31
   12.1       Survival of Representations and Warranties.......................31
   12.2       Notices..........................................................32
   12.3       Successors and Assigns; Third Party Beneficiaries................33
   12.4       Amendment and Waiver.............................................33
   12.5       Counterparts.....................................................34
   12.6       Headings.........................................................34
   12.7       GOVERNING LAW....................................................34
   12.8       Severability.....................................................34
   12.9       Rules of Construction............................................34
   12.10      Entire Agreement.................................................34
   12.11      Fees.............................................................34
   12.12      Publicity; Confidentiality.......................................35
   12.13      Further Assurances...............................................35
   12.14      Legal Representation.............................................35
</TABLE>

                                     -iii-
<PAGE>   5

EXHIBITS

A                 Bylaws
B                 Form of Certificate of Designations
C                 Certificate of Incorporation
D                 Form of Registration Rights Agreement
E                 Form of Brobeck Phleger & Harrison LLP Opinion

SCHEDULES

2.1               Initial Purchased Shares and Purchase Price
2.3               Additional Purchased Shares and Purchase Price
3.1(a)            Corporate Existence
3.1(c)            Corporate Power
3.2               Execution, Delivery and Performance
3.3               Authorizations and Consents
3.5               Litigation
3.7(b)            Capitalization
3.7(c)            List of Subsidiaries and their Equity Holders
3.8               Contractual Obligations
3.13              Employee Benefit Plans
3.16(a)(iii)      Infringements by the Company of Intellectual Property
                  of Others
3.16(a)(iv)       Intellectual Property Litigation
3.16(b)           Infringements of Intellectual Property of the Company
3.16(d)           Intellectual Property Licenses, Sublicenses, Distributor
                  Agreements and Other Agreements

<PAGE>   6

                            STOCK PURCHASE AGREEMENT

     STOCK PURCHASE AGREEMENT, dated as of May 1, 2001 (this "Agreement"), by
and among Tickets.com, Inc., a Delaware corporation (the "Company"), General
Atlantic Partners 74, L.P., a Delaware limited partnership ("GAP LP"), GAP
Coinvestment Partners II, L.P., a Delaware limited partnership ("GAP
Coinvestment"), GapStar, LLC, a Delaware limited liability company ("GapStar"
and, collectively with GAP LP and GAP Coinvestment, the "GAP Purchasers") and
International Capital Partners, Inc., Profit Sharing Trust, a Connecticut trust
("ICP" and together with the GAP Purchasers, the "Purchasers").

     WHEREAS, at the First Closing (as hereinafter defined), upon the terms and
conditions set forth in this Agreement, the Company proposes to issue and sell
to each of the Purchasers the aggregate number of shares of Series F Senior
Cumulative Redeemable Preferred Stock, par value $0.000225 per share (the
"Preferred Stock"), of the Company set forth opposite such Purchaser's name on
Schedule 2.1 hereto, for the aggregate purchase price set forth opposite such
Purchaser's name on Schedule 2.1 hereto; and

     WHEREAS, at the Second Closing (as hereinafter defined), upon the terms and
conditions set forth in this Agreement, the Company proposes to issue and sell
to each of the Purchasers the aggregate number of shares of Preferred Stock set
forth opposite such Purchaser's name on Schedule 2.3 hereto, for the aggregate
purchase price set forth opposite such Purchaser's name on Schedule 2.3 hereto;
and

     WHEREAS, each share of Preferred Stock is convertible (subject to
adjustment) into one share, par value $0.000225 per share, of common stock of
the Company (the "Common Stock").

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set
forth herein and for good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the parties hereto agree as follows:

                                   ARTICLE I

                                   DEFINITIONS

     1.1 Definitions. As used in this Agreement, and unless the context requires
a different meaning, the following terms have the meanings indicated:

     "Additional Purchased Shares" has the meaning set forth in Section 2.3 of
this Agreement.

     "Affiliate" shall mean any Person who is an "affiliate" as defined in Rule
12b-2 of the General Rules and Regulations under the Exchange Act. In addition,
the

<PAGE>   7

following shall be deemed to be Affiliates of GAP Coinvestment, GAP LP and
GapStar: (a) GAP LLC, the members of GAP LLC, the limited partners of GAP
Coinvestment and the limited partners of GAP LP; (b) any Affiliate of GAP LLC,
the members of GAP LLC, the limited partners of GAP Coinvestment or the limited
partners of GAP LP; and (c) any limited liability company or partnership a
majority of whose members or partners, as the case may be, are members or former
members of GAP LLC or consultants or key employees of General Atlantic Service
Corporation, a Delaware corporation and an Affiliate of GAP LLC. In addition,
GAP LP, GAP Coinvestment and GapStar shall be deemed to be Affiliates of one
another.

     "Agreement" means this Agreement as the same may be amended, supplemented
or modified in accordance with the terms hereof.

     "Assets" has the meaning set forth in Section 3.18 of this Agreement.

     "Board of Directors" means the Board of Directors of the Company.

     "Business Day" means any day other than a Saturday, Sunday or other day on
which commercial banks in the State of New York are authorized or required by
law or executive order to close.

     "Bylaws" means the bylaws of the Company in effect on the First Closing
Date attached hereto as Exhibit A, as the same may be amended from time to time.

     "Certificate of Designations" means the Certificate of Designations with
respect to the Preferred Stock adopted by the Board of Directors and duly filed
with the Secretary of State of the State of Delaware on or before the First
Closing Date substantially in the form attached hereto as Exhibit B.

     "Certificate of Incorporation" means the Amended and Restated Certificate
of Incorporation of the Company in effect on the First Closing Date attached
hereto as Exhibit C, as the same may be amended from time to time.

     "Claims" has the meaning set forth in Section 3.5 of this Agreement.

     "Code" means the Internal Revenue Code of 1986, as amended, or any
successor statute thereto.

     "Commission" means the United States Securities and Exchange Commission or
any similar agency then having jurisdiction to enforce the Securities Act.

     "Common Stock" has the meaning set forth in the recitals to this Agreement.

     "Commonly Controlled Entity" means any entity which is under common control
with the Company within the meaning of Code section 414(b), (c), (m), (o) or
(t).

     "Company" has the meaning set forth in the preamble to this Agreement.

                                     - 2 -
<PAGE>   8

     "Company Plan" has the meaning set forth in Section 3.13 of this Agreement.

     "Condition of the Company" means the assets, business, properties,
prospects, operations or condition (financial or otherwise) of the Company and
its Subsidiaries, taken as a whole.

     "Contingent Obligation" means, as applied to any Person, any direct or
indirect liability of that Person with respect to any Indebtedness, lease,
dividend, guaranty, letter of credit or other obligation, contractual or
otherwise (the "primary obligation") of another Person (the "primary obligor"),
whether or not contingent, (a) to purchase, repurchase or otherwise acquire such
primary obligations or any property constituting direct or indirect security
therefor, (b) to advance or provide funds (i) for the payment or discharge of
any such primary obligation, or (ii) to maintain working capital or equity
capital of the primary obligor or otherwise to maintain the net worth or
solvency or any balance sheet item, level of income or financial condition of
the primary obligor, (c) to purchase property, securities or services primarily
for the purpose of assuring the owner of any such primary obligation of the
ability of the primary obligor to make payment of such primary obligation, or
(d) otherwise to assure or hold harmless the owner of any such primary
obligation against loss or failure or inability to perform in respect thereof.
The amount of any Contingent Obligation shall be deemed to be an amount equal to
the stated or determinable amount of the primary obligation in respect of which
such Contingent Obligation is made or, if not stated or determinable, the
maximum reasonably anticipated liability in respect thereof.

     "Contractual Obligations" means, as to any Person, any provision of any
security issued by such Person or of any agreement, undertaking, contract,
indenture, mortgage, deed of trust or other instrument to which such Person is a
party or by which it or any of its property is bound.

     "Copyrights" means any foreign or United States copyright registrations and
applications for registration thereof, and any non-registered copyrights.

     "Environmental Laws" means federal, state, local and foreign laws,
principles of common laws, civil laws, regulations, and codes, as well as
orders, decrees, judgments or injunctions, issued, promulgated, approved or
entered thereunder relating to pollution, protection of the environment or
public health and safety.

     "ERISA" means the Employee Retirement Income Security Act of 1974, as
amended.

     "Exchange Act" means the Securities Exchange Act of 1934, as amended, and
the rules and regulations of the Commission thereunder.

     "Financial Statements" has the meaning set forth in Section 3.9 of this
Agreement.

                                     - 3 -
<PAGE>   9

     "First Closing" has the meaning set forth in Section 2.2 of this Agreement.

     "First Closing Date" has the meaning set forth in Section 2.2 of this
Agreement.

     "GAAP" means United States generally accepted accounting principles in
effect from time to time.

     "GAP Coinvestment" has the meaning set forth in the preamble to this
Agreement.

     "GAP LLC" means General Atlantic Partners, LLC, a Delaware limited
liability company and the general partner of GAP LP and the managing member of
GapStar, and any successor to such entity.

     "GAP LP" has the meaning set forth in the preamble to this Agreement.

     "GapStar" has the meaning set forth in the preamble to this Agreement.

     "Governmental Authority" means the government of any nation, state, city,
locality or other political subdivision thereof, any entity exercising
executive, legislative, judicial, regulatory or administrative functions of or
pertaining to government, and any corporation or other entity owned or
controlled, through stock or capital ownership or otherwise, by any of the
foregoing.

     "Governmental Order" means any order, writ, rule, judgment, injunction,
decree, stipulation, determination, award, citation or notice of violation
entered by or with any Governmental Authority.

     "ICP" has the meaning set forth in the preamble to this Agreement.

     "Indebtedness" means, as to any Person, (a) all obligations of such Person
for borrowed money (including, without limitation, reimbursement and all other
obligations with respect to surety bonds, letters of credit and bankers'
acceptances, whether or not matured), (b) all obligations of such Person to pay
the deferred purchase price of property or services, except trade accounts
payable and accrued commercial or trade liabilities arising in the ordinary
course of business, (c) all interest rate and currency swaps, caps, collars and
similar agreements or hedging devices under which payments are obligated to be
made by such Person, whether periodically or upon the happening of a
contingency, (d) all indebtedness created or arising under any conditional sale
or other title retention agreement with respect to property acquired by such
Person (even though the rights and remedies of the seller or lender under such
agreement in the event of default are limited to repossession or sale of such
property), (e) all obligations of such Person under leases which have been or
should be, in accordance with GAAP, recorded as capital leases, (f) all
indebtedness secured by any Lien (other than Liens in favor of lessors under
leases other than leases included in clause (e)) on any property or asset owned
or held by that Person regardless of whether the indebtedness secured thereby

                                     - 4 -
<PAGE>   10

shall have been assumed by that Person or is non-recourse to the credit of that
Person, and (g) any Contingent Obligation of such Person.

     "Indemnified Party" has the meaning set forth in Section 9.1 of this
Agreement.

     "Indemnifying Party" has the meaning set forth in Section 9.1 of this
Agreement.

     "Initial Purchased Shares" has the meaning set forth in Section 2.1 of this
Agreement.

     "Intellectual Property" has the meaning set forth in Section 3.15 of this
Agreement.

     "Internet Assets" means any Internet domain names and other computer user
identifiers and any rights in and to sites on the worldwide web, including
rights in and to any text, graphics, audio and video files and html or other
code incorporated in such sites.

     "Knowledge" means the knowledge of the Company after due inquiry.

     "Liabilities" has the meaning set forth in Section 3.14 of this Agreement.

     "Lien" means any mortgage, deed of trust, pledge, hypothecation,
assignment, encumbrance, lien (statutory or other) or preference, priority,
right or other security interest or preferential arrangement of any kind or
nature whatsoever (excluding preferred stock and equity related preferences).

     "Losses" has the meaning set forth in Section 9.1 of this Agreement.

     "NASDAQ" means the National Market System of the National Association of
Securities Dealers, Inc. Automated Quotations System.

     "Orders" has the meaning set forth in Section 3.2 of this Agreement.

     "Patents" means any foreign or United States patents and patent
applications, including any divisions, continuations, continuations-in-part,
substitutions or reissues thereof, whether or not patents are issued on such
applications and whether or not such applications are modified, withdrawn or
resubmitted.

     "Permits" has the meaning set forth in Section 3.6 of this Agreement.

     "Person" means any individual, firm, corporation, partnership, trust,
incorporated or unincorporated association, joint venture, joint stock company,
limited liability company, Governmental Authority or other entity of any kind,
and shall include any successor (by merger or otherwise) of such entity.

                                     - 5 -
<PAGE>   11

     "Plan" means any employee benefit plan, arrangement, policy, program,
agreement or commitment (whether or not an employee plan within the meaning of
section 3(3) of ERISA), including, without limitation, any employment,
consulting or deferred compensation agreement, executive compensation, bonus,
incentive, pension, profit-sharing, savings, retirement, stock option, stock
purchase or severance pay plan, any life, health, disability or accident
insurance plan, whether oral or written, whether or not subject to ERISA, as to
which the Company or any Commonly Controlled Entity has or in the future could
have any direct or indirect, actual or contingent liability.

     "Preferred Stock" has the meaning set forth in the recitals to this
Agreement.

     "Proxy Statement" has the meaning set forth in Section 10.3 of this
Agreement.

     "Purchased Shares" has the meaning set forth in Section 2.3 of this
Agreement.

     "Purchasers" has the meaning set forth in the preamble to this Agreement.

     "Registration Rights Agreement" means the Registration Rights Agreement
substantially in the form attached hereto as Exhibit D.

     "Requirements of Law" means, as to any Person, any law, statute, treaty,
rule, regulation, right, privilege, qualification, license or franchise or
determination of an arbitrator or a court or other Governmental Authority or
stock exchange, in each case applicable or binding upon such Person or any of
its property or to which such Person or any of its property is subject or
pertaining to any or all of the transactions contemplated or referred to herein.

     "Requisite Company Vote" has the meaning set forth in Section 3.2 of this
Agreement.

     "Retiree Welfare Plan" means any welfare plan (as defined in Section 3(1)
of ERISA) that provides benefits to current or former employees beyond their
retirement or other termination of service (other than coverage mandated by
Section 4980A of the Code, commonly referred to as "COBRA," the cost of which is
fully paid by the current or former employee or his or her dependents).

     "SEC" has the meaning set forth in Section 3.9 of this Agreement.

     "SEC Documents" has the meaning set forth in Section 3.9 of this Agreement.

     "Second Closing" has the meaning set forth in Section 2.4 of this
Agreement.

                                     - 6 -
<PAGE>   12

     "Second Closing Date" has the meaning set forth in Section 2.4 of this
Agreement.

     "Securities Act" means the Securities Act of 1933, as amended, and the
rules and regulations of the Commission thereunder.

     "Software" means any computer software programs, source code, object code,
data and documentation, including, without limitation, any computer software
programs that incorporate and run the Company's pricing models, formulae and
algorithms.

     "Stock Equivalents" means any security or obligation which is by its terms
convertible into or exchangeable or exercisable for shares of Common Stock or
other capital stock of the Company, and any option, warrant or other
subscription or purchase right with respect to Common Stock or such other
capital stock.

     "Stockholder Approval" has the meaning set forth in Section 8.2 of this
Agreement.

     "Stock Option Plan" means the 1999 Stock Incentive Plan of the Company
pursuant to which up to 9,884,800 shares of restricted stock and options to
purchase shares of Common Stock are reserved and available for grant to
officers, directors, employees and consultants of the Company.

     "Subsidiaries" means, as of the relevant date of determination, with
respect to any Person, a corporation or other Person of which 50% or more of the
voting power of the outstanding voting equity securities or 50% or more of the
outstanding economic equity interest is held, directly or indirectly, by such
Person. Unless otherwise qualified, or the context otherwise requires, all
references to a "Subsidiary" or to "Subsidiaries" in this Agreement shall refer
to a Subsidiary or Subsidiaries of the Company.

     "Taxes" means any federal, state, provincial, county, local, foreign and
other taxes (including, without limitation, income, profits, windfall profits,
alternative, minimum, accumulated earnings, personal holding company, capital
stock, premium, estimated, excise, sales, use, occupancy, gross receipts,
franchise, ad valorem, severance, capital levy, production, transfer,
withholding, employment, unemployment compensation, payroll and property taxes,
import duties and other governmental charges and assessments), whether or not
measured in whole or in part by net income, and including deficiencies,
interest, additions to tax or interest, and penalties with respect thereto, and
including expenses associated with contesting any proposed adjustments related
to any of the foregoing.

     "Trade Secrets" means any trade secrets, research records, processes,
procedures, manufacturing formulae, technical know-how, technology, blue prints,
designs, plans, inventions (whether patentable and whether reduced to practice),
invention disclosures and improvements thereto.

                                     - 7 -
<PAGE>   13

     "Trademarks" means any foreign or United States trademarks, service marks,
trade dress, trade names, brand names, designs and logos, corporate names,
product or service identifiers, whether registered or unregistered, and all
registrations and applications for registration thereof.

     "Transaction Documents" means, collectively, this Agreement and the
Registration Rights Agreement.

                                   ARTICLE II

                      PURCHASE AND SALE OF PREFERRED STOCK

     2.1 Purchase and Sale of Preferred Stock at the First Closing. Subject to
the terms and conditions herein set forth, the Company agrees to issue and sell
to each Purchaser, and each Purchaser severally agrees to purchase from the
Company, on the First Closing Date the number of shares of Preferred Stock set
forth opposite such Purchaser's name on Schedule 2.1 hereto, for the aggregate
purchase price set forth opposite such Purchaser's name on Schedule 2.1 hereto
(all of the shares of Preferred Stock being purchased pursuant to this section
being referred to herein as the "Initial Purchased Shares").

     2.2 First Closing. Subject to the satisfaction or waiver of the conditions
set forth in Articles V and VI, the closing of the sale and purchase of the
Initial Purchased Shares (the "First Closing") shall take place at the offices
of Paul, Weiss, Rifkind, Wharton & Garrison, at 10:00 a.m., local time, on the
later to occur of (x) the second (2nd) Business Day following the date upon
which the conditions set forth in Articles V and VI shall be satisfied or waived
in accordance with this Agreement or (y) ten (10) days from the date hereof, or
at such other time, place and date that the Company, the GAP Purchasers and ICP
may agree in writing (the "First Closing Date"). On the First Closing Date, the
Company shall deliver to each of the Purchasers a certificate or certificates in
definitive form and registered in the name of each such Purchaser, representing
his, her or its Initial Purchased Shares against delivery by each of the
Purchasers to the Company of the aggregate purchase price therefor by wire
transfer of immediately available funds.

     2.3 Purchase and Sale of Preferred Stock at the Second Closing. Subject to
the terms and conditions herein set forth, the Company agrees to issue and sell
to each Purchaser, and each Purchaser severally agrees to purchase from the
Company, on the Second Closing Date the number of shares of Preferred Stock set
forth opposite such Purchaser's name on Schedule 2.3 hereto, for the aggregate
purchase price set forth opposite such Purchaser's name on Schedule 2.3 hereto
(all of the shares of Preferred Stock being purchased pursuant to this section
being referred to herein as the "Additional Purchased Shares" and, together with
the Initial Purchased Shares, the "Purchased Shares").

     2.4 Second Closing. Subject to the satisfaction or waiver of the conditions
set forth in Articles VII and VIII, the closing of the sale and purchase of the

                                     - 8 -
<PAGE>   14

Additional Purchased Shares (the "Second Closing") shall take place at the
offices of Paul, Weiss, Rifkind, Wharton & Garrison, at 10:00 a.m., local time,
on the second (2nd) Business Day following the date upon which the conditions
set forth in Articles VII and VIII shall be satisfied or waived in accordance
with this Agreement (provided, that in any case such conditions must be
satisfied no later than 75 days following the First Closing Date) or at such
other time, place and date that the Company, the GAP Purchasers and ICP may
agree in writing (the "Second Closing Date"). On the Second Closing Date, the
Company shall deliver to each of the Purchasers a certificate or certificates in
definitive form and registered in the name of each such Purchaser, representing
his, her or its Additional Purchased Shares against delivery by each of the
Purchasers to the Company of the aggregate purchase price therefor by wire
transfer of immediately available funds.

     2.5 Certificates of Designations. The Purchased Shares shall have the
preferences and rights set forth in the Certificate of Designations.

     2.6 Use of Proceeds. The Company shall use the proceeds from the sale of
the Purchased Shares to the Purchasers to fund the Company's working capital.

                                  ARTICLE III

                  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

     The Company represents and warrants to each of the Purchasers as follows:

     3.1 Corporate Existence and Power. Each of the Company and its Subsidiaries
(a) is a corporation duly organized, validly existing and, except as set forth
on Schedule 3.1(a), in good standing under the laws of the jurisdiction of its
incorporation, (b) has all requisite power and authority to own and operate its
property, to lease the property it operates as lessee and to conduct the
business in which it is currently, or is proposed to be, engaged, (c) is duly
qualified as a foreign corporation, licensed and, except as set forth on
Schedule 3.1(c), in good standing under the laws of each jurisdiction in which
its ownership, lease or operation of property or the conduct of its business
requires such qualification, except where the failure to be so qualified could
not reasonably be expected to have a material adverse effect on the Condition of
the Company and (d) has the corporate power and authority to execute, deliver
and perform its obligations under this Agreement and the Registration Rights
Agreement. No jurisdiction, other than those referred to in clause (c) above,
has claimed, in writing or otherwise, that either the Company or any of its
Subsidiaries is required to qualify as a foreign corporation or other entity
therein, and neither the Company nor any of its Subsidiaries files any
franchise, income or other tax returns in any other jurisdiction based upon the
ownership or use of property therein or the derivation of income therefrom.
Neither the Company nor any of its Subsidiaries owns or leases property in any
jurisdiction other than its jurisdiction of incorporation and the jurisdictions
referred to in clause (c) above.

                                     - 9 -
<PAGE>   15

     3.2 Authorization; No Contravention. Except as set forth on Schedule 3.2,
the execution, delivery and performance by the Company of this Agreement and the
Registration Rights Agreement and the transactions contemplated hereby and
thereby (a) have been duly authorized by all necessary corporate action of the
Company, (b) do not contravene the terms of the Certificate of Incorporation or
the Bylaws or the certificate of incorporation, bylaws or other organizational
documents of any of its Subsidiaries, (c) do not violate, conflict with or
result in any breach, default or contravention of (or with due notice or lapse
of time or both would result in any breach, default or contravention of), or the
creation of any Lien under, any Contractual Obligation of the Company or its
Subsidiaries or any Requirements of Law applicable to the Company or its
Subsidiaries and (d) do not violate any judgment, injunction, writ, award,
decree or order of any nature (collectively, "Orders") of any Governmental
Authority against, or binding upon, the Company or its Subsidiaries. The
approval by a majority of the holders of the Common Stock present and voting at
a duly called meeting of the Company's stockholders of the sale and issuance of
the Additional Purchased Shares (the "Requisite Company Vote") is the only vote
required by the Company's stockholders in connection with the sale and purchase
of the Purchased Shares.

     3.3 Governmental Authorization; Third Party Consents. Except as set forth
in Schedule 3.3, no approval, consent, compliance, exemption, authorization or
other action by, or notice to, or filing with, any Governmental Authority or any
other Person, and no lapse of a waiting period under a Requirement of Law, is
necessary or required in connection with the execution, delivery or performance
(including, without limitation, the sale, issuance and delivery of the Purchased
Shares) by, or enforcement against, the Company of this Agreement and the
Registration Rights Agreement or the transactions contemplated hereby and
thereby.

     3.4 Binding Effect. This Agreement and the Registration Rights Agreement
have been duly executed and delivered by the Company, and constitute the legal,
valid and binding obligations of the Company, enforceable against the Company in
accordance with their terms, except as enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, fraudulent conveyance or
transfer, moratorium or similar laws affecting the enforcement of creditors'
rights generally and by general principles of equity relating to enforceability
(regardless of whether considered in a proceeding at law or in equity).

     3.5 Litigation. Except as set forth on Schedule 3.5 or disclosed in the SEC
Documents, there are no actions, suits, proceedings, claims, complaints,
disputes, arbitrations or investigations (collectively, "Claims") pending or, to
the Knowledge of the Company, threatened, at law, in equity, in arbitration or
before any Governmental Authority against the Company or its Subsidiaries nor is
the Company aware that there is any basis for any of the foregoing. The
foregoing includes, without limitation, Claims pending or, to the Knowledge of
the Company, threatened or any basis therefor known by the Company involving (i)
the prior employment of any of the employees of the Company or its Subsidiaries
or (ii), the use of any information or techniques allegedly proprietary to any
of their former employers in connection with the business of the Company. No
Order has been issued by any court or other Governmental Authority

                                     - 10 -
<PAGE>   16

against the Company purporting to enjoin or restrain the execution, delivery or
performance of this Agreement or the Registration Rights Agreement.

     3.6  Compliance with Laws.

          (a)  The Company and its Subsidiaries are in compliance in all
material respects with all Requirements of Law and all Orders issued by any
court or Governmental Authority against the Company and such Subsidiaries in all
respects. To the Company's Knowledge, there is no existing or proposed
Requirement of Law which could reasonably be expected to prohibit or restrict
the Company or its Subsidiaries from, or otherwise materially adversely effect
the Company or its Subsidiaries in, conducting their businesses in any
jurisdiction in which it now conducts or proposes to conduct such businesses.

          (b)  (i)  The Company and its Subsidiaries have all material licenses,
permits and approvals of any Governmental Authority (collectively, "Permits")
that are necessary for the conduct of the business of the Company; (ii) such
Permits are in full force and effect; and (iii) no violations are or have been
recorded in respect of any Permit.

          (c)  No material expenditure is presently required by the Company to
comply with any existing Requirement of Law or Order.

     3.7  Capitalization.

          (a)  (i)  On the First Closing Date, after giving effect to the
transactions contemplated by this Agreement, the authorized capital stock of the
Company shall consist of 225,000,000 shares of Common Stock and 45,000,000
shares of undesignated "blank check" preferred stock. As of the close of
business on May 1, 2001, 59,277,000 shares of Common Stock were issued and
outstanding. As of the date of this Agreement, the maximum number of shares
underlying options to purchase shares of Common Stock which may be issued under
the Stock Option Plan is 5,508,633, of which 4,376,167 options have been
granted.

               (ii)  On the Second Closing Date, after giving effect to the
transactions contemplated by this Agreement, the authorized capital stock of the
Company shall consist of 225,000,000 shares of Common Stock and 45,000,000
shares of undesignated "blank check" preferred stock.

          (b)  Except as set forth on Schedule 3.7(b) or disclosed in the SEC
Documents, there are no options, warrants, conversion privileges, subscription
or purchase rights or other rights presently outstanding to purchase or
otherwise acquire (i) any authorized but unissued, unauthorized or treasury
shares of the Company's capital stock, (ii) any Stock Equivalents or (iii) other
securities of the Company and there are no commitments, contracts, agreements,
arrangements or understandings by the Company to issue any shares of the
Company's capital stock or any Stock Equivalents or other securities of the
Company. The Purchased Shares are duly authorized, and when issued and sold to
the Purchasers after payment therefor, will be validly issued, fully paid and

                                     - 11 -
<PAGE>   17

non-assessable, will be issued in compliance with the registration and
qualification requirements of all applicable federal, state and foreign
securities laws and will be free and clear of all other Liens. The shares of
Common Stock issuable upon conversion of the Purchased Shares have been duly
reserved for issuance upon conversion of the Preferred Shares and, when issued
in compliance with the provisions of the Certificate of Designations, will be
validly issued, fully paid and non-assessable and not subject to any preemptive
rights or similar rights that have not been satisfied and will be free and clear
of all other Liens. All of the issued and outstanding shares of Common Stock are
all duly authorized, validly issued, fully paid and non-assessable, and were
issued in compliance with the registration and qualification requirements of all
applicable federal, state and foreign securities laws.

          (c)  Schedule 3.7(c) sets forth, as of the First Closing Date, a true
and complete list of (x) each of the Subsidiaries of the Company, (y) the
percentage of the authorized shares of capital stock of such Subsidiary owned by
the Company and (z) the stockholders of such Subsidiary and, opposite the name
of each stockholder, the amount of all outstanding capital stock and Stock
Equivalents owned by such stockholder. The Company owns all of the issued and
outstanding capital stock of the Subsidiaries, free and clear of all Liens. All
of such shares of capital stock are duly authorized, validly issued, fully paid
and non-assessable, and were issued in compliance with the registration and
qualification requirements of all applicable federal, state and foreign
securities laws. Except as set forth on Schedule 3.7(c), there are no options,
warrants, conversion privileges, subscription or purchase rights or other rights
presently outstanding to purchase or otherwise acquire any authorized but
unissued, unauthorized or treasury shares of capital stock or other securities
of, or any proprietary interest in, any of the Subsidiaries, and there is no
outstanding security of any kind convertible into or exchangeable for such
shares or proprietary interest. Except as set forth on Schedule 3.7(c), neither
the Company nor any of its Subsidiaries, owns any interest, or has a right to
acquire any interest, in any Person that is not a Subsidiary.

          (d)  The Common Stock currently is listed for trading on the Nasdaq
and (i) except as set forth on Schedule 3.7(d), the Company and the Common Stock
meet the currently applicable criteria for continued listing and trading on
Nasdaq, (ii) no suspension of trading in the Common Stock is in effect and (iii)
the Company has delivered to Nasdaq all required notices.

     3.8  No Default or Breach; Contractual Obligations. Neither the Company nor
any of its Subsidiaries have received notice of a default nor is in default
under, or with respect to, any material Contractual Obligation nor does any
condition exist that with notice or lapse of time or both would constitute a
default thereunder. Except as described in the SEC Documents or as set forth on
Schedule 3.8, neither the Company nor any of its Subsidiaries is a party to any
Contractual Obligations, whether written or oral, (i) which involve an amount in
excess of $100,000 or (ii) which are otherwise material to the Condition of the
Company. All of such Contractual Obligations are valid, subsisting, in full
force and effect and binding upon the Company and its Subsidiaries, as the case
may be, and, to the Knowledge of the Company, the other parties thereto, and the
Company and its Subsidiaries have paid in full or accrued all

                                     - 12 -
<PAGE>   18

amounts due thereunder and have satisfied in full or provided for all of their
liabilities and obligations thereunder. To the Knowledge of the Company, no
other party to any such Contractual Obligation is in default thereunder, nor
does any condition exist that with notice or lapse of time or both would
constitute a default by such other party thereunder.

     3.9  SEC Documents; Financial Statements. Since November 3, 1999, the
Company has filed all reports, schedules, forms, statements and other documents
required to be filed by it with the Securities and Exchange Commission (the
"SEC") pursuant to the reporting requirements of the Exchange Act (all of the
foregoing filed prior to the date hereof and all exhibits included therein and
financial statements and schedules thereto and documents incorporated by
reference therein being hereinafter referred to as the "SEC Documents"). As of
their respective dates, the SEC Documents complied in all material respects with
the requirements of the Exchange Act and the rules and regulations of the SEC
promulgated thereunder applicable to the SEC Documents, and none of the SEC
Documents, at the time they were filed with the SEC, contained any untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. As of their
respective dates, the financial statements of the Company (the "Financial
Statements") included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto. The Financial Statements have been
prepared in accordance with GAAP, consistently applied, during the periods
involved (except in the case of unaudited interim statements, to the extent they
may exclude footnotes or may be condensed or summary statements) and fairly
present in all material respects the financial position of the Company as of the
dates thereof and the results of its operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end
audit adjustments). No other information provided by or on behalf of the Company
to the Purchasers which is not included in the SEC Documents contains any untrue
statement of a material fact or omits to state any material fact necessary in
order to make the statements therein, in the light of the circumstance under
which they are or were made, not misleading.

     3.10 No Material Adverse Change; Ordinary Course of Business. Since
December 31, 2000, (a) there has not been any material adverse change, nor is
any such change reasonably expected, in the Condition of the Company, (b) the
Company and its Subsidiaries have not participated in any transaction material
to the Condition of the Company or otherwise acted outside the ordinary course
of business, including, without limitation, declaring or paying any dividend or
declaring or making any distribution to its stockholders except out of the
earnings of the Company and such Subsidiaries, (c) the Company and its
Subsidiaries have not increased the compensation of any of its officers or the
rate of pay of any of its employees, except as part of regular compensation
increases in the ordinary course of business, (d) the Company and its
Subsidiaries have not created or assumed any Lien on a material asset of the
Company and such Subsidiaries, (e) the Company and its Subsidiaries have not
entered into any Contractual Obligation, other than in the ordinary course of
business and (f) there has not occurred a

                                     - 13 -
<PAGE>   19

material change in the accounting principles or practice of the Company or any
of its Subsidiaries except as required by reason of a change in GAAP.

     3.11 Taxes. (a) The Company and its Subsidiaries have paid all Taxes which
have come due and are required to be paid by it through the date hereof, and all
deficiencies or other additions to Tax, interest and penalties owed by them in
connection with any such Taxes, other than Taxes being disputed by the Company
or its Subsidiaries in good faith for which adequate reserves have been made in
accordance with GAAP; (b) the Company and its Subsidiaries have timely filed or
caused to be filed all returns for Taxes that they are required to file on and
through the date hereof (including all applicable extensions), and all such Tax
returns are accurate and complete; (c) with respect to all Tax returns of the
Company and its Subsidiaries, (i) there is no unassessed Tax deficiency proposed
or, to the Knowledge of the Company, threatened against the Company or its
Subsidiaries and (ii) no audit is in progress with respect to any return for
Taxes, no extension of time is in force with respect to any date on which any
return for Taxes was or is to be filed and no waiver or agreement is in force
for the extension of time for the assessment or payment of any Tax; (d) all
provisions for Tax liabilities of the Company and its Subsidiaries with respect
to the Financial Statements have been made in accordance with GAAP consistently
applied, and all liabilities for Taxes of the Company and its Subsidiaries
attributable to periods prior to or ending on the First Closing Date or the
Second Closing Date, as the case may be, have been adequately provided for on
the Financial Statements; and (e) there are no Liens for Taxes on the assets of
the Company and its Subsidiaries.

     3.12 Private Offering. No form of general solicitation or general
advertising was used by the Company or its representatives in connection with
the offer or sale of the Purchased Shares. No registration of the Purchased
Shares, pursuant to the provisions of the Securities Act or any state securities
or "blue sky" laws, will be required by the offer, sale or issuance of the
Purchased Shares. The Company agrees that neither it, nor anyone acting on its
behalf, shall offer to sell the Purchased Shares or any other securities of the
Company so as to require the registration of the Purchased Shares pursuant to
the provisions of the Securities Act or any state securities or "blue sky" laws,
unless such Purchased Shares or other securities are so registered.

     3.13 Employee Benefit Plans. Schedule 3.13 hereto and the SEC Documents
together list each Plan that the Company maintains or to which the Company
contributes (the "Company Plans"). The Company and its Subsidiaries have no
liability under any Plans other than the Company Plans. Except as set forth on
Schedule 3.13, neither the Company nor its Subsidiaries nor any Commonly
Controlled Entity maintains or contributes to, or has within the preceding six
years maintained or contributed to, or may have any liability with respect to
any Plan subject to Title IV of ERISA or Section 412 of the Code or any
"multiple employer plan" within the meaning of the Code or ERISA. Each Company
Plan (and related trust, insurance contract or fund) has been established and
administered in accordance with its terms, and complies in form and in operation
with the applicable requirements of ERISA and the Code and other applicable
Requirements of Law. All contributions (including all employer contributions and
employee salary reduction contributions) which are due have been paid to each
Company

                                     - 14 -
<PAGE>   20

Plan. No Claim with respect to the administration or the investment of the
assets of any Company Plan (other than routine claims for benefits) is pending.
Each Company Plan that is intended to be qualified under Section 401(a) of the
Code is so qualified and has been so qualified during the period since its
adoption; each trust created under any such Plan is exempt from tax under
Section 501(a) of the Code and has been so exempt since its creation. No Company
Plan is a Retiree Welfare Plan. Neither the consummation of the transactions
contemplated by this Agreement nor any termination of employment following such
transactions will accelerate the time of the payment or vesting of, or increase
the amount of, compensation due to any employee or former employee whether or
not such payment would constitute an "excess parachute payment" under section
280G of the Code. There are no unfunded obligations under any Company Plan that
are not fully reflected on the Financial Statements. The Company has no
liability, whether absolute or contingent, including any obligations under any
Company Plan, with respect to any misclassification of any person as an
independent contractor rather than as an employee.

     3.14 Liabilities. The Company and its Subsidiaries do not have any direct
or indirect obligation or liability (the "Liabilities") other than (a)
Liabilities fully and adequately reflected in or reserved against on the
Financial Statements and (b) Liabilities incurred since December 31, 2000 in the
ordinary course of business. The Company has no Knowledge of any circumstance,
condition, event or arrangement that could reasonably be expected to give rise
hereafter to any Liabilities of the Company or its Subsidiaries except in the
ordinary course of business.

     3.15 Intellectual Property.

          (a)  The Company and its Subsidiaries are the owners of all, or have
the license or right to use, sell and license all of, the Copyrights, Patents,
Trade Secrets, Trademarks, Internet Assets, Software and other proprietary
rights (collectively, "Intellectual Property") that are used in connection with
their businesses as presently conducted or contemplated in the business plan of
the Company and its Subsidiaries, free and clear of all Liens.

               (i)  None of the Company's Intellectual Property is subject to
any outstanding Order, and no action, suit, proceeding, hearing, investigation,
charge, complaint, claim or demand is pending or, to the Knowledge of the
Company, threatened, which challenges the validity, enforceability, use or
ownership of the item.

               (ii) With regard to all Intellectual Property licenses,
sublicenses, distributor agreements and other agreements under which the Company
or its Subsidiaries are either a licensor, licensee or distributor, except such
licenses, sublicenses and other agreements relating to off-the-shelf software,
which is commercially available on a retail basis and used solely on the
computers of the Company or its Subsidiaries, the Company and its Subsidiaries
have substantially performed all obligations imposed upon them thereunder, and
are not, nor to the Knowledge of the Company is any other party thereto, in
breach of or default thereunder in any respect, nor is there any event which
with notice or lapse of time or both would constitute a default thereunder. All
of such

                                     - 15 -
<PAGE>   21

Intellectual Property licenses are valid, enforceable and in full force and
effect, and will continue to be so on identical terms immediately following
either the First Closing or Second Closing, as the case may be, except as
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, fraudulent conveyance or transfer, moratorium or similar laws
affecting the enforcement of creditors' rights generally and by general
principles of equity relating to enforceability (regardless of whether
considered in a proceeding at law or in equity).

               (iii) Other than as set forth on Schedule 3.16(a)(iii), none of
the Intellectual Property currently sold or licensed by the Company or its
Subsidiaries to any Person or used by or licensed to the Company or its
Subsidiaries by any Person infringes upon or otherwise violates any Intellectual
Property rights of others.

               (iv)  Except as set forth on Schedule 3.16(a)(iv), no litigation
is pending and no Claim has been made against the Company or its Subsidiaries
or, to the Knowledge of the Company, is threatened, contesting the right of the
Company or its Subsidiaries to sell or license to any Person or use the
Intellectual Property presently sold or licensed to such Person or used by the
Company or its Subsidiaries.

          (b)  Except as set forth on Schedule 3.16(b), to the Knowledge of the
Company, no Person is infringing upon or otherwise violating the Intellectual
Property rights of the Company and its Subsidiaries.

          (c)  No former employer of any employee of the Company or its
Subsidiaries, and no current or former client of any consultant of the Company
or its Subsidiaries, has made a claim against the Company, its Subsidiaries or
any Affiliates thereof or, to the Knowledge of the Company, against any other
Person, that such employee or such consultant is utilizing Intellectual Property
of such former employer or client.

          (d)  Except as set forth on Schedule 3.16(d) or disclosed in the SEC
Documents, neither the Company nor any of its Subsidiaries are parties to or
bound by any license or other agreement requiring the payment by the Company or
such Subsidiaries of any royalty payment, excluding such agreements relating to
software licensed for use solely on the computers of the Company or such
Subsidiaries.

          (e)  To the Knowledge of the Company, no employee of the Company or
its Subsidiaries is in violation of any Requirement of Law applicable to such
employee, or any term of any employment agreement, patent or invention
disclosure agreement or other contract or agreement relating to the relationship
of such employee with the Company or its Subsidiaries or any prior employer.

          (f)  To the Knowledge of the Company, none of the Trade Secrets of the
Company or its Subsidiaries, wherever located, the value of which is contingent
upon maintenance of confidentiality thereof, have been disclosed to any Person
other than employees, representatives and agents of the Company or its

                                     - 16 -
<PAGE>   22

Subsidiaries, except as required pursuant to the filing of a patent application
by the Company or such Subsidiaries.

          (g)  It is not necessary for the businesses of the Company and its
Subsidiaries to use any Intellectual Property owned by any director, officer,
employee or consultant of the Company or its Subsidiaries (or Persons the
Company or any of its Subsidiaries presently intend to hire). To the Company's
Knowledge, at no time during the conception or reduction to practice of any of
the Company's or its Subsidiaries' Intellectual Property was any developer,
inventor or other contributor to such Intellectual Property operating under any
grants from any Governmental Authority or subject to any employment agreement,
invention assignment, nondisclosure agreement or other Contractual Obligation
with any Person that could adversely affect the Company's or such Subsidiaries'
rights to their Intellectual Property.

          (h)  All present employees of the Company and its Subsidiaries have
executed and delivered proprietary invention agreements with the Company or such
Subsidiaries as the case may be, and are obligated under the terms thereof to
assign all inventions made by them during the course of employment to the
Company or its Subsidiaries. No such employee or present consultant of the
Company or its Subsidiaries has excluded works or inventions made prior to his
employment with or work for the Company or its Subsidiaries from his assignment
of inventions pursuant to such proprietary invention agreements.

     3.16 Privacy of Customer Information. Neither the Company nor its
Subsidiaries uses any of the customer information it receives through its
websites or otherwise in an unlawful manner, or in a manner violative of the
Company's or such Subsidiaries' privacy policy or the privacy rights of its
customers. The Company and its Subsidiaries have not collected any customer
information through their websites in an unlawful manner or in violation of its
privacy policy. The Company and its Subsidiaries have adequate security measures
in place to protect the customer information they receive through their websites
and which they store in their computer systems from illegal use by third parties
or use by third parties in a manner violative of the rights of privacy of their
customers. The Company and its Subsidiaries represent to their customers that
they assure complete security as to the customer information they receive
through their websites.

     3.17 Environmental Matters. The Company and its Subsidiaries are in
compliance with all applicable Environmental Laws. There is no civil, criminal
or administrative judgment, action, suit, demand, claim, hearing, notice of
violation, investigation, proceeding, notice or demand letter pending or, to the
Knowledge of the Company, threatened against the Company or its Subsidiaries
pursuant to Environmental Laws. To the Knowledge of the Company, there are no
past or present events, conditions, circumstances, activities, practices,
incidents, agreements, actions or plans which could reasonably be expected to
prevent compliance with, or which have given rise to or will give rise to
liability which would have a material adverse effect on the Condition of the
Company under, Environmental Laws.

                                     - 17 -
<PAGE>   23

     3.18 Broker's, Finder's or Similar Fees. There are no brokerage
commissions, finder's fees or similar fees or commissions payable by the Company
or any of its Subsidiaries in connection with the transactions contemplated
hereby based on any agreement, arrangement or understanding with the Company or
any of its Subsidiaries or any action taken by any such Person.

                                   ARTICLE IV

                REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS

     Each of the Purchasers hereby represents and warrants, severally and not
jointly, to the Company as follows:

     4.1  Existence and Power. Such Purchaser (a) is a limited partnership,
corporation, limited liability company or trust duly organized and validly
existing under the laws of the jurisdiction of its formation and (b) has (i) if
such Purchaser is an individual, the legal capacity or (ii) if such Purchaser is
a limited partnership, limited liability company or trust, requisite
partnership, corporate, limited liability company or trust, as the case may be,
power and authority to execute, deliver and perform its obligations under this
Agreement and the Registration Rights Agreement.

     4.2  Authorization; No Contravention. The execution, delivery and
performance by such Purchaser of this Agreement and the Registration Rights
Agreement and the transactions contemplated hereby and thereby, (a) if
applicable, have been duly authorized by all necessary partnership, corporate
limited liability company, trust or other action, as the case may be, (b) if
applicable, do not contravene the terms of such Purchaser's organizational
documents, or any amendment thereof, and (c) do not violate, conflict with or
result in any breach or contravention of, or the creation of any Lien under, any
Contractual Obligation of such Purchaser or any Requirement of Law applicable to
such Purchaser (except for the Lien created on the Purchased Shares purchased by
GapStar to secure its obligations under a bona fide loan made to acquire such
Purchased Shares), and (d) do not violate any Orders of any Governmental
Authority against, or binding upon, such Purchaser.

     4.3  Governmental Authorization; Third Party Consents. No approval,
consent, compliance, exemption, authorization or other action by, or notice to,
or filing with, any Governmental Authority or any other Person, and no lapse of
a waiting period under any Requirement of Law, is necessary or required in
connection with the execution, delivery or performance (including, without
limitation, the purchase of the Purchased Shares) by, or enforcement against,
such Purchaser of this Agreement and the Registration Rights Agreement or the
transactions contemplated hereby and thereby.

     4.4  Binding Effect. This Agreement and the Registration Rights Agreement
have been duly executed and delivered by such Purchaser and constitutes the
legal, valid and binding obligations of such Purchaser, enforceable against it
in accordance with its terms, except as enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, fraudulent conveyance or
transfer, moratorium or

                                     - 18 -
<PAGE>   24

similar laws affecting the enforcement of creditors' rights generally or by
equitable principles relating to enforceability (regardless of whether
considered in a proceeding at law or in equity).

     4.5  Purchase for Own Account. The Purchased Shares to be acquired by such
Purchaser pursuant to this Agreement are being or will be acquired for its own
account and with no intention of distributing or reselling such Purchased Shares
or any part thereof in any transaction that would be in violation of the
securities laws of the United States of America, or any state, without
prejudice, however, to the rights of such Purchaser at all times to sell or
otherwise dispose of all or any part of such Purchased Shares under an effective
registration statement under the Securities Act, or under an exemption from such
registration available under the Securities Act, and subject, nevertheless, to
the disposition of such Purchaser's property being at all times within its
control. If such Purchaser should in the future decide to dispose of any of such
Purchased Shares, such Purchaser understands and agrees that it may do so only
in compliance with the Securities Act and applicable state securities laws, as
then in effect. Such Purchaser agrees to the imprinting, so long as required by
law, of a legend on certificates representing all of its Purchased Shares and
shares of Common Stock issuable upon conversion of its Purchased Shares to the
following effect:

     THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE SECURITIES LAWS
OF ANY STATE. THE SECURITIES MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES
LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS
OF SUCH ACT AND SUCH LAWS.

     4.6  Restricted Securities. Such Purchaser understands that the Purchased
Shares will not be registered at the time of their issuance under the Securities
Act for the reason that the sale provided for in this Agreement is exempt
pursuant to Section 4(2) of the Securities Act and that the reliance of the
Company on such exemption is predicated in part on such Purchaser's
representations set forth herein.

     4.7  Broker's, Finder's or Similar Fees. There are no brokerage
commissions, finder's fees or similar fees or commissions payable by such
Purchaser in connection with the transactions contemplated hereby based on any
agreement, arrangement or understanding with such Purchaser or any action taken
by such Purchaser.

     4.8  Accredited Investor. Such Purchaser is an "Accredited Investor" within
the meaning of Rule 501 of Regulation D under the Securities Act, as presently
in effect.

                                     - 19 -
<PAGE>   25

                                   ARTICLE V

                          CONDITIONS OF THE PURCHASERS
                                TO FIRST CLOSING

     The obligation of the Purchasers to purchase the Initial Purchased Shares,
to pay the purchase price therefor at the First Closing and to perform any
obligations hereunder shall be subject to the satisfaction as determined by, or
waiver by, the GAP Purchasers and ICP, acting collectively, of the following
conditions on or before the First Closing Date.

     5.1  Representations and Warranties. The representations and warranties of
the Company contained in this Agreement shall be true and correct in all
material respects (except for any such representations and warranties which are
qualified by their terms by a reference to materiality or material adverse
effect, which representation as so qualified shall be true and correct in all
respects) at and on the First Closing Date as if made at and on such date.

     5.2  Compliance with this Agreement. The Company shall have performed and
complied in all material respects with all of its agreements set forth herein
that are required to be performed by the Company on or before the First Closing
Date.

     5.3  Officer's Certificate. The Purchasers shall have received a
certificate from the Company, in form and substance satisfactory to the GAP
Purchasers and ICP dated the First Closing Date, and signed by an executive
officer of the Company, certifying as to the matters set forth in Sections 5.1
and 5.2.

     5.4  Secretary's Certificate. The Purchasers shall have received a
certificate from the Company, in form and substance satisfactory to the GAP
Purchasers and ICP, dated the First Closing Date and signed by the Secretary or
an Assistant Secretary of the Company, certifying (a) that the Company is in
good standing with the Secretary of State of the State of Delaware, (b) that the
attached copies of the Certificate of Incorporation, the Bylaws, and resolutions
of the Board of Directors of the Company approving this Agreement and the
Registration Rights Agreement and the transactions contemplated hereby and
thereby, are all true, complete and correct and remain unamended and in full
force and effect and (c) as to the incumbency and specimen signature of each
officer of the Company executing this Agreement, each other Transaction Document
and any other document delivered in connection herewith on behalf of the
Company.

     5.5  Filing of Certificate of Designations. The Certificate of Designations
shall have been duly filed by the Company with the Secretary of State of the
State of Delaware in accordance with the General Corporation Law of the State of
Delaware, and the Purchasers shall have received evidence of such filing in form
and substance reasonably satisfactory to the GAP Purchasers and ICP.

                                     - 20 -
<PAGE>   26

     5.6  Initial Purchased Shares. The Company shall be prepared to deliver to
each of the Purchasers certificates in definitive form representing the number
of Initial Purchased Shares set forth opposite such Purchaser's name on Schedule
2.1 hereto, registered in the name of such Purchaser.

     5.7  Registration Rights Agreement. The Company shall have duly executed
and delivered the Registration Rights Agreement.

     5.8  Opinion of Counsel. The Purchasers shall have received an opinion of
Brobeck, Phleger & Harrison LLP, dated the First Closing Date, relating to the
transactions contemplated by or referred to herein, substantially in the form
attached hereto as Exhibit E.

     5.9  Nasdaq Waiver. The Company shall have received from the NASDAQ Stock
Market a waiver in form and substance reasonably satisfactory to the GAP
Purchasers and ICP from Nasdaq Marketplace Rules 4350 and 4351 to the extent
applicable in connection with the sale and issuance of the Initial Purchased
Shares and complied with any conditions contained in such waiver in order to
consummate the transactions contemplated hereby at the First Closing. The Common
Stock issuable upon conversion of the Initial Purchased Shares will be accepted
for listing on the Nasdaq Stock Market pending official notice of issuance.

     5.10 Good Standing Certificates. The Company shall have delivered to the
Purchasers as of the Closing Date, good standing certificates for the Company
and each of its Subsidiaries for each of their respective jurisdictions of
incorporation.

     5.11 No Material Adverse Change. Since the date hereof, there shall have
been no material adverse change in the Condition of the Company.

     5.12 Consents and Approvals. All consents, exemptions, authorizations, or
other actions by, or notice to, or filings with, Governmental Authorities and
other Persons in respect of all Requirements of Law and with respect to those
Contractual Obligations of the Company which are necessary or required in
connection with the execution, delivery or performance by, or enforcement
against, the Company of this Agreement and the Registration Rights Agreement
shall have been obtained and be in full force and effect, and the Purchasers
shall have been furnished with appropriate evidence thereof and all applicable
waiting periods shall have expired without any action being taken or threatened
which would have a material adverse effect on the Condition of the Company.

     5.13 No Material Judgment or Order. There shall not be on the Closing Date
any Order of a court of competent jurisdiction or any ruling of any Governmental
Authority or any condition imposed under any Requirement of Law which would, in
the reasonable judgment of the GAP Purchasers and ICP, (a) prohibit or restrict
(i) the purchase of the Purchased Shares or (ii) the consummation of the
transactions contemplated by this Agreement, (b) subject the Purchasers to any
material penalty or onerous condition under or pursuant to any Requirement of
Law if the Purchased Shares

                                     - 21 -
<PAGE>   27

were to be purchased hereunder or (c) restrict the operation of the business of
the Company as conducted on the date hereof in a manner that would have a
material adverse effect on the Condition of the Company. The purchase of, and
payment for, the Purchased Shares by the Purchasers shall not be prohibited by
any law or Governmental Order or regulation.

     5.14 No Litigation. No action, suit, proceeding, claim or dispute shall
have been brought or otherwise arisen at law, in equity, in arbitration or
before any Governmental Authority against the Company which would, if adversely
determined (a) have a material adverse effect on the Condition of the Company or
(b) have a material adverse effect on the ability of the Company to perform its
obligations under this Agreement or the Registration Rights Agreement.

     5.15 Board of Directors. The Company shall have amended its bylaws (among
other things, increasing the size of the Board of Directors of the Company to
seven (7) members), in form and substance satisfactory to the GAP Purchaser. Two
of the members of the Board of Directors of the Company shall have been
designated by the GAP Purchasers and one vacancy shall have been reserved for
the Additional Series F Director (as defined in the Certificate of Designation).

                                   ARTICLE VI

                   CONDITIONS OF THE COMPANY TO FIRST CLOSING

     The obligation of the Company to issue and sell the Purchased Shares and
the obligation of the Company to perform its other obligations hereunder shall
be subject to the satisfaction as determined by, or waiver by, the Company of
the following conditions on or before the First Closing Date:

     6.1 Payment of Purchase Price. Each Purchaser shall be prepared to pay the
aggregate purchase price for the Initial Company Purchased Shares to be
purchased by such Purchaser.

     6.2 Registration Rights Agreement. Each Purchaser shall have duly executed
and delivered the Registration Rights Agreement.

     6.3 No Injunctions or Regulatory Restraints; Illegality. The sale of the
Shares by the Company to the Purchasers shall not be prohibited by any law or
Government Order or regulation.

                                  ARTICLE VII

                 CONDITIONS OF THE PURCHASERS TO SECOND CLOSING

     The obligation of the Purchasers to purchase the Additional Purchased
Shares, to pay the purchase price therefor at the Second Closing and to perform
any obligations hereunder shall be subject to the satisfaction as determined by,
or waiver by,

                                     - 22 -
<PAGE>   28

the GAP Purchasers and ICP of the following conditions on or before the Second
Closing Date.

     7.1  Representations and Warranties. The representations and warranties of
the Company contained in this Agreement shall be true and correct in all
material respects (except for any such representations and warranties which are
qualified by their terms by a reference to materiality or material adverse
effect, which representation as so qualified shall be true and correct in all
respects) at and on the Second Closing Date as if made at and on such date.

     7.2  Compliance with this Agreement. The Company shall have performed and
complied in all material respects with all of its agreements set forth herein
that are required to be performed by the Company on or before the Second Closing
Date.

     7.3  Officer's Certificate. The Purchasers shall have received a
certificate from the Company, in form and substance satisfactory to the GAP
Purchasers and ICP dated the Second Closing Date, and signed by an executive
officer of the Company, certifying as to the matters set forth in Sections 7.1
and 7.2.

     7.4  Secretary's Certificate. The Purchasers shall have received a
certificate from the Company, in form and substance satisfactory to the GAP
Purchasers and ICP, dated the Second Closing Date and signed by the Secretary or
an Assistant Secretary of the Company, certifying (a) that the Company is in
good standing with the Secretary of State of the State of Delaware, (b) that the
attached copies of the Certificate of Incorporation, the Bylaws, and resolutions
of the Board of Directors of the Company approving this Agreement and each of
the Registration Rights Agreement and the transactions contemplated hereby and
thereby, are all true, complete and correct and remain unamended and in full
force and effect and (c) as to the incumbency and specimen signature of each
officer of the Company executing this Agreement, each other Transaction Document
and any other document delivered in connection herewith on behalf of the
Company.

     7.5  Additional Purchased Shares. The Company shall be prepared to deliver
to each of the Purchasers certificates in definitive form representing the
number of Additional Purchased Shares set forth opposite such Purchaser's name
on Schedule 2.3 hereto, registered in the name of such Purchaser.

     7.6  Opinion of Counsel. The Purchasers shall have received an opinion of
Brobeck, Phleger & Harrison LLP, dated the First Closing Date, relating to the
transactions contemplated by or referred to herein, substantially in the form
attached hereto as Exhibit E.

     7.7  Stockholder Approval. The Company shall have obtained (i) stockholder
approval by the Requisite Company Vote in connection with the issuance of the
Additional Purchased Shares in accordance with the terms of this Agreement at a
duly called meeting of the stockholders of the Company and (ii) stockholder
approval of the reverse stock split as contemplated by Section 10.3.

                                     - 23 -
<PAGE>   29

     7.8  Good Standing Certificates. The Company shall have delivered to the
Purchasers as of the Closing Date, good standing certificates for the Company
and each of its Subsidiaries for each of their respective jurisdictions of
incorporation.

     7.9  No Material Adverse Change. Since the First Closing Date, there shall
have been no material adverse change in the Condition of the Company.

     7.10 Consents and Approvals. All consents, exemptions, authorizations, or
other actions by, or notice to, or filings with, Governmental Authorities and
other Persons in respect of all Requirements of Law and with respect to those
Contractual Obligations of the Company which are necessary or required in
connection with the execution, delivery or performance by, or enforcement
against, the Company of this Agreement and the Registration Rights Agreement
shall have been obtained and be in full force and effect, and the Purchasers
shall have been furnished with appropriate evidence thereof and all applicable
waiting periods shall have expired without any action being taken or threatened
which would have a material adverse effect on the Condition of the Company.

     7.11 No Material Judgment or Order. There shall not be on the Closing Date
any Order of a court of competent jurisdiction or any ruling of any Governmental
Authority or any condition imposed under any Requirement of Law which would, in
the reasonable judgment of the GAP Purchasers and ICP, (a) prohibit or restrict
(i) the purchase of the Purchased Shares or (ii) the consummation of the
transactions contemplated by this Agreement, (b) subject the Purchasers to any
material penalty or onerous condition under or pursuant to any Requirement of
Law if the Purchased Shares were to be purchased hereunder or (c) restrict the
operation of the business of the Company as conducted on the date hereof in a
manner that would have a material adverse effect on the Condition of the
Company.

     7.12 No Litigation. No action, suit, proceeding, claim or dispute shall
have been brought or otherwise arisen at law, in equity, in arbitration or
before any Governmental Authority against the Company which would, if adversely
determined (a) have a material adverse effect on the Condition of the Company or
(b) have a material adverse effect on the ability of the Company to perform its
obligations under this Agreement or the Registration Rights Agreement.

     7.13 Amendment of Certificate of Incorporation. The Company shall have
amended it certificate of incorporation and bylaws (among other things,
effecting a reverse stock split), in form and substance satisfactory to the GAP
Purchasers and ICP.

                                  ARTICLE VIII

                   CONDITIONS OF THE COMPANY TO SECOND CLOSING

     The obligation of the Company to issue and sell the Additional Purchased
Shares and the obligation of the Company to perform its other obligations
hereunder shall

                                     - 24 -
<PAGE>   30

be subject to the satisfaction as determined by, or waiver by, the Company of
the following conditions on or before the Second Closing Date:

     8.1  Payment of Purchase Price. Each Purchaser shall be prepared to pay the
aggregate purchase price for the Additional Purchased Shares to be purchased by
such Purchaser.

     8.2  Stockholder Approval. The Company will take all reasonable action
necessary in accordance with applicable law and its certificate of incorporation
and bylaws to convene a meeting of stockholders (which may be the Company's
annual meeting of stockholders) to be held at or before the 75th day following
the First Closing to obtain (a) the approval and authorization of the issuance
and sale of the Preferred Stock to the Purchasers and the issuance of Common
Stock issuable upon conversion of the Preferred Stock, and (b) such other
matters as may be necessary or advisable to consummate the transactions
contemplated by this Agreement (such approval by stockholders of all such maters
is herein referred to as, the "Stockholder Approval").

                                   ARTICLE IX

                                 INDEMNIFICATION

     9.1  Indemnification. Except as otherwise provided in this Article IX, the
Company (the "Indemnifying Party") agrees to indemnify, defend and hold harmless
each of the Purchasers and its Affiliates and their respective officers,
directors, agents, employees, subsidiaries, partners, members and controlling
persons (each, an "Indemnified Party") to the fullest extent permitted by law
from and against any and all losses, Claims, or written threats thereof
(including, without limitation, any Claim by a third party), damages, expenses
(including reasonable fees, disbursements and other charges of counsel
reasonably incurred by the Indemnified Party in any action between the
Indemnifying Party and the Indemnified Party or between the Indemnified Party
and any third party or otherwise) or other liabilities (collectively, "Losses")
resulting from or arising out of any breach of any representation or warranty,
covenant or agreement by the Company in this Agreement or the Registration
Rights Agreement. The amount of any payment to any Indemnified Party herewith in
respect of any Loss shall be of sufficient amount to make such Indemnified Party
whole for any diminution in value of the Purchased Shares. Additionally, in
connection with the obligation of the Indemnifying Party to indemnify for
expenses as set forth above, the Indemnifying Party shall, upon presentation of
appropriate invoices containing reasonable detail, reimburse each Indemnified
Party for all such expenses (including reasonable fees, disbursements and other
charges of counsel incurred by the Indemnified Party in any action between the
Indemnifying Party and the Indemnified Party or between the Indemnified Party
and any third party) as they are incurred by such Indemnified Party; provided,
however, that if an Indemnified Party is reimbursed under this Article IX for
any expenses, such reimbursement of expenses shall be refunded to the extent it
is finally judicially determined that the Losses in question resulted primarily
from the willful misconduct or gross negligence of such Indemnified Party.

                                     - 25 -
<PAGE>   31

     9.2  Notification. Each Indemnified Party under this Article IX shall,
promptly after the receipt of notice of the commencement of any Claim against
such Indemnified Party in respect of which indemnity may be sought from the
Indemnifying Party under this Article IX, notify the Indemnifying Party in
writing of the commencement thereof. The omission of any Indemnified Party to so
notify the Indemnifying Party of any such action shall not relieve the
Indemnifying Party from any liability which it may have to such Indemnified
Party (a) other than pursuant to this Article IX or (b) under this Article IX
unless, and only to the extent that, such omission results in the Indemnifying
Party's forfeiture of substantive rights or defenses. In case any such Claim
shall be brought against any Indemnified Party, and it shall notify the
Indemnifying Party of the commencement thereof, the Indemnifying Party shall be
entitled to assume the defense thereof at its own expense, with counsel
satisfactory to such Indemnified Party in its reasonable judgment; provided,
however, that any Indemnified Party may, at its own expense, retain separate
counsel to participate in such defense at its own expense. Notwithstanding the
foregoing, in any Claim in which both the Indemnifying Party, on the one hand,
and an Indemnified Party, on the other hand, are, or are reasonably likely to
become, a party, such Indemnified Party shall have the right to employ separate
counsel and to control its own defense of such Claim if, in the reasonable
opinion of counsel to such Indemnified Party, either (x) one or more defenses
are available to the Indemnified Party that are not available to the
Indemnifying Party or (y) a conflict or potential conflict exists between the
Indemnifying Party, on the one hand, and such Indemnified Party, on the other
hand, that would make such separate representation advisable; provided, however,
that the Indemnifying Party (i) shall not be liable for the fees and expenses of
more than one counsel to all Indemnified Parties and (ii) shall reimburse the
Indemnified Parties for all of such fees and expenses of such counsel incurred
in any action between the Indemnifying Party and the Indemnified Parties or
between the Indemnified Parties and any third party, as such expenses are
incurred. The Indemnifying Party agrees that it will not, without the prior
written consent of the Purchasers, settle, compromise or consent to the entry of
any judgment in any pending or threatened Claim relating to the matters
contemplated hereby (if any Indemnified Party is a party thereto or has been
actually threatened to be made a party thereto) unless such settlement,
compromise or consent includes an unconditional release of each Indemnified
Party from all liability arising or that may arise out of such Claim. The
Indemnifying Party shall not be liable for any settlement of any Claim effected
against an Indemnified Party without its written consent, which consent shall
not be unreasonably withheld. The rights accorded to an Indemnified Party
hereunder shall be in addition to any rights that any Indemnified Party may have
at common law, by separate agreement or otherwise; provided, however, that
notwithstanding the foregoing or anything to the contrary contained in this
Agreement, nothing in this Article IX shall restrict or limit any rights that
any Indemnified Party may have to seek equitable relief.

     9.3  Contribution. If the indemnification provided for in this Article IX
from the Indemnifying Party is unavailable to an Indemnified Party hereunder in
respect of any Losses referred to herein, then the Indemnifying Party, in lieu
of indemnifying such Indemnified Party, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such Losses in such proportion
as is appropriate to reflect the relative fault of the Indemnifying Party and
Indemnified Party in connection with the

                                     - 26 -
<PAGE>   32

actions which resulted in such Losses, as well as any other relevant equitable
considerations. The relative faults of such Indemnifying Party and Indemnified
Party shall be determined by reference to, among other things, whether any
action in question, including any untrue or alleged untrue statement of a
material fact or omission or alleged omission to state a material fact, has been
made by, or relates to information supplied by, such Indemnifying Party or
Indemnified Party, and the parties relative intent, knowledge, access to
information and opportunity to correct or prevent such action. The amount paid
or payable by a party as a result of the Losses referred to above shall be
deemed to include, subject to the limitations set forth in Sections 9.1 and 9.2,
any legal or other fees, charges or expenses reasonably incurred by such party
in connection with any investigation or proceeding.

                                   ARTICLE X

                                   COVENANTS

     The Company hereby covenants and agrees with the Purchasers as follows:

     10.1 Conduct of Business of the Company. Except as contemplated by this
Agreement or with the prior written consent of the Purchasers, during the period
from the date of this Agreement to the Second Closing Date, the Company will
conduct its operations only in the ordinary course of business consistent with
past practice and, to the extent consistent therewith, with no less diligence
and effort then would be applied in the absence of this Agreement, will use its
reasonable best efforts to preserve intact the business organization of the
Company, to keep available the services of the present officers and key
employees of the Company, and to preserve the good will of customers, suppliers
and all other Persons having business relationships with the Company. Without
limiting the generality of the foregoing, and except as otherwise contemplated
by this Agreement, prior to the Second Closing Date, the Company will not,
without the prior written consent of the GAP Purchasers and ICP, acting
collectively, which consent will not be unreasonably withheld or delayed: (a)
engage in any transaction (including, without limitation, capital expenditures)
out of the ordinary course of its business and consistent with past practices;
(b) dispose of any of its assets or properties except to the extent these are
used, retired or replaced in the ordinary course of its business; (c) fail to
keep in force any governmental licenses, permits, authorizations, consents or
approvals required by the Company to own its assets and properties or to carry
on its business as currently conducted; (d) fail to keep in force its
Intellectual Property rights; (e) fail to perform all material obligations
required to be performed by it under any of the Material Contracts; (f) enter
into transactions with affiliates of the Company; (g) pay dividends to, or
redeem the shares of, stockholders of the Company other than pursuant to an
existing restricted stock purchase agreement with current or former employees;
and (h) amend the Certificate of Incorporation or the Bylaws of the Company.

                                     - 27 -
<PAGE>   33

     10.2 Satisfaction of Conditions.

          (a)  Subject to the terms and conditions of this Agreement, the
Company agrees to use its reasonable best efforts to cause the conditions set
forth in Articles V and VII of this Agreement to be satisfied, and to take, or
cause to be taken, all action and to do, or cause to be done, all things
necessary, proper or advisable under applicable laws and regulations to
consummate and make effective as promptly as practicable the transactions
contemplated by this Agreement, including cooperating fully with the other
parties to this Agreement, including by provision of information and making of
all necessary filings.

          (b)  Subject to the terms and conditions of this Agreement, each
Purchaser severally but not jointly agrees to use its reasonable best efforts to
cause the conditions set forth in Articles V and VII of this Agreement to be
satisfied, and to take, or cause to be taken, all action and to do, or cause to
be done, all things necessary, proper or advisable under applicable laws and
regulations to consummate and make effective as promptly as practicable the
transactions contemplated by this Agreement, including cooperating fully with
the other parties to this Agreement, including by provision of information and
making of all necessary filings.

     10.3 Preparation of the Proxy Statement; Stockholders Meeting.

          (a)  As promptly as practicable following the date of this Agreement,
the Company shall prepare and file with the SEC a proxy statement relating to
the adoption by the Company's stockholders of this Agreement (as amended or
supplemented from time to time, the "Proxy Statement") and the Company shall use
commercially reasonable efforts to respond as promptly as practicable to any
comments of the SEC with respect thereto and to cause the Proxy Statement to be
mailed to the Company's stockholders as promptly as practicable following the
date of this Agreement. The Company shall promptly notify the GAP Purchasers and
ICP upon the receipt of any comments from the SEC or its staff or any request
from the SEC or its staff for amendments or supplements to the Proxy Statement
and shall provide the GAP Purchasers and ICP with copies of all correspondence
between the Company and its representatives, on the one hand, and the SEC and
its staff, on the other hand. Notwithstanding the foregoing, prior to filing or
mailing the Proxy Statement (or any amendment or supplement thereto) or
responding to any comments of the SEC with respect thereto, the Company (i)
shall provide the GAP Purchasers and ICP an opportunity to review and comment on
such document or response, (ii) shall include in such document or response all
comments reasonably proposed by the Purchasers and (iii) shall not file or mail
such document or respond to the SEC prior to receiving the GAP Purchasers' and
ICP's approval, which approval shall not be unreasonably withheld or delayed.

          (b)  If requested by the Company, each Purchaser shall use its
commercially reasonable efforts to assist the Company in preparing the Proxy
Statement, including, without limitation, providing to the Company any
information regarding such Purchaser required to be included therein.

                                     - 28 -
<PAGE>   34

          (c)  The Company shall, as promptly as practicable following the date
of this Agreement, establish a record date (which will be as promptly as
reasonably practicable following the date of this Agreement) for, duly call,
give notice of, convene and hold a meeting of its stockholders (the
"Stockholders Meeting") for the purpose of obtaining the Requisite Company Vote.
The Company shall, through its Board of Directors, recommend to its stockholders
that they adopt this Agreement, and shall include such recommendation in the
Proxy Statement.

     10.4 Reservation of Common Stock. The Company shall at all times reserve
and keep available out of its authorized shares of Common Stock, solely for the
purpose of issue or delivery upon conversion of the Purchased Shares, as
provided in the Certificate of Designations, the maximum number of shares of
Common Stock that may be issuable or deliverable upon such conversion. Such
shares of Common Stock are duly authorized and, when issued or delivered in
accordance with the Certificate of Designations, shall be validly issued, fully
paid and non-assessable. The Company shall issue such shares of Common Stock, in
accordance with the terms of the Certificate of Designations, and otherwise
comply with the terms hereof and thereof.

     10.5 NASDAQ Listing.

          (a)  The Company shall use its best efforts to prevent the Common
Stock from being delisted on the NASDAQ Stock Market, including without
limitation, (i) taking all actions reasonably related to maintaining NASDAQ
listing standards including, but not limited to, the actions required pursuant
to Section 10.3, (ii) following recommendations by NASDAQ or advice of counsel
and (ii) refraining from taking actions reasonably expected to cause the Company
to not meet NASDAQ listing standards.

          (b)  If requested by the Company, each Purchaser shall use
commercially reasonable efforts to assist the Company in preparing any materials
to be submitted to NASDAQ by the Company for the purposes of maintaining the
Company's listing thereon.

     10.6 Approval by the Company's Stockholders. Subject to requirements of
applicable law, the board of directors of the Company shall recommend such
approval, adoption and authorization, and the Company shall take all reasonable
lawful action to solicit such approval, adoption and authorization of the
Stockholder Approval. At any such meeting of stockholders, all of the Shares
then owned by the Purchasers and their Affiliates will be voted in favor of the
Stockholder Approval. The Proxy Statement with respect to such meeting of
stockholders will conform to the requirements of this Agreement and, at the date
thereof and at the date of such meeting, will not include any untrue statement
of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements made therein, in light of the
circumstances under which they were made, not misleading; provided that the
foregoing shall not apply to the extent that any such untrue statement of a
material fact or omission to state a material fact was made by the Company in
reliance upon and in conformity with information concerning the Purchasers
furnished to the Company by the

                                     - 29 -
<PAGE>   35

Purchasers specifically for use in the Proxy Statement. No amendment or
supplement to the Proxy Statement will be made by the Company without
consultation with the GAP Purchasers, ICP and each of their legal counsels.

     10.7  Insurance. The Company currently maintains insurance with an
insurance company or association and it shall continue to maintain such
coverage.

     10.8  Books and Records. The Company shall keep proper books of record and
account, in which full and correct entries shall be made of all financial
transactions and the assets and business of the Company in accordance with GAAP
consistently applied.

     10.9  Back-ups of Computer Software. The Company shall make back-ups of all
material computer software programs and databases and shall maintain such
software programs and databases at secure off-site locations.

     10.10 Inspection. The Company shall permit representatives of the
Purchasers to visit and inspect any of its properties, to examine its corporate,
financial and operating records and make copies thereof or abstracts therefrom,
and to discuss its affairs, finances and accounts with their respective
directors, officers and independent public accountants, all at such reasonable
times during normal business hours and as often as may be reasonably requested
upon reasonable advance notice to the Company.

     10.11 Board of Directors. The Company will use its reasonable commercial
efforts to cause one of the vacancies on the Board of Directors to be filled by
a representative of MLB.com on or prior to the Second Closing Date.

                                   ARTICLE XI

                            TERMINATION OF AGREEMENT

     11.1  Termination. This Agreement may be terminated prior to the First
Closing as follows:

           (a) at any time on or prior to the First Closing Date, by mutual
written consent of the Company and the GAP Purchasers and ICP;

           (b) at the election of the Company or the Purchasers and ICP, acting
collectively, by written notice to the other parties hereto after 5:00 p.m., New
York time, on June 30, 2001 if the First Closing shall not have occurred, unless
such date is extended by the mutual written consent of the Company, the GAP
Purchasers and ICP; provided, however, that the right to terminate this
Agreement under this Section 11.1(b) shall not be available (i) to any party
whose breach of any representation, warranty, covenant or agreement under this
Agreement has been the cause of, or resulted in, the failure of the First
Closing to occur on or before such date or (ii) if the First Closing has not
occurred solely because any party hereto has not yet obtained a necessary
approval from any Governmental Authority;

                                     - 30 -
<PAGE>   36

          (c)  at the election of the Company, if there has been a material
breach of any representation, warranty, covenant or agreement on the part of any
of the Purchasers contained in this Agreement, which breach has not been cured
within fifteen (15) Business Days of notice to the Purchasers of such breach; or

          (d)  at the election of the GAP Purchasers and ICP, if there has been
a material breach of any representation, warranty, covenant or agreement on the
part of the Company contained in this Agreement, which breach has not been cured
within fifteen (15) Business Days notice to the Company of such breach.

     If this Agreement so terminates, it shall become null and void and have no
further force or effect, except as provided in Section 11.2.

     11.2 Survival. Notwithstanding Section 12.1, if this Agreement is
terminated and the transactions contemplated hereby are not consummated as
described above, this Agreement shall become void and of no further force and
effect, except for the provisions of Article I and this Section 11.2; provided,
however, that (a) none of the parties hereto shall have any liability in respect
of a termination of this Agreement pursuant to Section 11.1(a) or Section
11.1(b) and (b) nothing shall relieve any of the parties from liability for
actual damages resulting from a termination of this Agreement pursuant to
Section 11.1(c) or 11.1(d); and provided, further, that none of the parties
hereto shall have any liability for speculative, indirect, unforeseeable or
consequential damages or lost profits resulting from any legal action relating
to any termination of this Agreement.

                                   ARTICLE XII

                                  MISCELLANEOUS

     12.1 Survival of Representations and Warranties. All of the representations
and warranties made herein shall survive the execution and delivery of this
Agreement until the date that is ninety (90) days after the receipt by the
Purchasers of audited financial statements of the Company for the fiscal year
ending December 31, 2001 (or, if such fiscal year changes and no such audited
consolidated financial statements are available, then the successor fiscal
year), except for (a) Section 3.7, which shall survive until the later of the
third anniversary of the First Closing Date or the Second Closing Date, as the
case may be and (b) Section 3.11, which shall survive until the later to occur
of (i) the lapse of the statute of limitations with respect to the assessment of
any Tax to which such representation and warranty relates (including any
extensions or waivers thereof) and (ii) sixty (60) days after the final
administrative or judicial determination of the Taxes to which such
representation and warranty relates, and no claim with respect to Section 3.11
may be asserted thereafter with the exception of claims arising out of any fact,
circumstance, action or proceeding to which the party asserting such claim shall
have given notice to the other parties to this Agreement prior to the
termination of such period of reasonable belief that a tax liability will
subsequently arise therefrom.

                                     - 31 -
<PAGE>   37

     12.2 Notices. All notices, demands and other communications provided for or
permitted hereunder shall be made in writing and shall be by registered or
certified first-class mail, return receipt requested, telecopier, courier
service or personal delivery:

          (a)  if to the Company:

               Tickets.com
               555 Anton Boulevard, 12th Floor
               Costa Mesa, CA  92626
               Telecopy:  (714) 327-5410
               Attention:  W. Thomas Gimple

               with a copy to:

               Brobeck Phleger & Harrison LLP
               550 South Hope Street
               Los Angeles, CA 90071-2604
               Telecopy:  (213) 745-3345
               Attention:  Richard S. Chernicoff, Esq.

          (b)  if to the GAP Purchasers:

               c/o General Atlantic Service Corporation
               3 Pickwick Plaza
               Greenwich, CT 06830
               Telecopy:  (203) 622-8818
               Attention:  Steven A. Denning

               with a copy to:

               Paul, Weiss, Rifkind, Wharton & Garrison
               1285 Avenue of the Americas
               New York, NY 10019-6064
               Telecopy:  (212) 757-3990
               Attention:  Douglas A. Cifu, Esq.

          (c)  if to ICP:

               International Capital Partners, Inc., Profit
                  Sharing Trust
               300 First Stamford Place
               Stamford, CT 06902
               Telecopy:  (203) 969-2212
               Attention:  Nicholas E. Sinacori

                                     - 32 -
<PAGE>   38

               with copy to:

               Cummings & Lockwood
               Four Stamford Plaza
               Stamford, CT  06904
               Telecopy:  203-351-4534
               Attention:  Stephen Marcovich, Esq.

     All such notices, demands and other communications shall be deemed to have
been duly given when delivered by hand, if personally delivered; when delivered
by courier, if delivered by commercial courier service; five (5) Business Days
after being deposited in the mail, postage prepaid, if mailed; and when receipt
is mechanically acknowledged, if telecopied. Any party may by notice given in
accordance with this Section 12.2 designate another address or Person for
receipt of notices hereunder.

     12.3 Successors and Assigns; Third Party Beneficiaries. This Agreement
shall inure to the benefit of and be binding upon the successors and permitted
assigns of the parties hereto. Subject to applicable securities laws and the
terms and conditions thereof, (x) the Purchasers may assign any of their rights
under this Agreement or the Registration Rights Agreement to any of their
respective Affiliates and (y) ICP may assign its obligation to purchase up to
$4.0 million of the Purchased Shares to the accredited investors previously
identified to the Company and the GAP Purchasers pursuant to an assignment and
assumption agreement reasonably satisfactory to the Company and the GAP
Purchasers. The Company may not assign any of its rights under this Agreement
without the written consent of the GAP Purchasers and ICP. Except as provided in
Article IX, no Person other than the parties hereto and their successors and
permitted assigns is intended to be a beneficiary of this Agreement.

     12.4 Amendment and Waiver.

          (a)  No failure or delay on the part of the Company or the Purchasers
in exercising any right, power or remedy hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such right, power or
remedy preclude any other or further exercise thereof or the exercise of any
other right, power or remedy. The remedies provided for herein are cumulative
and are not exclusive of any remedies that may be available to the Company or
the Purchasers at law, in equity or otherwise.

          (b)  Any amendment, supplement or modification of or to any provision
of this Agreement, any waiver of any provision of this Agreement, and any
consent to any departure by the Company or the Purchasers from the terms of any
provision of this Agreement, shall be effective (i) only if it is made or given
in writing and signed by each of (A) the Company, (B) the GAP Purchasers and (C)
ICP, and (ii) only in the specific instance and for the specific purpose for
which made or given. For the avoidance of doubt, to the extent that any term or
condition herein (either generally or in a particular instance and either
retroactively or prospectively) may be waived or must be satisfied, only the
written consent of the GAP Purchasers and ICP shall be required to effect such
waiver on behalf of the Purchasers or for the satisfaction of such provision on
behalf of the Purchasers; provided, that any such waiver effected or

                                     - 33 -
<PAGE>   39

satisfaction granted in accordance with this sentence shall be binding upon each
holder of any securities purchased under this Agreement at the time outstanding
(including securities into which such securities are convertible) and each
future holder of all such securities. Except where notice is specifically
required by this Agreement, no notice to or demand on the Company in any case
shall entitle the Company to any other or further notice or demand in similar or
other circumstances.

     12.5  Counterparts. This Agreement may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same agreement.

     12.6  Headings. The headings in this Agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

     12.7  GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE
PRINCIPLES OF CONFLICTS OF LAW THEREOF.

     12.8  Severability. If any one or more of the provisions contained herein,
or the application thereof in any circumstance, is held invalid, illegal or
unenforceable in any respect for any reason, the validity, legality and
enforceability of any such provision in every other respect and of the remaining
provisions hereof shall not be in any way impaired, unless the provisions held
invalid, illegal or unenforceable shall substantially impair the benefits of the
remaining provisions hereof.

     12.9  Rules of Construction. Unless the context otherwise requires,
references to sections or subsections refer to sections or subsections of this
Agreement.

     12.10 Entire Agreement. This Agreement, together with the exhibits and
schedules hereto, and the Registration Rights Agreement are intended by the
parties as a final expression of their agreement and intended to be a complete
and exclusive statement of the agreement and understanding of the parties hereto
in respect of the subject matter contained herein and therein. There are no
restrictions, promises, representations, warranties or undertakings, other than
those set forth or referred to herein or therein. This Agreement, together with
the exhibits and schedules hereto, and the Registration Rights Agreement
supersede all prior agreements and understandings between the parties with
respect to such subject matter.

     12.11 Fees. Upon each of the First Closing and the Second Closing, the
Company shall reimburse each of the Purchasers for all of their reasonable fees,
disbursements and other charges of counsel reasonably incurred in connection
with the transactions contemplated by this Agreement; provided, that each of the
Purchasers shall have purchased the aggregate number of shares of Preferred
Stock set forth opposite such Purchaser's name on Schedules 2.1 or 2.3 hereto,

                                     - 34 -
<PAGE>   40

as the case may be, for the aggregate purchase price set forth opposite such
Purchaser's name on Schedules 2.1 and 2.3 hereto, as the case may be (the
"Aggregate Investment"). In the event that the Company does not consummate the
Aggregate Investment, the Company shall reimburse each of the Purchasers for all
of their reasonable fees, disbursements and other charges of counsel reasonably
incurred in connection with the transactions contemplated by this Agreement, up
to an aggregate amount of $100,000; provided, that the Purchasers have not
materially changed the terms and conditions set forth in this Agreement.

     12.12 Publicity; Confidentiality. Except as may be required by applicable
Requirements of Law, none of the parties hereto shall issue a publicity release
or public announcement or otherwise make any disclosure concerning this
Agreement, the transactions contemplated hereby, the Purchasers or the financial
affairs or proprietary information of the Company, without prior approval by the
other parties hereto; provided, however, that nothing in this Agreement shall
restrict any of the Purchasers from disclosing information (a) that is already
publicly available, (b) that was known to such Purchaser on a non-confidential
basis prior to its disclosure by the Company, (c) that may be required or
appropriate in response to any summons or subpoena or in connection with any
litigation, provided that such Purchaser will use reasonable efforts to notify
the Company in advance of such disclosure so as to permit the Company to seek a
protective order or otherwise contest such disclosure, and such Purchaser will
use reasonable efforts to cooperate, at the expense of the Company, with the
Company in pursuing any such protective order, (d) to the extent that such
Purchaser reasonably believes it appropriate in order to protect its investment
in the Purchased Shares or in order to comply with any Requirement of Law, (e)
to such Purchaser's or the Company's officers, directors, shareholders,
advisors, employees, members, partners, controlling persons, auditors or counsel
or (f) to Persons from whom releases, consents or approvals are required, or to
whom notice is required to be provided, pursuant to the transactions
contemplated by the Registration Rights Agreement; and provided further, that
GAP LLC and ICP may disclose on their worldwide web pages the name of the
Company, the name of the Chief Executive Officer of the Company, a brief
description of the business of the Company and the aggregate amount of each of
the Purchasers' investment in the Company. If any announcement is required by
law or the rules of any securities exchange or market on which shares of Common
Stock are traded to be made by any party hereto, prior to making such
announcement such party will deliver a draft of such announcement to the other
parties and shall give the other parties reasonable opportunity to comment
thereon.

     12.13 Further Assurances. Each of the parties shall execute such documents
and perform such further acts (including, without limitation, obtaining any
consents, exemptions, authorizations or other actions by, or giving any notices
to, or making any filings with, any Governmental Authority or any other Person)
as may be reasonably required or desirable to carry out or to perform the
provisions of this Agreement.

     12.14 Legal Representation. It is acknowledged that the GAP Purchasers have
retained Paul, Weiss, Rifkind, Wharton & Garrison to act as their counsel in
connection with the transactions contemplated by the Registration Rights
Agreement and that Paul, Weiss, Rifkind, Wharton & Garrison has not acted as
counsel for ICP in

                                     - 35 -
<PAGE>   41

connection with the transaction contemplated by the Transaction Documents and
that ICP does not have the status of a client of Paul, Weiss, Rifkind, Wharton &
Garrison for conflict of interest or any other purposes as a result thereof.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                     - 36 -
<PAGE>   42

     IN WITNESS WHEREOF, the undersigned have executed, or have caused to be
executed, this Stock Purchase Agreement on the date first written above.

                                         TICKETS.COM, INC.

                                         By: /s/ W. THOMAS GIMPLE
                                             -----------------------------------
                                         Name: W. Thomas Gimple
                                         Title: Chief Executive Officer

                                         GENERAL ATLANTIC PARTNERS 74, L.P.

                                         By:  GENERAL ATLANTIC PARTNERS, LLC,
                                                its General Partner

                                              By: /s/ BRADEN R. KELLY
                                                  ------------------------------
                                              Name: Braden R. Kelly
                                              Title: A Managing Member

                                         GAP COINVESTMENT PARTNERS II, L.P.

                                         By: /s/ BRADEN R. KELLY
                                             -----------------------------------
                                         Name: Braden R. Kelly
                                         Title: A General Partner

                                         GAPSTAR, LLC

                                         By: GENERAL ATLANTIC PARTNERS, LLC,
                                               its Managing Member

                                             By: /s/ BRADEN R. KELLY
                                                 -------------------------------
                                             Name: Braden R. Kelly
                                             Title: A Managing Member

                                     - 37 -
<PAGE>   43

                                         INTERNATIONAL CAPITAL PARTNERS, INC.,
                                           PROFIT SHARING TRUST

                                         By: /s/ N.E. SINACORI
                                             -----------------------------------
                                         Name: N.E. Sinacori
                                         Title: Trustee

                                     - 38 -
<PAGE>   44

                                                                    Schedule 2.1

                   Initial Purchased Shares and Purchase Price

<TABLE>
<CAPTION>
              Purchaser                       Initial Purchased Shares             Purchase Price
              ---------                       ------------------------             --------------
<S>                                           <C>                                  <C>

GAP LP                                                6,242,145                      $3,745,287
GAP Coinvestment                                        867,230                      $  520,338
GapStar                                                 473,958                      $  284,375
International Capital Partners, Inc.                  3,250,000                      $1,950,000
                                                     ----------                      ----------
                                     Total:          10,833,333                      $6,500,000
                                                     ==========                      ==========
</TABLE>

<PAGE>   45

                                                                    Schedule 2.3

                 Additional Purchased Shares and Purchase Price

<TABLE>
<CAPTION>
              Purchaser                       Additional Purchased Shares          Purchase Price
              ---------                       ---------------------------          --------------
<S>                                           <C>                                  <C>

GAP LP                                                 8,162,805                     $4,897,683
GAP Coinvestment                                       1,134,070                     $  680,442
GapStar                                                  619,792                     $  371,875
International Capital Partners, Inc.                   4,250,000                     $2,550,000
                                                      ----------                     ----------
                                     Total:           14,166,667                     $8,500,000
                                                      ==========                     ==========
</TABLE>

<PAGE>   46

                                                                       EXHIBIT B

                                TICKETS.COM, INC.

                    CERTIFICATE OF THE POWERS, DESIGNATIONS,

                          PREFERENCES AND RIGHTS OF THE

             SERIES F SENIOR CUMULATIVE REDEEMABLE PREFERRED STOCK,

                          PAR VALUE $0.000225 PER SHARE

         Pursuant to Section 151 of the Delaware General Corporation Law

     The undersigned, W. Thomas Gimple, Chief Executive Officer of Tickets.com,
Inc., a Delaware corporation (the "Corporation"), DOES HEREBY CERTIFY that the
following resolution, creating a series of ________________ shares of preferred
stock was duly adopted by the Board of Directors of the Corporation (the "Board
of Directors"), on ____________ __, 2001.

     WHEREAS, the Board of Directors is authorized, within the limitations and
restrictions stated in the Certificate of Incorporation of the Corporation (the
"Certificate of Incorporation"), to provide by resolution or resolutions for the
issuance of shares of preferred stock, par value $0.000225 per share, of the
Corporation, in one or more classes or series with such voting powers, full or
limited, or no voting powers, and such designations, preferences and relative,
participating, optional or other special rights, and qualifications, limitations
or restrictions as shall be stated and expressed in the resolution or
resolutions providing for the issuance thereof adopted by the Board of
Directors, and as are not stated and expressed in the Certificate of
Incorporation, or any amendment thereto, including (but without limiting the
generality of the foregoing) such provisions as may be desired concerning
voting, redemption, dividends, dissolution or the distribution of assets and
such other subjects or matters as may be fixed by resolution or resolutions of
the Board of Directors under the General Corporation Law of the State of
Delaware; and

     WHEREAS, it is the desire of the Board of Directors, pursuant to its
authority as aforesaid, to authorize and fix the terms of a series of preferred
stock and the number of shares constituting such series.

     NOW, THEREFORE, BE IT RESOLVED:

     1.   Designation and Number of Shares. There shall be hereby created and
established a series of preferred stock designated as "Series F Senior
Cumulative Redeemable Preferred Stock" (the "Series F Preferred Stock"). The
authorized number of shares of Series F Preferred Stock shall be [ ].
Capitalized terms used herein and not otherwise defined shall have the meanings
set forth in Section 10 below.

<PAGE>   47
                                                                               2

     2.   Rank.

          (a)  The Series F Preferred Stock shall with respect to dividends,
distributions of assets and rights upon the occurrence of a Liquidation rank
senior to (i) all classes of common stock of the Corporation (including, without
limitation, the Common Stock, par value $0.000225 per share, of the Corporation
(the "Common Stock")) and (ii) each other class or series of Capital Stock of
the Corporation (the "Junior Stock") hereafter created which does not expressly
rank pari passu with or senior to the Series F Preferred Stock.

          (b)  The Series F Preferred Stock shall, with respect to payment
of the Participation Payment upon the occurrence of a Sale Transaction, rank
senior to the Junior Stock.

          (c)  Notwithstanding anything to the contrary contained in the
Certificate of Incorporation, the vote of the holders of a majority of the
Series F Preferred Stock shall be a prerequisite to the designation or issuance
of any shares of Capital Stock ranking pari passu with or senior to the Series F
Preferred Stock in the event of a Liquidation or with respect to the payment of
dividends or the Participation Payment.

     3.   Dividends.

          (a)  If the Corporation declares and pays cash dividends on the Common
Stock then, in that event, the holders of shares of Series F Preferred Stock
shall be entitled to share in such dividends on a pro rata basis, as if their
shares had been converted into shares of Common Stock pursuant to Section 7(a)
below immediately prior to the record date for determining the stockholders of
the Corporation eligible to receive such dividends.

          (b)  The holders of shares of Series F Preferred Stock shall be
entitled to receive, out of funds legally available therefor, cumulative
dividends at an annual rate equal to the excess (if any) of (i) 9% of the
Accreted Value over (ii) any cash dividends paid in accordance with Section 3(a)
above, calculated on the basis of a 360-day year, consisting of twelve 30-day
months, and such dividends shall accrue quarterly from the date of issuance
thereof, whether or not declared. Accrued and unpaid dividends shall compound on
a quarterly basis and be added to the Accreted Value of each share of Series F
Preferred Stock. The Board of Directors may fix a record date for the
determination of holders of shares of Series F Preferred Stock entitled to
receive payment of such dividends, which record date shall not be more than
sixty (60) days prior to the applicable dividend payment date. All accrued and
unpaid dividends, if any, shall, to the extent funds are legally available
therefor, be mandatorily paid immediately prior to the earlier to occur of (i) a
Liquidation, (ii) an optional conversion of shares of Series F Preferred Stock
pursuant to Section 7(a) below, (iii) an automatic conversion of shares of
Series F Preferred Stock pursuant to Section 7(b) below and (iv) a redemption of
shares of Series F Preferred Stock pursuant to Section 5 hereof (the "Mandatory
Dividend Payment Date").

<PAGE>   48
                                                                               3

          (c)  On the Mandatory Dividend Payment Date, all accrued dividends
shall be paid, (x) in the case of a Liquidation or a redemption pursuant to
Section 5 below, in cash, (y) in the case of an optional conversion or an
automatic conversion triggered by a Sale Transaction, in shares of Common Stock
or in cash, at the option of the holders of a majority of the shares of the
Series F Preferred Stock. If dividends are to be paid in shares of Common Stock
pursuant to the preceding sentence, the value of such shares shall be
determined, (A) in the case of a Sale Transaction (other than as set forth in
clause (B), below), by the Net Per Share Price paid for shares of Common Stock
on such Sale Transaction or (B) in the case of a Sale Transaction in which no
Net Per Share Price is paid for shares of Common Stock or in the case of an
optional conversion of shares of Series F Preferred Stock, in good faith by the
Board of Directors.

     4.   Liquidation Preference.

          (a)  Participation Payment. Upon the occurrence of a Liquidation, the
holders of shares of Series F Preferred Stock shall be entitled (i) to be paid
for each share of Series F Preferred Stock held thereby, out of, but only to the
extent of, the assets of the Corporation legally available for distribution to
its stockholders, an amount equal to the sum of (A) the Accreted Value per share
plus (B) as provided in Section 3 above, all accrued and unpaid dividends, if
any, with respect to each share of Series F Preferred Stock, up to the date
fixed for such liquidation (together with the Accreted Value, the "Participation
Payment"), before any payment or distribution is made to any Junior Stock, and
(ii) such number of fully paid and non-assessable shares of Common Stock as is
equal to the product of the number of shares of Series F Preferred Stock held
thereby and the quotient of (X) the Accreted Value divided by (Y) the conversion
price of $0.60 per share, subject to adjustment as provided in Section 7(d)
below. If the assets of the Corporation available for distribution to the
holders of shares of Series F Preferred Stock shall be insufficient to permit
payment in full to such holders of the sums to which such holders are entitled
to receive in such case, then all of the assets available for distribution to
holders of shares of Series F Preferred Stock shall be distributed among and
paid to such holders ratably in proportion to the amounts that would be payable
to such holders if such assets were sufficient to permit payment in full.

          (b)  No Additional Payment. After the holders of all shares of Series
F Preferred Stock shall have been paid in full the amounts to which they are
entitled in Section 4(a) above, the holders of shares of Series F Preferred
Stock shall not be entitled to any further participation in any distribution of
assets of the Corporation and the remaining assets of the Corporation shall be
distributed to the holders of the Junior Stock.

          (d)  Notice. Written notice of a Liquidation stating a payment or
payments and the place where such payment or payments shall be payable, shall be
delivered in person, mailed by certified mail, return receipt requested, mailed
by overnight mail or sent by telecopier, not less than ten (10) days prior to
the earliest payment date stated therein, to the holders of record of shares of
Series F Preferred Stock,

<PAGE>   49
                                                                               4

such notice to be addressed to each such holder at its address as shown by the
records of the Corporation.

          (e)  Sale Transactions. A Sale Transaction shall be deemed to be a
Liquidation pursuant to this Section 4, and the shares of Series F Preferred
Stock shall automatically convert into the consideration specified in Section
7(b) hereof.

     5.   Redemption.

          (a)  Optional Redemption.

               (i)   The Corporation shall not have any right to redeem any
shares of Series F Preferred Stock prior to ________ , 2003. On and after
___________, 2003 but prior to _______________ , 2006 (any such date, an
"Optional Redemption Measurement Date"), if the Redemption Per Share Price on
such Optional Redemption Measurement Date exceeds the amounts set forth in the
chart that follows with respect to such applicable Optional Redemption Date
(expressed as a percentage of the Conversion Price), (the "Hurdle Rate"), the
Corporation shall have the right, as its sole option and election, to redeem
(unless otherwise prevented by law) all, but not less than all, of the shares of
Series F Preferred Stock in cash, at a price per share equal to the greater of
either (i) the sum of (x) the Accreted Value plus (y) as provided in Section 3
above, all accrued and unpaid dividends through the Optional Redemption
Measurement Date, if any, with respect to each share of Series F Preferred
Stock, or (ii) the product of the Per Share Price as of the Optional Redemption
Measurement Date and the number of shares of Common Stock into which the Series
F Preferred Stock is convertible on such date (as provided in Section 7(a)
below, in immediately available funds:

                                               HURDLE RATE AS A PERCENTAGE
            IF REDEEMED DURING THE PERIOD        OF THE CONVERSION PRICE
          ---------------------------------    ---------------------------

          ________, 2003 to _________, 2004                200%
          ________, 2004 to _________, 2005                250%
          ________, 2005 to _________, 2006                300%

               (ii)  Written notice of any election by the Corporation to redeem
the shares of Series F Preferred Stock pursuant to this Section 5(a) and the
date selected for such redemption (the "Optional Redemption Date") shall be
delivered in person, mailed by certified mail, return receipt requested, mailed
by overnight mail or sent by telecopier not less than thirty (30), nor more than
sixty (60), days prior to such Optional Redemption Date to the holders of record
of the shares of Series F Preferred Stock such notice to be addressed to each
such holder at its address as shown in the records of the Corporation. The total
sum payable per share of Series F Preferred Stock to be redeemed (the "Optional
Redeemed Shares") on such Optional Redemption Date is referred to as the
"Optional Redemption Price," and the payment to be made on such Optional
Redemption Date for the Optional Redeemed Shares is referred to as the "Optional
Redemption Payment." The Optional Redemption Payment shall be made by

<PAGE>   50
                                                                               5

wire transfer of immediately available funds to accounts designated in writing
by the holders of shares of Series F Preferred Stock. Upon notice from the
Corporation, each holder of shares of Series F Preferred Stock so redeemed shall
promptly surrender to the Corporation, at any place where the Corporation shall
maintain a transfer agent for its shares of Series F Preferred Stock,
certificates representing the shares so redeemed, duly endorsed in blank or
accompanied by proper instruments of transfer. Notwithstanding anything to the
contrary set forth in this Certificate of Designation, any holder of Series F
Preferred Stock may convert its shares of Series F Preferred Stock pursuant to
Section 7(a) until the Optional Redemption Price has been paid by the
Corporation to any such holders hereof.

               (iii) Termination of Rights. If shares of Series F Preferred
Stock are to be redeemed pursuant to Section 5(a) above, then on and after such
Optional Redemption Date, all rights of any holder of such shares of Series F
Preferred Stock shall cease and terminate; and such Optional Redeemed Shares
shall no longer be deemed to be outstanding, whether or not the certificates
representing such shares have been received by the Corporation; provided,
however, that, if the Corporation defaults in the payment of the Optional
Redemption Payment, the rights of the holders of such shares of Series F
Preferred Stock shall continue until the Corporation cures such default.

          (b)  Automatic Redemption. On the date that is five (5) years after
the date shares of Series F Preferred Stock are initially issued (the "Automatic
Redemption Date"), such shares of Series F Preferred Stock shall automatically,
with no further action required to be taken by the Corporation or the holder
thereof, be redeemed (unless otherwise prevented by law) in cash, at a
redemption price per share equal to the greater of (i) the Accreted Value plus,
as provided in Section 3 above, all accrued and unpaid dividends through the
Automatic Redemption Date, if any, with respect to each share of Series F
Preferred Stock or (ii) the product of the Per Share Price and the number of
shares of Common Stock into which the Series F Preferred Stock is convertible on
such Automatic Redemption Date. Written notice of such Automatic Redemption Date
shall be delivered in person, mailed by certified mail, return receipt
requested, mailed by overnight mail or sent by telecopier not less than thirty
(30), nor more than sixty (60), days prior to the Automatic Redemption Date to
the holders of record of the shares of Series F Preferred Stock such notice to
be addressed to each such holder at its address as shown in the records of the
Corporation. The total sum payable per share of Series F Preferred Stock to be
redeemed (the "Redeemed Shares") on the Automatic Redemption Date is referred to
as the "Redemption Price," and the payment to be made on the Automatic
Redemption Date for the Redeemed Shares is referred to as the "Redemption
Payment." The Redemption Payment shall be made by wire transfer of immediately
available funds to accounts designated in writing by the holders of shares of
Series F Preferred Stock. Upon notice from the Corporation, each holder of
shares of Series F Preferred Stock so redeemed shall promptly surrender to the
Corporation, at any place where the Corporation shall maintain a transfer agent
for its shares of Series F Preferred Stock, certificates representing the shares
so redeemed, duly endorsed in blank or accompanied by proper instruments of
transfer. Notwithstanding anything to the contrary set forth in this Certificate
of Designation, any holder of Series F Preferred Stock may

<PAGE>   51
                                                                               6

convert its shares of Series F Preferred Stock pursuant to Section 7(a) hereof
until the Redemption Price has been paid by the Corporation to any such holders
hereto.

               (i)   Termination of Rights. If shares of Series F Preferred
Stock are to be redeemed pursuant to Section 5(b) above, then, except as set
forth in Section 5(b)(ii) below, on and after the Automatic Redemption Date, all
rights of any holder of such shares of Series F Preferred Stock shall cease and
terminate; and such Redeemed Shares shall no longer be deemed to be outstanding,
whether or not the certificates representing such shares have been received by
the Corporation; provided, however, that, if the Corporation defaults in the
payment of the Redemption Payment, the rights of the holders of such shares of
Series F Preferred Stock shall continue until the Corporation cures such
default.

               (ii)  Insufficient Funds for Redemption. If the funds of the
Corporation available for redemption of the Redeemed Shares on the Automatic
Redemption Date are insufficient to redeem the Redeemed Shares on such date, the
holders of Redeemed Shares shall share ratably in any funds available by law for
redemption of such shares according to the respective amounts which would be
payable with respect to the number of shares owned by them if the shares to be
so redeemed on such Automatic Redemption Date were redeemed in full. Any
Redeemed Shares that the Corporation is not able to redeem on the Automatic
Redemption Date due to insufficient funds shall continue to be outstanding until
redeemed and dividends on such shares shall continue to accrue and cumulate
until redeemed. The Corporation shall in good faith use all reasonable efforts
as expeditiously as possible to eliminate, or obtain an exception, waiver or
exemption from, any and all restrictions that prevented the Corporation from
paying the Redemption Price and redeeming all of the Redeemed Shares. At any
time thereafter when additional funds of the Corporation are available by law
for the redemption of the Redeemed Shares, such funds shall be used, at the end
of the next succeeding fiscal quarter, to redeem the balance of such shares, or
such portion thereof for which funds are available, on the basis set forth
above.

     6.   Voting Rights.

          (a)  In addition to the voting rights to which the holders of Series F
Preferred Stock are entitled under or granted by Delaware law, the holders of
Series F Preferred Stock shall be entitled to vote, in person or by proxy, at a
special or annual meeting of stockholders or in any written consent in lieu of
meeting, on all matters entitled to be voted on by holders of shares of Common
Stock voting together as a single class with the Common Stock (and with other
shares entitled to vote thereon, if any). With respect to any such vote, each
share of Series F Preferred Stock shall entitle the holder thereof to cast that
number of votes as is equal to the number of votes that such holder would be
entitled to cast had such holder converted its shares of Series F Preferred
Stock into shares of Common Stock pursuant to Section 7(a) below on the record
date for determining the stockholders of the Corporation eligible to vote on any
such matters.

          (b)  From and after the date hereof, General Atlantic Partners 74,
L.P. ("GAP LP"), GAP Coinvestment Partners II, L.P. ("GAP

<PAGE>   52
                                                                               7

Coinvestment"), GapStar, LLC ("GapStar") and/or any Affiliate thereof in the
aggregate own at least a majority of the outstanding shares of Series F
Preferred Stock, then the holders of shares of Series F Preferred Stock, voting
as a separate class, shall be entitled to elect two directors of the Corporation
(the "Series F Directors"). In addition, from and after August 15, 2001, if GAP
LP, GAP Coinvestment and GapStar and/or any Affiliate thereof in the aggregate
own at least a majority of the outstanding shares of Series F Preferred Stock,
then the holders of shares of Series F Preferred Stock, voting as a separate
class, shall be entitled to elect one additional director of the Corporation
(the "Additional Series F Director").

          (c)  Extraordinary Actions. Notwithstanding anything otherwise to the
contrary contained in this Certificate of Designation or the Certificate of
Incorporation, provided that fifty percent (50%) of the shares of Series F
Preferred Stock remain outstanding, none of the following actions may be taken,
directly or indirectly by the Corporation ("Extraordinary Actions") without the
approval of the holders of a majority of all issued and outstanding shares of
Series F Preferred Stock voting together as a single class, in person or by
proxy, at a special or annual meeting or by written consent:

               (i)   any modification, amendment or alteration or change to the
Certificate of Incorporation or the bylaws of the Corporation that would affect
the rights, preferences, powers (including, without limitation, voting powers)
and privileges of the Series F Preferred Stock;

               (ii)  the issuance, reservation for issuance or authorization of
any Capital Stock of the Corporation (excluding shares issuable upon the
exercise conversion of the Series F Preferred Stock or any other securities
convertible into or exchangeable for shares of capital stock issued and
outstanding on the date hereof and shares of Common Stock issuable upon exercise
of options granted pursuant to the Stock Option Plan), or any increase or
decrease in the authorized number of shares of Series F Preferred Stock;

               (iii) the redemption for cash of any Capital Stock that is junior
to, or pari passu with, the Series F Preferred Stock (other than the repurchase
of unvested Common Stock from employees, directors or consultants upon
termination of their employment with, or service to, the Corporation);

               (iv)  the declaration or payment of any dividend or other
distribution on or in respect of any Capital Stock that is junior to or pari
passu with the Series F Preferred Stock (other than dividends payable to holders
of Series F Preferred Stock and stock dividends);

               (v)   any action that results in a deemed dividend to the Series
F Preferred Stock under section 305 of the Internal Revenue Code;

<PAGE>   53
                                                                               8

               (vi)   the Corporation or any of its Subsidiaries issuing,
assuming or otherwise becoming liable for any long term debt in excess of
$3,000,000 in the aggregate;

               (vii)  the Corporation making or causing any Subsidiaries of the
Corporation to make, an aggregate amount of capital expenditures in excess of
(i) $1,500,000 individually or $4,000,000 in the aggregate in any 12-month
period, or (ii) $1,000,000, not included in the annual operating budget approved
by the Board of Directors;

               (viii) any change in the material accounting methods or policies
of the Corporation;

               (ix)   approval of the Liquidation of the Corporation or the
approval, authorization or recommendation of any Sale Transaction; and

               (x)    any modification of the number of directors constituting
the entire Board of Directors or any amendment or modification of this Section
6(c).

          (d)  In order to effect the provisions of Section 6(b), the Series F
Preferred Stock shall vote together as a single class with the Common Stock (and
all other classes and series of stock of the Corporation entitled to vote
thereon, if any) with respect to the election of all of the directors of the
Corporation. If the conditions set forth in the first sentence of Section 6(b)
necessary for the holders of shares of Series F Preferred Stock to vote as a
separate class for the election of directors are not satisfied, the Series F
Preferred Stock shall vote together as a single class with the Common Stock (and
all other classes and series of stock of the Corporation entitled to vote
thereon, if any) with respect to the election of all of the directors of the
Corporation elected by such holders. At any meeting held for the purpose of
electing directors or approving an Extraordinary Action, at a time when the
holders of shares of Series F Preferred Stock are entitled to vote as a separate
class for the election of directors and approval of an Extraordinary Action, the
presence in person or by proxy of the holders of a majority of the shares of
Series F Preferred Stock then outstanding shall constitute a quorum of the
Series F Preferred Stock for the election of the Series F Directors and the
Additional Series F Director and approval of an Extraordinary Action; the
holders of shares of Series F Preferred Stock shall be entitled to cast one vote
per share of Series F Preferred Stock in any such election; and the Series F
Directors and the Additional Series F Director shall be elected, or the
Extraordinary Action approved by the affirmative vote of the holders of a
majority of the outstanding shares of Series F Preferred Stock. A vacancy in the
directorship filled by the holders of the Series F Preferred Stock voting as a
separate class pursuant to this Section 6(d) shall be filled only by vote or
written consent of the holders of shares of Series F Preferred Stock.

<PAGE>   54
                                                                               9

     7.   Conversion.

          (a)  Optional Conversion. Any holder of shares of Series F Preferred
Stock shall have the right, at its option, at any time and from time to time, to
convert, subject to the terms and provisions of this Section 7, any or all of
such holder's shares of Series F Preferred Stock into such number of fully paid
and non-assessable shares of Common Stock as is equal to the product of the
number of shares of Series F Preferred Stock being so converted multiplied by
the quotient of (i) the Accreted Value divided by (ii) the conversion price of
$0.60 per share, subject to adjustment as provided in Section 7(d) below (such
price as in clause (ii), the "Conversion Price"). Such conversion right shall be
exercised by the surrender of certificate(s) representing the shares of Series F
Preferred Stock to be converted to the Corporation at any time during usual
business hours at its principal place of business to be maintained by it (or
such other office or agency of the Corporation as the Corporation may designate
by notice in writing to the holders of shares of Series F Preferred Stock),
accompanied by written notice that the holder elects to convert such shares of
Series F Preferred Stock and specifying the name or names (with address) in
which a certificate or certificates for shares of Common Stock are to be issued
and (if so required by the Corporation) by a written instrument or instruments
of transfer in form reasonably satisfactory to the Corporation duly executed by
the holder or its duly authorized legal representative and transfer tax stamps
or funds therefor, if required pursuant to Section 7(j) below. All certificates
representing shares of Series F Preferred Stock surrendered for conversion shall
be delivered to the Corporation for cancellation and canceled by it. As promptly
as practicable after the surrender of any shares of Series F Preferred Stock,
the Corporation shall (subject to compliance with the applicable provisions of
federal and state securities laws) deliver to the holder of such shares so
surrendered certificate(s) representing the number of fully paid and
non-assessable shares of Common Stock into which such shares are entitled to be
converted and, to the extent funds are legally available therefor, an amount
equal to all accrued and unpaid dividends, if any, payable with respect to such
shares in accordance with Section 3 above. At the time of the surrender of such
certificate(s), the Person in whose name any certificate(s) for shares of Common
Stock shall be issuable upon such conversion shall be deemed to be the holder of
record of such shares of Common Stock on such date, notwithstanding that the
share register of the Corporation shall then be closed or that the certificates
representing such Common Stock shall not then be actually delivered to such
Person.

          (b)  Automatic Conversion.

               (i)   Simultaneously with the closing of a Sale Transaction, each
outstanding share of Series F Preferred Stock shall be automatically converted,
with no further action required to be taken by the Corporation or the holder
thereof, into the following:

                    (A)  the Participation Payment; and

                    (B)  the number of fully paid and non-assessable shares of
Common Stock equal to the product of the number of shares of Series F

<PAGE>   55
                                                                              10

Preferred Stock being converted and the quotient of (x) the Accreted Value
divided by (y) the Conversion Price then in effect (after giving effect to any
adjustments pursuant to Section 7(d) below).

               (ii)  The Participation Payment set forth in Section 7(b)(i)
above shall be in addition to and not in lieu of accrued and unpaid dividends,
if any, payable in accordance with Section 3 above and shall be payable, to the
extent funds are legally available therefor, in the case of a Sale Transaction,
in cash or, at the option of the holders of a majority of shares of Series F
Preferred Stock, in shares of Common Stock if such shares remain outstanding
following the Sale Transaction or in the consideration to be received by holders
of shares of Common Stock. If the Participation Payment is to be paid in shares
of Common Stock, the value of such shares of Common Stock shall be determined
(A) in the case of a Sale Transaction (other than as set forth in clause (B),
below), by the Net Per Share Price paid for shares of Common Stock in such Sale
Transaction, or (B) in the case of a Sale Transaction in which no Net Per Share
Price is paid for shares of Common Stock, in good faith by the Board of
Directors.

               (iii) Any securities of the surviving Person to be delivered to
the holders of shares of Series F Preferred Stock pursuant to this Section 7(b)
shall be valued as follows:

                    (A)  With respect to securities that do not constitute
"restricted securities," as such term is defined in Rule 144(a)(3) promulgated
under the Securities Act, the value shall be deemed to be the Current Market
Price of such securities as of three (3) days prior to the date of distribution.

                    (B)  With respect to securities that constitute "restricted
securities," as such term is defined in Rule 144(a)(3) promulgated under the
Securities Act, and that are of the same class or series as securities that are
publicly traded, the value shall be adjusted to make an appropriate discount
from the value as set forth in Section 7(b)(iii)(A) above to reflect the
appropriate fair market value thereof, as mutually determined by the Board of
Directors and the holders of a majority of the shares of Series F Preferred
Stock, or if there is no active public market with respect to such class or
series of securities, such securities shall be valued in accordance with Section
7(b)(iii)(A) above, giving appropriate weight, if any, to such restriction as
determined in good faith by the Board of Directors.

               (iv)  Immediately upon conversion as provided herein, each holder
of shares of Series F Preferred Stock shall be deemed to be the holder of record
of the Common Stock issuable upon conversion of such holder's shares of Series F
Preferred Stock, notwithstanding that the share register of the Corporation
shall then be closed or that certificates representing the Common Stock shall
not then actually be delivered to such Person. Upon written notice from the
Corporation, each holder of shares of Series F Preferred Stock so converted
shall promptly surrender to the Corporation at its principal place of business
to be maintained by it (or at such other office or agency of the Corporation as
the Corporation may designate by such notice to

<PAGE>   56
                                                                              11

the holders of shares of Series F Preferred Stock) certificates representing the
shares so converted.

          (c)  Termination of Rights. On the date of such optional conversion
pursuant to Section 7(a) above or of such automatic conversion pursuant to
Section 7(b) above, all rights with respect to the shares of Series F Preferred
Stock so converted, including the rights, if any, to receive notices and vote,
shall terminate, except only the rights of holders thereof to (i) receive
certificates for the number of shares of Common Stock into which such shares of
Series F Preferred Stock have been converted, (ii) receive the Participation
Payment in the case of an automatic conversion pursuant to Section 7(b) above,
(iii) the payment of dividends, if any, pursuant to Section 3 above and (iv)
exercise the rights to which they are entitled as holders of Common Stock.

          (d)  Antidilution Adjustments. The Conversion Price, and the number
and type of securities to be received upon conversion of shares of Series F
Preferred Stock, shall be subject to adjustment as follows:

               (i)  Dividend, Subdivision, Combination or Reclassification of
Common Stock. In the event that the Corporation shall at any time or from time
to time, prior to conversion of shares of Series F Preferred Stock (w) pay a
dividend or make a distribution on the outstanding shares of Common Stock
payable in Capital Stock, (x) subdivide the outstanding shares of Common Stock
into a larger number of shares, (y) combine the outstanding shares of Common
Stock into a smaller number of shares or (z) issue any shares of its Capital
Stock in a reclassification of the Common Stock (other than any such event for
which an adjustment is made pursuant to another clause of this Section 7(d)),
then, and in each such case, the Conversion Price in effect immediately prior to
such event shall be adjusted (and any other appropriate actions shall be taken
by the Corporation) so that the holder of any share of Series F Preferred Stock
thereafter surrendered for conversion shall be entitled to receive the number of
shares of Common Stock or other securities of the Corporation that such holder
would have owned or would have been entitled to receive upon or by reason of any
of the events described above, had such share of Series F Preferred Stock been
converted immediately prior to the occurrence of such event. An adjustment made
pursuant to this Section 7(d)(i) shall become effective retroactively (x) in the
case of any such dividend or distribution, to a date immediately following the
close of business on the record date for the determination of holders of Common
Stock entitled to receive such dividend or distribution or (y) in the case of
any such subdivision, combination or reclassification, to the close of business
on the day upon which such corporate action becomes effective.

               (ii) Issuance of Common Stock or Common Stock Equivalent below
Conversion Price.

                    (A)  If the Corporation shall at any time or from time to
time prior to conversion of shares of Series F Preferred Stock, issue or sell
any shares of Common Stock or Common Stock Equivalents at a price per share of
Common Stock (the "New Issue Price") that is less than the Conversion Price then
in effect as of

<PAGE>   57
                                                                              12

the record date or Issue Date (as defined below), as the case may be (the
"Relevant Date") treating the price per share of Common Stock, in the case of
the issuance of any Common Stock Equivalent, as equal to (x) the sum of the
price for such Common Stock Equivalent plus any additional consideration payable
(without regard to any anti-dilution adjustments) upon the conversion, exchange
or exercise of such Common Stock Equivalent divided by (y) the number of shares
of Common Stock initially underlying such Common Stock Equivalent), other than
(A) issuances or sales for which an adjustment is made pursuant to another
clause of this Section 7(d) and (B) issuances in connection with an Excluded
Transaction, then, and in each such case, the Conversion Price then in effect
shall be adjusted to equal the New Issue Price.

                    (B)  Such adjustment shall be made whenever such shares of
Common Stock or Common Stock Equivalents are issued, and shall become effective
retroactively (x) in the case of an issuance to the stockholders of the
Corporation, as such, to a date immediately following the close of business on
the record date for the determination of stockholders entitled to receive such
shares of Common Stock or Common Stock Equivalents and (y) in all other cases,
on the date (the "Issue Date") of such issuance; provided, however, that the
determination as to whether an adjustment is required to be made pursuant to
this Section 7(d)(ii) shall only be made upon the issuance of such shares of
Common Stock or Common Stock Equivalents, and not upon the issuance of any
security into which the Common Stock Equivalents convert, exchange or may be
exercised.

                    (C)  In case at any time any shares of Common Stock or
Common Stock Equivalents or any rights or options to purchase any shares of
Common Stock or Common Stock Equivalents shall be issued or sold for cash, the
consideration received therefor shall be deemed to be the amount received by the
Corporation therefor, without deduction therefrom of any expenses incurred or
any underwriting commissions or concessions or discounts paid or allowed by the
Corporation in connection therewith. In case any shares of Common Stock or
Common Stock Equivalents or any rights or options to purchase any Common Stock
or Common Stock Equivalents shall be issued or sold for a consideration other
than cash, the amount of the consideration other than cash received by the
Corporation shall be deemed to be the fair market value of such consideration,
without deduction therefrom of any expenses incurred or any underwriting
commissions or concessions or discounts paid or allowed by the Corporation in
connection therewith, as determined in good faith by the Board of Directors.

                    (D)  If any Common Stock Equivalents (or any portions
thereof) which shall have given rise to an adjustment pursuant to this Section
7(d)(ii) shall have expired or terminated without the exercise thereof and/or if
by reason of the terms of such Common Stock Equivalents there shall have been an
increase or increases, with the passage of time or otherwise, in the price
payable upon the exercise or conversion thereof, then the Conversion Price
hereunder shall be readjusted (but to no greater extent than originally
adjusted) in order to (1) eliminate from the computation any additional shares
of Common Stock corresponding to such Common Stock Equivalents as shall have
expired or terminated, (2) treat the additional shares of Common Stock, if any,

<PAGE>   58
                                                                              13

actually issued or issuable pursuant to the previous exercise of such Common
Stock Equivalents as having been issued for the consideration actually received
and receivable therefor and (3) treat any of such Common Stock Equivalents which
remain outstanding as being subject to exercise or conversion on the basis of
such exercise or conversion price as shall be in effect at the time.

               (iii) Certain Distributions. In case the Corporation shall at any
time or from time to time, prior to conversion of shares of Series F Preferred
Stock, distribute to all holders of shares of the Common Stock (including any
such distribution made in connection with a merger or consolidation in which the
Corporation is the resulting or surviving Person and the Common Stock is not
changed or exchanged) cash, evidences of indebtedness of the Corporation or
another issuer, securities of the Corporation or another issuer or other assets
(excluding cash dividends in which holders of shares of Series F Preferred Stock
participate, in the manner provided in Section 3, dividends payable in shares of
Common Stock for which adjustment is made under another paragraph of this
Section 7(d) and any distribution in connection with an Excluded Transaction) or
rights or warrants to subscribe for or purchase of any of the foregoing, then,
and in each such case, the Conversion Price then in effect shall be adjusted
(and any other appropriate actions shall be taken by the Corporation) by
multiplying the Conversion Price in effect immediately prior to the date of such
distribution by a fraction (x) the numerator of which shall be the Current
Market Price of the Common Stock immediately prior to the date of distribution
less the then fair market value (as determined by the Board of Directors in the
exercise of their fiduciary duties) of the portion of the cash, evidences of
indebtedness, securities or other assets so distributed or of such rights or
warrants applicable to one share of Common Stock and (y) the denominator of
which shall be the Current Market Price of the Common Stock immediately prior to
the date of distribution (but such fraction shall not be greater than one);
provided, however, that no adjustment shall be made with respect to any
distribution of rights or warrants to subscribe for or purchase securities of
the Corporation if the holder of shares of Series F Preferred Stock would
otherwise be entitled to receive such rights or warrants upon conversion at any
time of shares of Series F Preferred Stock into Common Stock. Such adjustment
shall be made whenever any such distribution is made and shall become effective
retroactively to a date immediately following the close of business on the
record date for the determination of stockholders entitled to receive such
distribution.

               (iv)  Other Changes. In case the Corporation at any time or from
time to time, prior to the conversion of shares of Series F Preferred Stock,
shall take any action affecting its Common Stock similar to or having an effect
similar to any of the actions described in any of Sections 7(d)(i), (ii) or
(iii) above or Section 7(g) below (but not including any action described in any
such Section) and the Board of Directors in good faith determines that it would
be equitable in the circumstances to adjust the Conversion Price as a result of
such action, then, and in each such case, the Conversion Price shall be adjusted
in such manner and at such time as the Board of Directors in good faith
determines would be equitable in the circumstances (such determination to be
evidenced in a resolution, a certified copy of which shall be mailed to the
holders of shares of Series F Preferred Stock).

<PAGE>   59
                                                                              14

               (v)   No Adjustment. Notwithstanding anything herein to the
contrary, no adjustment under this Section 7(d) need be made to the Conversion
Price if the Corporation receives written notice from holders of a majority of
the outstanding shares of Series F Preferred Stock that no such adjustment is
required.

          (e)  Abandonment. If the Corporation shall take a record of the
holders of its Common Stock for the purpose of entitling them to receive a
dividend or other distribution, and shall thereafter and before the distribution
to stockholders thereof legally abandon its plan to pay or deliver such dividend
or distribution, then no adjustment in the Conversion Price shall be required by
reason of the taking of such record.

          (f)  Certificate as to Adjustments. Upon any adjustment in the
Conversion Price, the Corporation shall within a reasonable period (not to
exceed ten (10) days) following any of the foregoing transactions deliver to
each registered holder of shares of Series F Preferred Stock a certificate,
signed by an executive officer of the Corporation, setting forth in reasonable
detail the event requiring the adjustment and the method by which such
adjustment was calculated and specifying the increased or decreased Conversion
Price then in effect following such adjustment.

          (g)  Reorganization, Reclassification. In case of any merger or
consolidation of the Corporation (other than a Sale Transaction except as
provided below) or any capital reorganization, reclassification or other change
of outstanding shares of Common Stock (other than a change in par value, or from
par value to no par value, or from no par value to par value) (each, a
"Transaction"), the Corporation shall execute and deliver to each holder of
shares of Series F Preferred Stock at least twenty (20) Business Days prior to
effecting such Transaction a certificate, signed by an executive officer of the
Corporation, stating that the holder of each share of Series F Preferred Stock
shall have the right to receive in such Transaction, in exchange for each share
of Series F Preferred Stock, a security identical to (and not less favorable
than) the Series F Preferred Stock, and provision shall be made therefor in the
agreement, if any, relating to such Transaction.

          (h)  Notices. In case at any time or from time to time:

               (w)  the Corporation shall declare a dividend (or any other
distribution) on its shares of Common Stock;

               (x)  the Corporation shall authorize the granting to the holders
of its Common Stock rights or warrants to subscribe for or purchase any shares
of Capital Stock of any class or of any other rights or warrants;

               (y)  there shall be any Transaction; or

               (z)  there shall occur a Sale Transaction;

then the Corporation shall mail to each holder of shares of Series F Preferred
Stock at such holder's address as it appears on the transfer books of the
Corporation, as promptly

<PAGE>   60
                                                                              15

as possible but in any event at least ten (10) days prior to the applicable date
hereinafter specified, a notice stating (A) the date on which a record is to be
taken for the purpose of such dividend, distribution or granting of rights or
warrants or, if a record is not to be taken, the date as of which the holders of
Common Stock of record to be entitled to such dividend, distribution or granting
of rights or warrants are to be determined, or (B) the date on which such
Transaction, or Sale Transaction is expected to become effective and the date as
of which it is expected that holders of Common Stock of record shall be entitled
to exchange their Common Stock for shares of stock or other securities or
property or cash deliverable upon such Transaction or Sale Transaction.
Notwithstanding the foregoing, in the case of any event to which Section 7(g)
above is applicable, the Corporation shall also deliver the certificate
described in Section 7(g) above to each holder of shares of Series F Preferred
Stock at least twenty (20) Business Days' prior to effecting such reorganization
or reclassification as aforesaid.

          (i)  Reservation of Common Stock. The Corporation shall at all times
reserve and keep available for issuance upon the conversion of shares of Series
F Preferred Stock, such number of its authorized but unissued shares of Common
Stock as will from time to time be sufficient to permit the conversion of all
outstanding shares of Series F Preferred Stock, and shall take all action to
increase the authorized number of shares of Common Stock if at any time there
shall be insufficient authorized but unissued shares of Common Stock to permit
such reservation or to permit the conversion of all outstanding shares of Series
F Preferred Stock; provided that (x) the holders of shares of Series F Preferred
Stock vote such shares in favor of any such action that requires a vote of
stockholders and (y) such holders cause the Series F Director to vote in favor
of any such action that requires a vote of the Board of Directors.

          (j)  No Conversion Tax or Charge. The issuance or delivery of
certificates for Common Stock upon the conversion of shares of Series F
Preferred Stock shall be made without charge to the converting holder of shares
of Series F Preferred Stock for such certificates or for any tax in respect of
the issuance or delivery of such certificates or the securities represented
thereby, and such certificates shall be issued or delivered in the respective
names of, or (subject to compliance with the applicable provisions of federal
and state securities laws) in such names as may be directed by, the holders of
the shares of Series F Preferred Stock converted; provided, however, that the
Corporation shall not be required to pay any tax which may be payable in respect
of any transfer involved in the issuance and delivery of any such certificate in
a name other than that of the holder of the shares of Series F Preferred Stock
converted, and the Corporation shall not be required to issue or deliver such
certificate unless or until the Person or Persons requesting the issuance or
delivery thereof shall have paid to the Corporation the amount of such tax or
shall have established to the reasonable satisfaction of the Corporation that
such tax has been paid.

     8.  Certain Remedies. Any registered holder of shares of Series F Preferred
Stock shall be entitled to an injunction or injunctions to prevent breaches of
the provisions of this Certificate of Designations and to enforce specifically
the terms and provisions of this Certificate of Designations in any court of the
United States or any

<PAGE>   61
                                                                              16

state thereof having jurisdiction, this being in addition to any other remedy to
which such holder may be entitled at law or in equity.

     9.   Business Day. If any payment shall be required by the terms hereof to
be made on a day that is not a Business Day, such payment shall be made on the
immediately succeeding Business Day.

     10.  Definitions. As used in this Certificate of Designations, the
following terms shall have the following meanings (with terms defined in the
singular having comparable meanings when used in the plural and vice versa),
unless the context otherwise requires:

     "Accreted Value" means, with respect to each share of Series F Preferred
Stock, an amount equal to the Stated Value per share of Series F Preferred Stock
plus an amount equal to any dividends accrued but not yet paid under Section
3(b).

     "Additional Series F Director" shall have the meaning ascribed to it in
Section 6(b) hereof.

     "Affiliate" shall mean any Person who is an "affiliate" as defined in Rule
12b-2 of the General Rules and Regulations under the Exchange Act. In addition,
the following shall be deemed to be Affiliates of GAP Coinvestment, GAP LP and
GapStar: (a) GAP LLC, the members of GAP LLC, the limited partners of GAP
Coinvestment and the limited partners of GAP LP; (b) any Affiliate of GAP LLC,
the members of GAP LLC, the limited partners of GAP Coinvestment and the limited
partners of GAP LP; and (c) any limited liability company or partnership a
majority of whose members or partners, as the case may be, are members or former
members of GAP LLC or consultants or key employees of General Atlantic Service
Corporation, a Delaware corporation and an Affiliate of GAP LLC. In addition,
GAP LP, GapStar and GAP Coinvestment shall be deemed to be Affiliates of one
another.

     "Automatic Redemption Date" shall have the meaning ascribed to it in
Section 5(b) hereof.

     "Board of Directors" has the meaning set forth in the preamble to this
Certificate of Designations.

     "Business Day" means any day except a Saturday, a Sunday, or other day on
which commercial banks in the State of New York are authorized or required by
law or executive order to close.

     "Capital Stock" means, with respect to any Person, any and all shares,
interests, participations, rights in, or other equivalents (however designated
and whether voting or non-voting) of, such Person's capital stock and any and
all rights, warrants or options exchangeable for or convertible into such
capital stock (but excluding any debt security whether or not it is exchangeable
for or convertible into such capital stock).

<PAGE>   62
                                                                              17

     "Commission" means the United States Securities and Exchange Commission.

     "Common Stock" shall have the meaning ascribed to it in Section 2(a)
hereof.

     "Common Stock Equivalent" means any security or obligation which is by its
terms convertible or exchangeable into shares of Common Stock or another Common
Stock Equivalent, and any option, warrant or other subscription or purchase
right with respect to Common Stock.

     "Conversion Price" shall have the meaning ascribed to it in Section 7(a)
hereof.

     "Corporation" shall have the meaning ascribed to it in the first paragraph
of this Certificate of Designation.

     "Current Market Price" per share shall mean, as of the date of
determination, (a) the average of the daily Market Price under clause (a), (b)
or (c) of the definition thereof of the Common Stock during the immediately
preceding thirty (30) Trading Days ending on such date, and (b) if the Common
Stock is not then listed or admitted to trading on any national securities
exchange or quoted in the over-the-counter market, then the Market Price under
clause (d) of the definition thereof on such date.

     "Exchange Act" means the Securities Exchange Act of 1934, as amended, and
the rules and regulations of the Commission promulgated thereunder.

     "Excluded Transaction" means (a) any issuance of up to an aggregate of
10,506,313 shares of restricted stock or options to purchase shares of Common
Stock (subject to adjustment in the event of stock splits, combinations or
similar occurrences) to employees, officers or directors of the Corporation
pursuant to the Stock Option Plan or and (b) any issuance of Common Stock (i)
upon the conversion of shares of Series F Preferred Stock, (ii) as a dividend on
shares of Series F Preferred Stock or (iii) upon conversion or exercise of any
Common Stock Equivalents and/or (c) any issuance of Common Stock in connection
with any Participation Payment.

     "Extraordinary Actions" shall have the meaning ascribed to it in Section
6(c) hereof.

     "GAP Coinvestment" shall have the meaning ascribed to it in Section 6(b)
hereof.

     "GAP LLC" means General Atlantic Partners, LLC, a Delaware limited
liability company and the general partner of GAP LP and the managing member of
GapStar, and any successor to such entity.

     "GAP LP" shall have the meaning ascribed to it in Section 6(b) hereof.

<PAGE>   63
                                                                              18

     "GapStar" shall have the meaning ascribed to it in Section 6(b) hereof.

     "Hurdle Rate" shall have the meaning ascribed to it in Section 5(a) hereof.

     "Issue Date" shall have the meaning ascribed to it in Section 7(d)(ii)
hereof.

     "Junior Stock" shall have the meaning ascribed to it in Section 2(a)
hereof.

     "Liquidation" shall mean the voluntary or involuntary liquidation under
applicable bankruptcy or reorganization legislation, or the dissolution or
winding up of the Corporation.

     "Mandatory Dividend Payment Date" shall have the meaning ascribed to it in
Section 3(b) hereof.

     "Market Price" shall mean, as of the date of determination, (a) if the
Common Stock is listed on a national securities exchange, the closing price per
share of Common Stock on such date published in The Wall Street Journal
(National Edition) or, if no such closing price on such date is published in The
Wall Street Journal (National Edition), the average of the closing bid and asked
prices on such date, as officially reported on the principal national securities
exchange on which the Common Stock is then listed or admitted to trading; or (b)
if the Common Stock is not then listed or admitted to trading on any national
securities exchange but is designated as a national market system security by
the National Association of Securities Dealers, Inc., the last trading price of
the Common Stock on such date; or (c) if there shall have been no trading on
such date or if the Common Stock is not designated as a national market system
security by the National Association of Securities Dealers, Inc., the average of
the reported closing bid and asked prices of the Common Stock on such date as
shown by the NASDAQ and reported by any member firm of the New York Stock
Exchange selected by the Corporation; or (d) if none of (a), (b) or (c) is
applicable, a market price per share determined in good faith by the Board of
Directors.

     "NASDAQ" means the National Market System of the National Association of
Securities Dealers, Inc. Automated Quotations System.

     "Net Per Share Price" shall mean an amount equal to a quotient expressed as
a fraction (a) the numerator of which shall be the aggregate dollar amount paid
to the stockholders of the Corporation as consideration in a Sale Transaction
and (b) the denominator of which shall be the number of shares of Common Stock
outstanding on a fully diluted basis. In determining the aggregate dollar amount
paid to the stockholders of the Corporation as consideration in a Sale
Transaction, any securities of the surviving Person or securities of the
Corporation other than Common Stock shall be valued as follows:

               (i)   With respect to securities that do not constitute
"restricted securities," as such term is defined in Rule 144(a)(3) promulgated
under the

<PAGE>   64
                                                                              19

Securities Act, the value shall be the Current Market Price of such securities
as of three (3) days prior to the date of distribution.

               (ii)  With respect to securities that constitute "restricted
securities," as such term is defined in Rule 144(a)(3) promulgated under the
Securities Act, and that are of the same class or Series F securities that are
publicly traded, the value shall be adjusted to make an appropriate discount
from the value as set forth above in clause (i) to reflect the appropriate fair
market value thereof, as mutually determined by the Board of Directors and the
holders of a majority of the shares of Series F Preferred Stock, or if there is
no active public market with respect to such class or series of securities, such
securities shall be valued in accordance with clause (i) above, giving
appropriate weight, if any, to such restriction as determined in good faith by
the Board of Directors.

     "New Issue Price" shall have the meaning ascribed to it in Section 7(d)(ii)
hereof.

     "Optional Redeemed Shares" shall have the meaning ascribed to it in Section
5(a) hereof.

     "Optional Redemption Date" shall have the meaning ascribed to it in Section
5(a) hereof.

     "Optional Redemption Payment" shall have the meaning ascribed to it in
Section 5(a) hereof.

     "Optional Redemption Price" shall have the meaning ascribed to it in
Section 5(a) hereof.

     "Participation Payment" shall have the meaning ascribed to it in Section
4(a) hereof.

     "Per Share Price" as of any date, shall mean the volume-weighted average
trading price of a share of Common Stock, as reported on the NASDAQ or such
other exchange or quotation system that may on such date constitute the primary
exchange or quotation system on which the shares of Common Stock are then listed
or quoted, on each of the twenty (20) consecutive Trading Days ending on and
including the Trading Day prior to such date.

     "Person" means any individual, firm, corporation, partnership, limited
liability company, trust, incorporated or unincorporated association, joint
venture, joint stock company, governmental body or other entity of any kind.

     "Redeemed Shares" shall have the meaning ascribed to it in Section 5(b)
hereof.

     "Redemption Payment" shall have the meaning ascribed to it in Section 5(b)
hereof.

<PAGE>   65
                                                                              20

     "Redemption Per Share Price" as of any date, shall mean the volume-weighted
average trading price of a share of Common Stock, as reported on the NASDAQ or
such other exchange or quotation system that may on such date constitute the
primary exchange or quotation system on which the shares of Common Stock are
then listed or quoted, on each of the ninety (90) consecutive Trading Days
ending on and including the Trading Day prior to such date

     "Redemption Price" shall have the meaning ascribed to it in Section 5(b)
hereof. "Relevant Date" shall have the meaning ascribed to it in
Section 7(d)(ii) hereof.

     "Sale Transaction" shall mean (a) (i) the merger or consolidation of the
Corporation into or with one or more Persons, (ii) the merger or consolidation
of one or more Persons into or with the Corporation or (iii) a tender offer or
other business combination if, in the case of (i), (ii) or (iii), the
stockholders of the Corporation prior to such merger or consolidation do not
retain at least a majority of the voting power of the surviving Person, (b) the
voluntary sale, conveyance, exchange or transfer to another Person of (i) the
voting Capital Stock of the Corporation if, after such sale, conveyance,
exchange or transfer, the stockholders of the Corporation prior to such sale,
conveyance, exchange or transfer do not retain at least a majority of the voting
power of the Corporation or (ii) all or substantially all of the assets of the
Corporation, or (c) the sale of assets of the Corporation, other than such a
sale in the ordinary course of business, the gross proceeds of which exceed
$10,000,000; provided, that with respect to (b)(ii) above, for the avoidance of
doubt, the sale, conveyance, exchange or transfer of the Ticketing Service Group
shall be deemed to be such a Sale, conveyance or transfer of substantially all
of the assets of the Corporation.

     "Securities Act" means the Securities Act of 1933, as amended, and the
rules and regulations of the Commission promulgated thereunder.

     "Series F Directors" shall have the meaning ascribed to it in Section 6(b)
hereof.

     "Series F Preferred Stock" shall have the meaning ascribed to it in Section
1 hereof.

     "Stated Value" means $0.60 per share for each of the then outstanding
shares of Series F Preferred Stock, as adjusted for stock splits, stock
dividends, contributions or other recapitalizations of the Series F Preferred
Stock.

     "Stock Option Plan" means the Tickets.com, Inc. 199___ Stock Option Plan.

     "Subsidiaries" means, as of the relevant date of determination, with
respect to any Person, a corporation or other Person of which 50% or more of the
voting

<PAGE>   66
                                                                              21

power of the outstanding voting equity securities or 50% or more of the
outstanding economic equity interest is held, directly or indirectly, by such
Person.

     "Trading Day" shall mean any day for which quotations are available in
respect of shares of Common Stock on the NASDAQ (or such other exchange or
quotation system that may on such date constitute the primary exchange or
quotation system on which the shares of Common Stock are then listed or quoted).

     "Transaction" shall have the meaning ascribed to it in Section 7(g) hereof.

     "Value" shall mean (a) in the case of a Sale Transaction in which the
stockholders of the Corporation receive cash as consideration, the aggregate
dollar amount paid to such stockholders in such Sale Transaction or (b) in all
other cases, the fair market value of the Corporation as shall be determined in
good faith by the Board of Directors.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

<PAGE>   67
                                                                              22

     IN WITNESS WHEREOF, the undersigned has executed and subscribed this
certificate this __ day of ____________, 2001.

                                               ---------------------------------
                                               W. Thomas Gimple
                                               Chief Executive Officer

<PAGE>   68

                                                                       EXHIBIT D

================================================================================

                          REGISTRATION RIGHTS AGREEMENT

                                      among

                               TICKETS.COM, INC.,

                       GENERAL ATLANTIC PARTNERS 74, L.P.,

                       GAP COINVESTMENT PARTNERS II, L.P.,

                                  GAPSTAR, LLC,

                                       and

                      INTERNATIONAL CAPITAL PARTNERS, INC.,
                              PROFIT SHARING TRUST

                             -----------------------

                             Dated: __________, 2001

                             -----------------------

================================================================================

<PAGE>   69

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                           Page
<S>                                                                                        <C>

1.  Definitions..............................................................................1

2.  General; Securities Subject to this Agreement............................................5
    (a)      Grant of Rights.................................................................5
    (b)      Registrable Securities..........................................................5
    (c)      Holders of Registrable Securities...............................................5

3.  Demand Registration......................................................................5
    (a)      Request for Demand Registration.................................................5
             ................................................................................6
    (b)      Incidental or "Piggy-Back" Rights with Respect to a Demand Registration.........6
             ................................................................................7
    (c)      Effective Demand Registration...................................................7
    (d)      Expenses........................................................................7
    (e)      Additional Demand Registration..................................................7
    (f)      Underwriting Procedures.........................................................7
             ................................................................................8
    (g)      Selection of Underwriters.......................................................8

4.  Incidental or "Piggy-Back" Registration..................................................8
    (a)      Request for Incidental Registration.............................................8
    (b)      Expenses........................................................................9

5.  Shelf Registration.......................................................................9
    (a)      Request for a Form S-3 Shelf Registration.......................................9
    (b)      Form S-3 Underwriting Procedures...............................................10
    (c)      Limitations on Form S-3 Registrations..........................................10
    (d)      Expenses.......................................................................11
    (e)      No Demand Registration.........................................................11

6.  Holdback Agreements.....................................................................11
    (a)      Restrictions on Public Sale by Designated Holders..............................11
    (b)      Restrictions on Public Sale by the Company.....................................11

7.  Registration Procedures.................................................................12
    (a)      Obligations of the Company.....................................................12
    (b)      Seller Information.............................................................15
    (c)      Notice to Discontinue..........................................................15
    (d)      Registration Expenses..........................................................15

8.  Indemnification; Contribution...........................................................16
    (a)      Indemnification by the Company.................................................16
</TABLE>

                                       i
<PAGE>   70

<TABLE>
<S>                                                                                        <C>

    (b)      Indemnification by Designated Holders..........................................16
    (c)      Conduct of Indemnification Proceedings.........................................17
    (d)      Contribution...................................................................18

9.  Rule 144................................................................................18

10. Miscellaneous...........................................................................18
    (a)      Recapitalizations, Exchanges, etc..............................................18
    (b)      No Inconsistent Agreements.....................................................19
    (c)      Remedies.......................................................................19
    (d)      Amendments and Waivers.........................................................19
    (e)      Notices........................................................................19
    (f)      Successors and Assigns; Third Party Beneficiaries..............................21
    (g)      Counterparts...................................................................21
    (h)      Headings.......................................................................21
    (I)      GOVERNING LAW..................................................................21
    (j)      Severability...................................................................21
    (k)      Rules of Construction..........................................................22
    (l)      Entire Agreement...............................................................22
    (m)      Further Assurances.............................................................22
    (n)      Other Agreements...............................................................22
</TABLE>

                                       ii
<PAGE>   71

                          REGISTRATION RIGHTS AGREEMENT

     REGISTRATION RIGHTS AGREEMENT, dated as of _________, 2001 (as amended,
modified and/or supplemented from time to time, this "Agreement"), by and among
Tickets.com, Inc., a Delaware corporation (the "Company"), General Atlantic
Partners 74, L.P., a Delaware limited partnership ("GAP LP"), GAP Coinvestment
Partners II, L.P., a Delaware limited partnership ("GAP Coinvestment"), GapStar,
LLC, a Delaware limited liability company ("GapStar") and International Capital
Partners, Inc., Profit Sharing Trust, a Connecticut corporation ("ICP")

     WHEREAS, pursuant to the Stock Purchase Agreement, dated as of ___________,
2001 (the "Stock Purchase Agreement"), by and among the Company, GAP LP, GAP
Coinvestment, GapStar and ICP, the Company has agreed to issue and sell to GAP
LP, GAP Coinvestment, GapStar and ICP, an aggregate of 15 million shares of
Series F Senior Cumulative Redeemable Preferred Stock, par value $0.000225 per
share, of the Company (the "Preferred Stock"); and

     WHEREAS, in order to induce each of GAP LP, GAP Coinvestment, GapStar and
ICP to purchase its shares of Preferred Stock, the Company has agreed to grant
registration rights with respect to the Registrable Securities (as hereinafter
defined) as set forth in this Agreement.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set
forth herein and for good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the parties hereto agree as follows:

     1.   Definitions. As used in this Agreement, and unless the context
requires a different meaning, the following terms have the meanings indicated:

     "Affiliate" shall mean any Person who is an "affiliate" as defined in Rule
12b-2 of the General Rules and Regulations under the Exchange Act. In addition,
the following shall be deemed to be Affiliates of GAP LP, GapStar and GAP
Coinvestment: (a) GAP LLC, the members of GAP LLC, the limited partners of GAP
Coinvestment and the limited partners of GAP LP; (b) any Affiliate of GAP LLC,
the members of GAP LLC, the limited partners of GAP Coinvestment and the limited
partners of GAP LP; and (c) any limited liability company or partnership a
majority of whose members or partners, as the case may be, are members or former
members of GAP LLC or consultants or key employees of General Atlantic Service
Corporation, a Delaware corporation and an Affiliate of GAP LLC. In addition,
GAP LP, GapStar and GAP Coinvestment shall be deemed to be Affiliates of one
another.

     "Additional Investors" has the meaning set forth in Section 10(f) of this
Agreement.

     "Agreement" has the meaning set forth in the preamble to this Agreement.

<PAGE>   72

                                                                               2

     "Approved Underwriter" has the meaning set forth in Section 3(g) of this
Agreement.

     "Board of Directors" means the Board of Directors of the Company.

     "Business Day" means any day other than a Saturday, Sunday or other day on
which commercial banks in the State of New York are authorized or required by
law or executive order to close.

     "Closing Price" means, with respect to the Registrable Securities, as of
the date of determination, (a) if the Registrable Securities are listed on a
national securities exchange, the closing price per share of a Registrable
Security on such date published in The Wall Street Journal (National Edition)
or, if no such closing price on such date is published in The Wall Street
Journal (National Edition), the average of the closing bid and asked prices on
such date, as officially reported on the principal national securities exchange
on which the Registrable Securities are then listed or admitted to trading; or
(b) if the Registrable Securities are not then listed or admitted to trading on
any national securities exchange but are designated as national market system
securities by the NASD, the last trading price per share of a Registrable
Security on such date; or (c) if there shall have been no trading on such date
or if the Registrable Securities are not designated as national market system
securities by the NASD, the average of the reported closing bid and asked prices
of the Registrable Securities on such date as shown by The Nasdaq Stock Market,
Inc. (or its successor) and reported by any member firm of The New York Stock
Exchange, Inc. selected by the Company; or (d) if none of (a), (b) or (c) is
applicable, a market price per share determined in good faith by the Board of
Directors or, if such determination is not satisfactory to the Designated Holder
for whom such determination is being made, by a nationally recognized investment
banking firm selected by the Company and such Designated Holder, the expenses
for which shall be borne equally by the Company and such Designated Holder. If
trading is conducted on a continuous basis on any exchange, then the closing
price shall be at 4:00 P.M. New York City time.

     "Commission" means the Securities and Exchange Commission or any similar
agency then having jurisdiction to enforce the Securities Act.

     "Common Stock" means the Common Stock, par value $0.000225 per share, of
the Company or any other capital stock of the Company into which such stock is
reclassified or reconstituted and any other common stock of the Company.

     "Company" has the meaning set forth in the preamble to this Agreement.

     "Company Underwriter" has the meaning set forth in Section 4(a) of this
Agreement.

     "Demand Registration" has the meaning set forth in Section 3(a) of this
Agreement.

<PAGE>   73
                                                                               3

     "Designated Holder" means each of the General Atlantic Stockholders, the
ICP Stockholders and any transferee of any of them to whom Registrable
Securities have been transferred in accordance with Section 10(f) of this
Agreement, other than a transferee to whom Registrable Securities have been
transferred pursuant to a Registration Statement under the Securities Act or
Rule 144 or Regulation S under the Securities Act (or any successor rule
thereto).

     "Exchange Act" means the Securities Exchange Act of 1934, as amended, and
the rules and regulations of the Commission thereunder.

     "Fifth Amended and Restated Investor Rights Agreement" means the Fifth
Amended and Restated Investor Rights Agreement, dated August 4, 1999, among the
Company and the other Persons named therein.

     "GAP Coinvestment" has the meaning set forth in the preamble to this
Agreement.

     "GAP LLC" means General Atlantic Partners, LLC, a Delaware limited
liability company and the general partner of GAP LP and the managing member of
GapStar, and any successor to such entity.

     "GAP LP" has the meaning set forth in the preamble to this Agreement.

     "GapStar" has the meaning set forth in the preamble to this Agreement.

     "General Atlantic Stockholders" means GAP LP, GAP Coinvestment, GapStar and
any transferee thereof to whom Registrable Securities are transferred in
accordance with Section 10(f) of this Agreement.

     "Holders' Counsel" has the meaning set forth in Section 7(a)(i) of this
Agreement.

     "ICP" has the meaning set forth in the preamble to this Agreement.

     "ICP Stockholders" means ICP and any transferee thereof to whom Registrable
Securities are transferred in accordance with Section 10(f) of this Agreement.

     "Incidental Registration" has the meaning set forth in Section 4(a) of this
Agreement.

     "Indemnified Party" has the meaning set forth in Section 8(c) of this
Agreement.

     "Indemnifying Party" has the meaning set forth in Section 8(c) of this
Agreement.

     "Initiating Holders" has the meaning set forth in Section 3(a) of this
Agreement.

<PAGE>   74
                                                                               4

     "Inspector" has the meaning set forth in Section 7(a)(vii) of this
Agreement.

     "Liability" has the meaning set forth in Section 8(a) of this Agreement.

     "Market Price" means, on any date of determination, the average of the
daily Closing Price of the Registrable Securities for the immediately preceding
thirty (30) days on which the national securities exchanges are open for
trading.

     "NASD" means the National Association of Securities Dealers, Inc.

     "Person" means any individual, firm, corporation, partnership, limited
liability company, trust, incorporated or unincorporated association, joint
venture, joint stock company, limited liability company, government (or an
agency or political subdivision thereof) or other entity of any kind, and shall
include any successor (by merger or otherwise) of such entity.

     "Preferred Stock" has the meaning set forth in the recitals to this
Agreement.

     "Records" has the meaning set forth in Section 7(a)(vii) of this Agreement.

     "Registrable Securities" means each of the following: (a) any and all
shares of Common Stock owned by the Designated Holders or issued or issuable
upon conversion of shares of Preferred Stock and any shares of Common Stock
issued or issuable upon conversion of any shares of preferred stock or exercise
of any warrants acquired by any of the Designated Holders after the date hereof,
(b) any other shares of Common Stock acquired or owned by any of the Designated
Holders after the date hereof if such Designated Holder is an Affiliate of the
Company and (c) any shares of Common Stock issued or issuable to any of the
Designated Holders with respect to the Registrable Securities by way of stock
dividend or stock split or in connection with a combination of shares,
recapitalization, merger, consolidation or other reorganization or otherwise and
any shares of Common Stock or voting common stock issuable upon conversion,
exercise or exchange thereof.

     "Registration Expenses" has the meaning set forth in Section 7(d) of this
Agreement.

     "Registration Statement" means a registration statement filed pursuant to
the Securities Act.

     "S-3 Initiating Holders" has the meaning set forth in Section 5(a) of this
Agreement.

     "S-3 Registration" has the meaning set forth in Section 5(a) of this
Agreement.

<PAGE>   75
                                                                               5

     "Securities Act" means the Securities Act of 1933, as amended, and the
rules and regulations of the Commission promulgated thereunder.

     "Stock Purchase Agreement" has the meaning set forth in the recitals to
this Agreement.

     "Valid Business Reason" has the meaning set forth in Section 3(a) of this
Agreement.

     2.   General; Securities Subject to this Agreement.

          (a)  Grant of Rights. The Company hereby grants registration rights to
the Designated Holders upon the terms and conditions set forth in this
Agreement.

          (b)  Registrable Securities. For the purposes of this Agreement, with
respect to each Designated Holder, Registrable Securities will cease to be
Registrable Securities, when (i) a Registration Statement covering such
Registrable Securities has been declared effective under the Securities Act by
the Commission and such Registrable Securities have been disposed of pursuant to
such effective Registration Statement, (ii) (x) the entire amount of the
Registrable Securities may be sold in a single sale, in the opinion of counsel
satisfactory to the Company and the Designated Holder, each in their reasonable
judgment, without any limitation as to volume pursuant to Rule 144 (or any
successor provision then in effect) under the Securities Act and (y) the
Designated Holder owning such Registrable Securities owns less than one percent
(1%) of the outstanding shares of Common Stock on a fully diluted basis, or
(iii) the Registrable Securities are proposed to be sold or distributed by a
Person not entitled to the registration rights granted by this Agreement.

          (c)  Holders of Registrable Securities. A Person is deemed to be a
holder of Registrable Securities whenever such Person owns of record Registrable
Securities, or holds an option to purchase, or a security convertible into or
exercisable or exchangeable for, Registrable Securities whether or not such
acquisition or conversion has actually been effected. If the Company receives
conflicting instructions, notices or elections from two or more Persons with
respect to the same Registrable Securities, the Company may act upon the basis
of the instructions, notice or election received from the registered owner of
such Registrable Securities. Registrable Securities issuable upon exercise of an
option or upon conversion of another security shall be deemed outstanding for
the purposes of this Agreement.

     3.   Demand Registration.

          (a)  Request for Demand Registration. At any time after the date
hereof, one or more of the General Atlantic Stockholders as a group, acting
through GAP LLC or its written designee (the "Initiating Holders"), may make a
written request to the Company to register, and the Company shall register,
under the Securities Act (other than pursuant to a Registration Statement on
Form S-4 or S-8 or any successor

<PAGE>   76
                                                                               6

thereto) (a "Demand Registration"), the number of Registrable Securities stated
in such request; provided, however, that (x) subject to Section 3(e), the
Company shall not be obligated to effect more than one such Demand Registration
for the General Atlantic Stockholders and (y) the Company shall not be obligated
to effect a registration pursuant to this Section 3(a) during such time as the
Company has an "evergreen" shelf registration with respect to all such
Registrable Securities pursuant to Rule 415 under the Securities Act on form S-3
(or any successor form) and such shelf registration has been declared, and
remains, effective. For purposes of the preceding sentence, two or more
Registration Statements filed in response to one demand shall be counted as one
Demand Registration. If the Board of Directors, in its good faith judgment,
determines that any registration of Registrable Securities should not be made or
continued because it would materially interfere with any material financing,
acquisition, corporate reorganization or merger or other material transaction
involving the Company (a "Valid Business Reason"), the Company may (x) postpone
filing a Registration Statement relating to a Demand Registration until such
Valid Business Reason no longer exists, but in no event for more than ninety
(90) days, and (y) in case a Registration Statement has been filed relating to a
Demand Registration, if the Valid Business Reason has not resulted from actions
taken by the Company, the Company, upon the approval of a majority of the Board
of Directors, such majority to include at least one director elected by the
holders of the Series F Preferred Stock, may cause such Registration Statement
to be withdrawn and its effectiveness terminated or may postpone amending or
supplementing such Registration Statement. The Company shall give written notice
of its determination to postpone or withdraw a Registration Statement and of the
fact that the Valid Business Reason for such postponement or withdrawal no
longer exists, in each case, promptly after the occurrence thereof.
Notwithstanding anything to the contrary contained herein, the Company may not
postpone or withdraw a filing under this Section 3(a) more than once in any
twelve (12) month period. Each request for a Demand Registration by the
Initiating Holders shall state the amount of the Registrable Securities proposed
to be sold and the intended method of disposition thereof.

          (b)  Incidental or "Piggy-Back" Rights with Respect to a Demand
Registration. Each of the Designated Holders (other than Initiating Holders
which have requested a registration under Section 3(a)) may offer its or his
Registrable Securities under any Demand Registration pursuant to this Section
3(b). Within seven (7) days after the receipt of a request for a Demand
Registration from an Initiating Holder, the Company shall (i) give written
notice thereof to all of the Designated Holders (other than Initiating Holders
which have requested a registration under Section 3(a)) and (ii) subject to
Section 3(f), include in such registration all of the Registrable Securities
held by such Designated Holders from whom the Company has received a written
request for inclusion therein within ten (10) days of the receipt by such
Designated Holders of such written notice referred to in clause (i) above. Each
such request by such Designated Holders shall specify the number of Registrable
Securities proposed to be registered. The failure of any Designated Holder to
respond within such 10-day period referred to in clause (ii) above shall be
deemed to be a waiver of such Designated Holder's rights under this Section 3
with respect to such Demand Registration. Any Designated Holder may waive its
rights under this Section 3 prior to the expiration of such 10-day period by
giving written notice to the Company, with a copy to the Initiating Holders. If
a

<PAGE>   77
                                                                               7

Designated Holder sends the Company a written request for inclusion of part or
all of such Designated Holder's Registrable Securities in a registration, such
Designated Holder shall not be entitled to withdraw or revoke such request
without the prior written consent of the Company in its sole discretion unless,
as a result of facts or circumstances arising after the date on which such
request was made relating to the Company or to market conditions, such
Designated Holder reasonably determines that participation in such registration
would have a material adverse effect on such Designated Holder.

          (c)  Effective Demand Registration. The Company shall use its
commercially reasonable efforts to cause any such Demand Registration to become
and remain effective not later than sixty (60) days after it receives a request
under Section 3(a) hereof. A registration shall not constitute a Demand
Registration until it has become effective and remains continuously effective
for the lesser of (i) the period during which all Registrable Securities
registered in the Demand Registration are sold and (ii) 120 days; provided,
however, that a registration shall not constitute a Demand Registration if (x)
after such Demand Registration has become effective, such registration or the
related offer, sale or distribution of Registrable Securities thereunder is
interfered with by any stop order, injunction or other order or requirement of
the Commission or other governmental agency or court for any reason not
attributable to the Initiating Holders and such interference is not thereafter
eliminated or (y) the conditions specified in the underwriting agreement, if
any, entered into in connection with such Demand Registration are not satisfied
or waived, other than by reason of a failure by the Initiating Holder.

          (d)  Expenses. The Company shall pay all Registration Expenses in
connection with a Demand Registration, whether or not such Demand Registration
becomes effective.

          (e)  Additional Demand Registration. If at least seventy-five percent
(75%) of the Registrable Securities proposed to be registered in such Demand
Registration are not included in such Demand Registration, then the General
Atlantic Stockholders as a group shall have the right to require the Company to
effect an additional registration under the Securities Act of all or part of the
Registrable Securities held by such General Atlantic Stockholders in accordance
with the provisions of this Section 3, and the Company shall pay the
Registration Expenses in connection with such additional registration.

          (f)  Underwriting Procedures. If the Initiating Holders holding a
majority of the Registrable Securities held by all of the Initiating Holders so
elect, the Company shall use its commercially reasonable efforts to cause such
Demand Registration to be in the form of a firm commitment underwritten offering
and the managing underwriter or underwriters selected for such offering shall be
the Approved Underwriter selected in accordance with Section 3(g). In connection
with any Demand Registration under this Section 3 involving an underwritten
offering, none of the Registrable Securities held by any Designated Holder
making a request for inclusion of such Registrable Securities pursuant to
Section 3(b) hereof shall be included in such underwritten offering unless such
Designated Holder accepts the terms of the offering as

<PAGE>   78
                                                                               8

agreed upon by the Company, the other Initiating Holders and the Approved
Underwriter, and then, subject to the immediately following sentence, only in
such quantity as will not, in the opinion of the Approved Underwriter,
jeopardize the success of such offering by the Initiating Holders. If the
Approved Underwriter advises the Company that the aggregate amount of such
Registrable Securities requested to be included in such offering is sufficiently
large to have a material adverse effect on the success of such offering, then
the Company shall include in such registration only the aggregate amount of
Registrable Securities that the Approved underwriter believes may be sold
without any such material adverse effect and shall reduce the amount of
Registrable Securities to be included in such registration, first, as to the
Company, second, as to any other stockholders of the Company who hold similar
registration rights to the Designated Holders hereunder pursuant to other
registration rights agreements as a group, pro rata within each group based upon
the number of Registrable Securities or other similar securities owned by each
such other stockholder of the Company as a group, if any, and third, as to the
(i) Designated Holders and (ii) any other stockholders of the Company who hold
and have exercised similar registration rights as the Initiating Holders
hereunder pursuant to other registration rights agreements as a group, pro rata
within each group based on the number of Registrable Securities or other similar
securities owned by each such Designated Holder or each such other stockholder
of the Company.

          (g)  Selection of Underwriters. If any Demand Registration, or S-3
Registration, as the case may be, of Registrable Securities is in the form of an
underwritten offering, the Company shall select and obtain an investment banking
firm of national reputation to act as the managing underwriter of the offering
(the "Approved Underwriter"); provided, however, that the Approved Underwriter
shall, in any case, also be approved by the Initiating Holders or S-3 Initiating
Holders, as the case may be, such approval not to be unreasonably withheld.

     4.   Incidental or "Piggy-Back" Registration.

          (a)  Request for Incidental Registration. If the Company proposes to
file a Registration Statement under the Securities Act with respect to an
offering by the Company for its own account (other than a Registration Statement
on Form S-4 or S-8 or any successor thereto) or for the account of any
stockholder of the Company other than the Designated Holders, then the Company
shall give written notice of such proposed filing to each of the Designated
Holders at least twenty (20) days before the anticipated filing date, and such
notice shall describe the proposed registration and distribution and offer such
Designated Holders the opportunity to register the number of Registrable
Securities as each such Designated Holder may request (an "Incidental
Registration"). The Company shall use its commercially reasonable efforts
(within twenty (20) days of the notice provided for in the preceding sentence)
to cause the managing underwriter or underwriters in the case of a proposed
underwritten offering (the "Company Underwriter") to permit each of the
Designated Holders who have requested in writing to participate in the
Incidental Registration to include its or his Registrable Securities in such
offering on the same terms and conditions as the securities of the Company or
the account of such other stockholder, as the case may be, included therein. In
connection with any Incidental Registration under this Section 4(a) involving

<PAGE>   79
                                                                               9

an underwritten offering, the Company shall not be required to include any
Registrable Securities in such underwritten offering unless the Designated
Holders thereof accept the terms of the underwritten offering as agreed upon
between the Company, such other stockholders, if any, and the Company
Underwriter, and then, subject to the immediately following sentence, only in
such quantity as the Company Underwriter believes will not jeopardize the
success of the offering by the Company. If the Company Underwriter determines
that the registration of all or part of the Registrable Securities which the
Designated Holders have requested to be included would materially adversely
affect the success of such offering, then the Company shall be required to
include in such Incidental Registration, to the extent of the amount that the
Company Underwriter believes may be sold without causing such adverse effect,
first, all of the securities to be offered for the account of the Company,
second, the Registrable Securities to be offered for the account of the
Designated Holders pursuant to this Section 4 or securities to be offered for
the account of other stockholders of the Company having similar "piggy-back"
registration rights to the Designated Holders hereunder pursuant to other
similar registration rights agreements, as a group pro rata based on the number
of Registrable Securities or similar securities owned by each such Designated
Holder or each such other stockholder of the Company, and third, any other
securities requested to be included in such offering.

          (b)  Expenses. The Company shall bear all Registration Expenses in
connection with any Incidental Registration pursuant to this Section 4, whether
or not such Incidental Registration becomes effective.

     5.   Shelf Registration.

          (a)  Request for a Form S-3 Shelf Registration. In the event that the
Company shall receive from the Designated Holders of at least 66 2/3% of the
Registrable Securities (the "S-3 Initiating Holders"), a written request that
the Company register for an offering to be made on a continuous basis pursuant
to Rule 415 under the Securities Act on Form S-3 (or any successor form then in
effect) (an "S-3 Registration"), all or a portion of the Registrable Securities
owned by such S-3 Initiating Holders, the Company shall give written notice of
such request to all of the Designated Holders (other than S-3 Initiating Holders
which have requested an S-3 Registration under this Section 5(a)) at least ten
(10) days before the anticipated filing date of such Form S-3, and such notice
shall describe the proposed registration and offer such Designated Holders the
opportunity to register the number of Registrable Securities as each such
Designated Holder may request in writing to the Company, given within ten (10)
days after their receipt from the Company of the written notice of such
registration. With respect to each S-3 Registration, the Company shall subject
to Section 5(b) (i) include in such offering the Registrable Securities of the
S-3 Initiating Holders and (ii) use its reasonable best efforts to (x) cause
such registration pursuant to this Section 5(a) to become and remain effective
as soon as practicable, but in any event not later than forty-five (45) days
after it receives a request therefor and (y) include in such offering the
Registrable Securities of the Designated Holders (other than S-3 Initiating
Holders which have requested an S-3 Registration under this Section 5(a)) who
have requested in writing to participate in such registration on the same terms
and conditions as the Registrable Securities of the S-3 Initiating Holders
included therein. The Company shall use its best

<PAGE>   80
                                                                              10

efforts to keep the S-3 Registration continuously effective under the Securities
Act until all the Registrable Securities are disposed of in accordance with the
plan of distribution for such S-3 Registration.

          (b)  Form S-3 Underwriting Procedures. If the S-3 Initiating Holders
holding a majority of the Registrable Securities held by all of the S-3
Initiating Holders so elect, the Company shall use its commercially reasonable
efforts to cause such S-3 Registration pursuant to this Section 5 to be in the
form of a firm commitment underwritten offering and the managing underwriter or
underwriters selected for such offering shall be the Approved Underwriter
selected in accordance with Section 3(g). In connection with any S-3
Registration under Section 5(a) involving an underwritten offering, the Company
shall not be required to include any Registrable Securities in such underwritten
offering unless the Designated Holders thereof accept the terms of the
underwritten offering as agreed upon between the Company, the Approved
Underwriter and the S-3 Initiating Holders, and then only in such quantity as
such underwriter believes will not jeopardize the success of such offering by
the S-3 Initiating Holders. If the Approved Underwriter believes that the
registration of all or part of the Registrable Securities which the S-3
Initiating Holders and the other Designated Holders have requested to be
included would materially adversely affect the success of such public offering,
then the Company shall be required to include in the underwritten offering, to
the extent of the amount that the Approved Underwriter believes may be sold
without causing such adverse effect, first, all of the Registrable Securities to
be offered for the account of the S-3 Initiating Holders, the Registrable
Securities to be offered for the account of the other Designated Holders who
requested inclusion of their Registrable Securities pursuant to Section 5(a),
and any other stockholder of the Company having similar shelf registration
rights as the S-3 Initiating Holders hereunder pursuant to other similar
registration rights agreements, as a group pro rata based on the number of
Registrable Securities or other similar securities owned by such S-3 Initiating
Holders, Designated Holders or other stockholders of the Company, second, the
Registrable Securities to be offered for the account of any other stockholders
of the Company who are entitled to registration of securities of the Company
based upon similar rights to those in Section 5(a), pro rata based upon the
number of registrable securities owned by such other stockholders, and third,
any other securities requested to be included in such offering.

          (c)  Limitations on Form S-3 Registrations. If the Board of Directors
has a Valid Business Reason, the Company may (x) postpone filing a Registration
Statement relating to a S-3 Registration until such Valid Business Reason no
longer exists, but in no event for more than ninety (90) days, and (y) in case a
Registration Statement has been filed relating to a S-3 Registration, if the
Valid Business Reason has not resulted from actions taken by the Company, the
Company, upon the approval of a majority of the Board of Directors, such
majority to include at least one director elected by the holders of the Series F
Preferred Stock, may cause such Registration Statement to be withdrawn and its
effectiveness terminated or may postpone amending or supplementing such
Registration Statement. The Company shall give written notice of its
determination to postpone or withdraw a Registration Statement and of the fact
that the Valid Business Reason for such postponement or withdrawal no longer

<PAGE>   81
                                                                              11

exists, in each case, promptly after the occurrence thereof. Notwithstanding
anything to the contrary contained herein, the Company may not postpone or
withdraw a filing due to a Valid Business Reason more than once in any twelve
(12) month period. In addition, the Company shall not be required to effect any
registration pursuant to Section 5(a), (i) within ninety (90) days after the
effective date of any other Registration Statement of the Company, (ii) if
within the twelve (12) month period preceding the date of such request, the
Company has effected two (2) registrations on Form S-3 pursuant to Section 5(a),
and (iii) if Form S-3 is not available for such offering by the S-3 Initiating
Holders.

          (d)  Expenses. The Company shall bear all Registration Expenses in
connection with any S-3 Registration pursuant to this Section 5, whether or not
such S-3 Registration become effective.

          (e)  No Demand Registration. No registration requested by any
Designated Holder pursuant to this Section 5 shall be deemed a Demand
Registration pursuant to Section 3.

     6.   Holdback Agreements.

          (a)  Restrictions on Public Sale by Designated Holders. To the extent
(i) requested by the Approved Underwriter or the Company Underwriter, as the
case may be, in the case of an underwritten public offering and (ii) all of the
Company's officers, directors and holders in excess of two percent (2%) of its
outstanding capital stock execute agreements identical to those referred to in
this Section 6(a), each Designated Holder agrees (x) not to effect any public
sale or distribution of any Registrable Securities or of any securities
convertible into or exchangeable or exercisable for such Registrable Securities,
including a sale pursuant to Rule 144 under the Securities Act, or offer to
sell, contract to sell (including without limitation any short sale), grant any
option to purchase or enter into any hedging or similar transaction with the
same economic effect as a sale any Registrable Securities and (y) not to make
any request for a Demand Registration or S-3 Registration under this Agreement,
during the ninety (90) day period or such shorter period, if any, mutually
agreed upon by such Designated Holder and the requesting party beginning on the
effective date of such Registration Statement (except as part of such
registration). No Designated Holder of Registrable Securities subject to this
Section 6(a) shall be released from any obligation under any agreement,
arrangement or understanding entered into pursuant to this Section 6(a) unless
all other Designated Holders of Registrable Securities subject to the same
obligation are also released.

          (b)  Restrictions on Public Sale by the Company. The Company agrees
not to effect any public sale or distribution of any of its securities, or any
securities convertible into or exchangeable or exercisable for such securities
(except pursuant to registrations on Form S-4 or S-8 or any successor thereto),
during the period beginning on the effective date of any Registration Statement
in which the Designated Holders of Registrable Securities are participating and
ending on the earlier of (i) the date on which all Registrable Securities
registered on such Registration Statement are sold and

<PAGE>   82
                                                                              12

(ii) 120 days after the effective date of such Registration Statement (except as
part of such registration).

     7.   Registration Procedures.

          (a)  Obligations of the Company. Whenever registration of Registrable
Securities has been requested pursuant to Section 3, Section 4 or Section 5 of
this Agreement, the Company shall use its commercially reasonable efforts to
effect the registration and sale of such Registrable Securities in accordance
with the intended method of distribution thereof as quickly as practicable, and
in connection with any such request, the Company shall, as expeditiously as
possible:

               (i)   prepare and file with the Commission a Registration
Statement on any form for which the Company then qualifies or which counsel for
the Company shall deem appropriate and which form shall be available for the
sale of such Registrable Securities in accordance with the intended method of
distribution thereof, and cause such Registration Statement to become effective;
provided, however, that (x) before filing a Registration Statement or prospectus
or any amendments or supplements thereto, the Company shall provide counsel
selected by the Designated Holders holding a majority of the Registrable
Securities being registered in such registration ("Holders' Counsel") and any
other Inspector with an adequate and appropriate opportunity to review and
comment on such Registration Statement and each prospectus included therein (and
each amendment or supplement thereto) to be filed with the Commission, subject
to such documents being under the Company's control, and (y) the Company shall
notify the Holders' Counsel and each seller of Registrable Securities of any
stop order issued or threatened by the Commission and take all action required
to prevent the entry of such stop order or to remove it if entered;

               (ii)  prepare and file with the Commission such amendments and
supplements to such Registration Statement and the prospectus used in connection
therewith as may be necessary to keep such Registration Statement effective for
the lesser of (x) 120 days and (y) such shorter period which will terminate when
all Registrable Securities covered by such Registration Statement have been
sold, and comply with the provisions of the Securities Act with respect to the
disposition of all securities covered by such Registration Statement during such
period in accordance with the intended methods of disposition by the sellers
thereof set forth in such Registration Statement;

               (iii) furnish to each seller of Registrable Securities, prior to
filing a Registration Statement, at least one copy of such Registration
Statement as is proposed to be filed, and thereafter such number of copies of
such Registration Statement, each amendment and supplement thereto (in each case
including all exhibits thereto), and the prospectus included in such
Registration Statement (including each preliminary prospectus) and any
prospectus filed under Rule 424 under the Securities Act as each such seller may
reasonably request in order to facilitate the disposition of the Registrable
Securities owned by such seller;

<PAGE>   83
                                                                              13

               (iv)  register or qualify such Registrable Securities under such
other securities or "blue sky" laws of such jurisdictions as any seller of
Registrable Securities may request, and to continue such qualification in effect
in such jurisdiction for as long as permissible pursuant to the laws of such
jurisdiction, or for as long as any such seller requests or until all of such
Registrable Securities are sold, whichever is shortest, and do any and all other
acts and things which may be reasonably necessary or advisable to enable any
such seller to consummate the disposition in such jurisdictions of the
Registrable Securities owned by such seller; provided, however, that the Company
shall not be required to (x) qualify generally to do business in any
jurisdiction where it would not otherwise be required to qualify but for this
Section 7(a)(iv), (y) subject itself to taxation in any such jurisdiction or (z)
consent to general service of process in any such jurisdiction;

               (v)   notify each seller of Registrable Securities at any time
when a prospectus relating thereto is required to be delivered under the
Securities Act, upon discovery that, or upon the happening of any event as a
result of which, the prospectus included in such Registration Statement contains
an untrue statement of a material fact or omits to state any material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading and the
Company shall promptly prepare a supplement or amendment to such prospectus and
furnish to each seller of Registrable Securities a reasonable number of copies
of such supplement to or an amendment of such prospectus as may be necessary so
that, after delivery to the purchasers of such Registrable Securities, such
prospectus shall not contain an untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made,
not misleading;

               (vi)  enter into and perform customary agreements (including an
underwriting agreement in form requested by the Approved Underwriter or Company
Underwriter, if any, selected as provided in Section 3, Section 4 or Section 5,
as the case may be) and take such other actions as are prudent and reasonably
required in order to expedite or facilitate the disposition of such Registrable
Securities, including causing its officers to participate in "road shows" and
other information meetings organized by the Approved Underwriter or Company
Underwriter;

               (vii) make available at reasonable times for inspection by any
seller of Registrable Securities, any managing underwriter participating in any
disposition of such Registrable Securities pursuant to a Registration Statement,
Holders' Counsel and any attorney, accountant or other agent retained by any
such seller or any managing underwriter (each, an "Inspector" and collectively,
the "Inspectors"), all financial and other records, pertinent corporate
documents and properties of the Company and its subsidiaries (collectively, the
"Records") as shall be reasonably necessary to enable them to exercise their due
diligence responsibility, and cause the Company's and its subsidiaries'
officers, directors and employees, and the independent public accountants of the
Company, to supply all information reasonably requested by any such Inspector in
connection with such Registration Statement. Records that the Company
determines, in good faith, to be confidential and which it notifies the
Inspectors are

<PAGE>   84
                                                                              14

confidential shall not be disclosed by the Inspectors (and the Inspectors shall
confirm their agreement in writing in advance to the Company if the Company
shall so request) unless (x) the disclosure of such Records is necessary, in the
Company's judgment, to avoid or correct a misstatement or omission in the
Registration Statement, (y) the release of such Records is ordered pursuant to a
subpoena or other order from a court of competent jurisdiction after exhaustion
of all appeals therefrom or (z) the information in such Records was known to the
Inspectors on a non-confidential basis prior to its disclosure by the Company or
has been made generally available to the public. Each seller of Registrable
Securities agrees that it shall, upon learning that disclosure of such Records
is sought in a court of competent jurisdiction, give notice to the Company and
allow the Company, at the Company's expense, to undertake appropriate action to
prevent disclosure of the Records deemed confidential;

               (viii) if such sale is pursuant to an underwritten offering,
obtain a "cold comfort" letter dated the effective date of the Registration
Statement and the date of the closing under the underwriting agreement from the
Company's independent public accountants in customary form and covering such
matters of the type customarily covered by "cold comfort" letters as Holders'
Counsel or the managing underwriter reasonably requests;

               (ix)   furnish, at the request of any seller of Registrable
Securities on the date such securities are delivered to the underwriters for
sale pursuant to such registration or, if such securities are not being sold
through underwriters, on the date the Registration Statement with respect to
such securities becomes effective, an opinion, dated such date, of counsel
representing the Company for the purposes of such registration, addressed to the
underwriters, if any, and to the seller making such request, covering such legal
matters with respect to the registration in respect of which such opinion is
being given as the underwriters, if any, and such seller may reasonably request
and are customarily included in such opinions;

               (x)    comply with all applicable rules and regulations of the
Commission, and make available to its security holders, as soon as reasonably
practicable but no later than fifteen (15) months after the effective date of
the Registration Statement, an earnings statement covering a period of twelve
(12) months beginning after the effective date of the Registration Statement, in
a manner which satisfies the provisions of Section 11(a) of the Securities Act
and Rule 158 thereunder;

               (xi)   cause all such Registrable Securities to be listed on each
securities exchange on which similar securities issued by the Company are then
listed, provided that the applicable listing requirements are satisfied;

               (xii)  keep Holders' Counsel advised in writing as to the
initiation and progress of any registration under Section 3, Section 4 or
Section 5 hereunder;

               (xiii) cooperate with each seller of Registrable Securities and
each underwriter participating in the disposition of such Registrable Securities
and

<PAGE>   85
                                                                              15

their respective counsel in connection with any filings required to be made with
the NASD; and

               (xiv)  take all other steps reasonably necessary to effect the
registration of the Registrable Securities contemplated hereby.

          (b)  Seller Information. The Company may require each seller of
Registrable Securities as to which any registration is being effected to
furnish, and such seller shall furnish, to the Company such information
regarding the distribution of such securities as the Company may from time to
time reasonably request in writing.

          (c)  Notice to Discontinue. Each Designated Holder agrees that, upon
receipt of any notice from the Company of the happening of any event of the kind
described in Section 7(a)(v), such Designated Holder shall forthwith discontinue
disposition of Registrable Securities pursuant to the Registration Statement
covering such Registrable Securities until such Designated Holder's receipt of
the copies of the supplemented or amended prospectus contemplated by Section
7(a)(v) and, if so directed by the Company, such Designated Holder shall deliver
to the Company (at the Company's expense) all copies, other than permanent file
copies then in such Designated Holder's possession, of the prospectus covering
such Registrable Securities which is current at the time of receipt of such
notice. If the Company shall give any such notice, the Company shall extend the
period during which such Registration Statement shall be maintained effective
pursuant to this Agreement (including, without limitation, the period referred
to in Section 7(a)(ii)) by the number of days during the period from and
including the date of the giving of such notice pursuant to Section 7(a)(v) to
and including the date when sellers of such Registrable Securities under such
Registration Statement shall have received the copies of the supplemented or
amended prospectus contemplated by and meeting the requirements of Section
7(a)(v).

          (d)  Registration Expenses. The Company shall pay all expenses arising
from or incident to its performance of, or compliance with, this Agreement,
including, without limitation, (i) Commission, stock exchange and NASD
registration and filing fees, (ii) all fees and expenses incurred in complying
with securities or "blue sky" laws (including reasonable fees, charges and
disbursements of counsel to any underwriter incurred in connection with "blue
sky" qualifications of the Registrable Securities as may be set forth in any
underwriting agreement), (iii) all printing, messenger and delivery expenses,
(iv) the fees, charges and expenses of one counsel to the Company and of its
independent public accountants and any other accounting fees, charges and
expenses incurred by the Company (including, without limitation, any expenses
arising from any "cold comfort" letters or any special audits incident to or
required by any registration or qualification) and, in the case of Demand
Registration or an S-3 Registration, any legal fees, charges and expenses of one
special counsel selected by the Initiating Holders or the S-3 Initiating
Holders, as the case may be, (v) any liability insurance or other premiums for
insurance obtained in connection with any Demand Registration or piggy-back
registration thereon, Incidental Registration or S-3 Registration pursuant to
the terms of this Agreement, regardless of whether such Registration Statement
is declared effective and (vi) fees and disbursements of

<PAGE>   86
                                                                              16

underwriters, selling brokers, dealers, managers and similar securities industry
professionals relating to distribution of Registrable Securities. All of the
expenses described in the preceding sentence of this Section 7(d) are referred
to herein as "Registration Expenses." The Designated Holders of Registrable
Securities sold pursuant to a Registration Statement shall bear the expense of
any broker's commission or underwriter's discount or commission relating to
registration and sale of such Designated Holders' Registrable Securities in
proportion to the number of Registrable Securities that each Designated Holder
shall have registered pursuant to such Registration Statement and, subject to
clause (iv) above, shall bear the fees and expenses of their own counsel.

     8.   Indemnification; Contribution.

          (a)  Indemnification by the Company. The Company agrees to indemnify
and hold harmless each Designated Holder, its partners, directors, officers,
affiliates and each Person who controls (within the meaning of Section 15 of the
Securities Act) such Designated Holder from and against any and all losses,
claims, damages, liabilities and expenses (including reasonable costs of
investigation) (each, a "Liability" and collectively, "Liabilities"), arising
out of or based upon any untrue, or allegedly untrue, statement of a material
fact contained in any Registration Statement, prospectus or preliminary
prospectus or notification or offering circular (as amended or supplemented if
the Company shall have furnished any amendments or supplements thereto) or
arising out of or based upon any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading under the circumstances such statements were made, except
insofar as such Liability arises out of or is based upon any untrue statement or
alleged untrue statement or omission or alleged omission contained in such
Registration Statement, preliminary prospectus or final prospectus in reliance
and in conformity with information concerning such Designated Holder furnished
in writing to the Company by such Designated Holder expressly for use therein,
including, without limitation, the information furnished to the Company pursuant
to Section 8(b). The Company shall also provide customary indemnities to any
underwriters of the Registrable Securities, their officers, directors and
employees and each Person who controls such underwriters (within the meaning of
Section 15 of the Securities Act) to the same extent as provided above with
respect to the indemnification of the Designated Holders of Registrable
Securities.

          (b)  Indemnification by Designated Holders. In connection with any
Registration Statement in which a Designated Holder is participating pursuant to
Section 3, Section 4 or Section 5 hereof, each such Designated Holder shall
promptly furnish to the Company in writing such information with respect to such
Designated Holder as the Company may reasonably request or as may be required by
law for use in connection with any such Registration Statement or prospectus and
all information required to be disclosed in order to make the information
previously furnished to the Company by such Designated Holder not materially
misleading or necessary to cause such Registration Statement not to omit a
material fact with respect to such Designated Holder necessary in order to make
the statements therein not misleading. Each Designated Holder agrees to
indemnify and hold harmless the Company, any underwriter retained by the Company
and each Person who controls the Company or such underwriter

<PAGE>   87
                                                                              17

(within the meaning of Section 15 of the Securities Act) to the same extent as
the foregoing indemnity from the Company to the Designated Holders, but only if
such statement or alleged statement or omission or alleged omission was made in
reliance upon and in conformity with information with respect to such Designated
Holder furnished in writing to the Company by such Designated Holder expressly
for use in such Registration Statement or prospectus, including, without
limitation, the information furnished to the Company pursuant to this Section
8(b); provided, however, that the total amount to be indemnified by such
Designated Holder pursuant to this Section 8(b) shall be limited to the net
proceeds received by such Designated Holder in the offering to which the
Registration Statement or prospectus relates.

          (c)  Conduct of Indemnification Proceedings. Any Person entitled to
indemnification hereunder (the "Indemnified Party") agrees to give prompt
written notice to the indemnifying party (the "Indemnifying Party") after the
receipt by the Indemnified Party of any written notice of the commencement of
any action, suit, proceeding or investigation or threat thereof made in writing
for which the Indemnified Party intends to claim indemnification or contribution
pursuant to this Agreement; provided, however, that the failure so to notify the
Indemnifying Party shall not relieve the Indemnifying Party of any Liability
that it may have to the Indemnified Party hereunder (except to the extent that
the Indemnifying Party is materially prejudiced or otherwise forfeits
substantive rights or defenses by reason of such failure). If notice of
commencement of any such action is given to the Indemnifying Party as above
provided, the Indemnifying Party shall be entitled to participate in and, to the
extent it may wish, jointly with any other Indemnifying Party similarly
notified, to assume the defense of such action at its own expense, with counsel
chosen by it and reasonably satisfactory to such Indemnified Party. The
Indemnified Party shall have the right to employ separate counsel in any such
action and participate in the defense thereof, but the fees and expenses of such
counsel shall be paid by the Indemnified Party unless (i) the Indemnifying Party
agrees to pay the same, (ii) the Indemnifying Party fails to assume the defense
of such action with counsel reasonably satisfactory to the Indemnified Party or
(iii) the named parties to any such action (including any impleaded parties)
include both the Indemnifying Party and the Indemnified Party and such parties
have been advised by such counsel that either (x) representation of such
Indemnified Party and the Indemnifying Party by the same counsel would be
inappropriate under applicable standards of professional conduct or (y) there
may be one or more legal defenses available to the Indemnified Party which are
different from or additional to those available to the Indemnifying Party. In
any of such cases, the Indemnifying Party shall not have the right to assume the
defense of such action on behalf of such Indemnified Party, it being understood,
however, that the Indemnifying Party shall not be liable for the fees and
expenses of more than one separate firm of attorneys (in addition to any local
counsel) for all Indemnified Parties. No Indemnifying Party shall be liable for
any settlement entered into without its written consent, which consent shall not
be unreasonably withheld. No Indemnifying Party shall, without the consent of
such Indemnified Party, effect any settlement of any pending or threatened
proceeding in respect of which such Indemnified Party is a party and indemnity
has been sought hereunder by such Indemnified Party, unless such settlement
includes an unconditional

<PAGE>   88
                                                                              18

release of such Indemnified Party from all liability for claims that are the
subject matter of such proceeding.

          (d)  Contribution. If the indemnification provided for in this Section
8 from the Indemnifying Party is unavailable to an Indemnified Party hereunder
in respect of any Liabilities referred to herein, then the Indemnifying Party,
in lieu of indemnifying such Indemnified Party, shall contribute to the amount
paid or payable by such Indemnified Party as a result of such Liabilities in
such proportion as is appropriate to reflect the relative fault of the
Indemnifying Party and Indemnified Party in connection with the actions which
resulted in such Liabilities, as well as any other relevant equitable
considerations. The relative faults of such Indemnifying Party and Indemnified
Party shall be determined by reference to, among other things, whether any
action in question, including any untrue or alleged untrue statement of a
material fact or omission or alleged omission to state a material fact, has been
made by, or relates to information supplied by, such Indemnifying Party or
Indemnified Party, and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such action. The amount paid
or payable by a party as a result of the Liabilities referred to above shall be
deemed to include, subject to the limitations set forth in Sections 8(a), 8(b)
and 8(c), any legal or other fees, charges or expenses reasonably incurred by
such party in connection with any investigation or proceeding; provided that the
total amount to be contributed by such Designated Holder shall be limited to the
net proceeds received by such Designated Holder in the offering.

     The parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 8(d) were determined by pro rata
allocation or by any other method of allocation which does not take account of
the equitable considerations referred to in the immediately preceding paragraph.
No Person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any Person
who was not guilty of such fraudulent misrepresentation.

     9.   Rule 144. The Company covenants that it shall (a) file any reports
required to be filed by it under the Exchange Act and (b) take such further
action as each Designated Holder may reasonably request (including providing any
information necessary to comply with Rule 144 under the Securities Act), all to
the extent required from time to time to enable such Designated Holder to sell
Registrable Securities without registration under the Securities Act within the
limitation of the exemptions provided by (i) Rule 144 under the Securities Act,
as such rule may be amended from time to time, or Regulation S under the
Securities Act or (ii) any similar rules or regulations hereafter adopted by the
Commission. The Company shall, upon the request of any Designated Holder,
deliver to such Designated Holder a written statement as to whether it has
complied with such requirements.

     10.  Miscellaneous.

          (a)  Recapitalizations, Exchanges, etc. The provisions of this
Agreement shall apply to the full extent set forth herein with respect to (i)
the shares of

<PAGE>   89
                                                                              19

Common Stock, (ii) any and all shares of voting common stock of the Company into
which the shares of Common Stock are converted, exchanged or substituted in any
recapitalization or other capital reorganization by the Company and (iii) any
and all equity securities of the Company or any successor or assign of the
Company (whether by merger, consolidation, sale of assets or otherwise) which
may be issued in respect of, in conversion of, in exchange for or in
substitution of, the shares of Common Stock and shall be appropriately adjusted
for any stock dividends, splits, reverse splits, combinations, recapitalizations
and the like occurring after the date hereof. The Company shall cause any
successor or assign (whether by merger, consolidation, sale of assets or
otherwise) to enter into a new registration rights agreement with the Designated
Holders on terms substantially the same as this Agreement as a condition of any
such transaction.

          (b)  No Inconsistent Agreements. Except for the Fifth Amended and
Restated Investor Rights Agreement, the Company represents and warrants that it
has not granted to any Person the right to request or require the Company to
register any securities issued by the Company, other than the rights granted to
the Designated Holders herein. The Company shall not enter into any agreement
with respect to its securities that is inconsistent with the rights granted to
the Designated Holders in this Agreement or grant any additional registration
rights to any Person or with respect to any securities which are not Registrable
Securities which are prior in right to or inconsistent with the rights granted
in this Agreement.

          (c)  Remedies. The Designated Holders, in addition to being entitled
to exercise all rights granted by law, including recovery of damages, shall be
entitled to specific performance of their rights under this Agreement. The
Company agrees that monetary damages would not be adequate compensation for any
loss incurred by reason of a breach by it of the provisions of this Agreement
and hereby agrees to waive in any action for specific performance the defense
that a remedy at law would be adequate.

          (d)  Amendments and Waivers. Except as otherwise provided herein, the
provisions of this Agreement may not be amended, modified or supplemented, and
waivers or consents to departures from the provisions hereof may not be given
unless consented to in writing by each of (i) the Company, (ii) the General
Atlantic Stockholders and (iii) the ICP Stockholders. Any such written consent
shall be binding upon the Company and all of the Designated Holders.

          (e)  Notices. All notices, demands and other communications provided
for or permitted hereunder shall be made in writing and shall be made by
registered or certified first-class mail, return receipt requested, telecopier,
courier service or personal delivery:

               (i)  if to the Company:

                    Tickets.com, Inc.
                    555 Anton Boulevard, 12th Floor
                    Costa Mesa, CA  92626
                    Telecopy:  (714) 327-5410
                    Attention: W. Thomas Gimple

<PAGE>   90
                                                                              20

                    with a copy to:

                    Brobeck Phleger & Harrison LLP
                    550 South Hope Street
                    Los Angeles, CA  90071-2604
                    Telecopy:  (213) 745-3345
                    Attention:  Richard S. Chernicoff, Esq.

                    if to GAP LP, GapStar or GAP Coinvestment:

                    c/o General Atlantic Service Corporation
                    3 Pickwick Plaza
                    Greenwich, CT  06830
                    Telecopy:  (203) 622-8818
                    Attention: Steven A. Denning

                    with a copy to:

                    Paul, Weiss, Rifkind, Wharton & Garrison
                    1285 Avenue of the Americas
                    New York, NY 10019-6064
                    Telecopy:  (212) 757-3990
                    Attention:  Douglas A. Cifu, Esq.

               (ii) if to ICP:

                    International Capital Partners, Inc.,
                      Profit Sharing Trust
                    300 First Stamford Place
                    Stamford, CT  06902
                    Telecopy:  (203) 969-2212
                    Attention: Nicholas E. Sinacori

                    with copy to:

                    Cummings & Lockwood
                    Four Stamford Plaza
                    Stamford, CT  06904
                    Telecopy:  203-351-4534
                    Attention:  Stephen Marcovich, Esq.

     All such notices, demands and other communications shall be deemed to have
been duly given when delivered by hand, if personally delivered; when delivered
by courier, if delivered by commercial courier service, seven (7) days after
being deposited

<PAGE>   91
                                                                              21

in the mail, postage prepaid, if mailed; and when receipt is mechanically
acknowledged, if telecopied. Any party may by notice given in accordance with
this Section 10(e) designate another address or Person for receipt of notices
hereunder.

          (f)  Successors and Assigns; Third Party Beneficiaries. This Agreement
shall inure to the benefit of and be binding upon the successors and permitted
assigns of the parties hereto as hereinafter provided. The Demand Registration
rights and the S-3 Registration rights and related rights of the General
Atlantic Stockholders or the ICP Stockholders contained in Sections 3 and 5
hereof, shall be (i) with respect to any Registrable Security that is
transferred to an Affiliate of a General Atlantic Stockholder or an ICP
Stockholder, automatically transferred to such Affiliate, (ii) with respect to
any Registrable Security that is transferred in accordance with the provisions
of Section 12.3 of the Stock Purchase Agreement to one of the accredited
investors previously identified to the Company and the GAP Purchasers (each, an
"Additional Investor" and collectively, the "Additional Investors"),
automatically transferred to such Additional Investor, (iii) with respect to any
Registrable Security that is transferred to any Person who has an investment
management agreement containing a power of attorney with that certain investment
advisor previously identified to the Company and the GAP Purchasers that acts on
behalf of certain of the Additional Investors, automatically to such Person and
(iv) with respect to any Registrable Security that is transferred in all cases
to a non-Affiliate or an Affiliate of an Additional Investor, transferred only
with the consent of the Company which consent shall not be unreasonably
withheld. The incidental or "piggy-back" registration rights of the Designated
Holders contained in Sections 3(b), 4 and 5 hereof and the other rights of each
of the Designated Holders with respect thereto shall be, with respect to any
Registrable Security, automatically transferred to any Person who is the
transferee of such Registrable Security. All of the obligations of the Company
hereunder shall survive any such transfer. Except as provided in Section 8, no
Person other than the parties hereto and their successors and permitted assigns
is intended to be a beneficiary of this Agreement.

          (g)  Counterparts. This Agreement may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same agreement.

          (h)  Headings. The headings in this Agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

          (i)  GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE
PRINCIPLES OF CONFLICTS OF LAW THEREOF.

          (j)  Severability. If any one or more of the provisions contained
herein, or the application thereof in any circumstance, is held invalid, illegal
or unenforceable in any respect for any reason, the validity, legality and
enforceability of any such provision in every other respect and of the remaining
provisions hereof shall not

<PAGE>   92
                                                                              22

be in any way impaired, unless the provisions held invalid, illegal or
unenforceable shall substantially impair the benefits of the remaining
provisions hereof.

          (k)  Rules of Construction. Unless the context otherwise requires,
references to sections or subsections refer to sections or subsections of this
Agreement.

          (l)  Entire Agreement. This Agreement is intended by the parties as a
final expression of their agreement and intended to be a complete and exclusive
statement of the agreement and understanding of the parties hereto in respect of
the subject matter contained herein. There are no restrictions, promises,
representations, warranties or undertakings, other than those set forth or
referred to herein. This Agreement supersedes all prior agreements and
understandings among the parties with respect to such subject matter.

          (m)  Further Assurances. Each of the parties shall execute such
documents and perform such further acts as may be reasonably required or
desirable to carry out or to perform the provisions of this Agreement.

          (n)  Other Agreements. Nothing contained in this Agreement shall be
deemed to be a waiver of, or release from, any obligations any party hereto may
have under, or any restrictions on the transfer of Registrable Securities or
other securities of the Company imposed by, any other agreement including, but
not limited to, the Stock Purchase Agreement.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

<PAGE>   93
                                                                              23

     IN WITNESS WHEREOF, the undersigned have executed, or have caused to be
executed, this Registration Rights Agreement on the date first written above.

                                           TICKETS.COM, INC.

                                           By:
                                               --------------------------------
                                           Name:
                                           Title:

                                           GENERAL ATLANTIC PARTNERS 74, L.P.

                                           By: GENERAL ATLANTIC PARTNERS, LLC,
                                               its General Partner

                                               By:
                                                   ----------------------------
                                               Name:
                                               Title:

                                           GAP COINVESTMENT PARTNERS II, L.P.

                                           By:
                                               --------------------------------
                                           Name:
                                           Title:

                                           GAPSTAR, LLC

                                           By: GENERAL ATLANTIC PARTNERS, LLC,
                                               its General Partner

                                               By:
                                                   ----------------------------
                                               Name:
                                               Title:

                                           INTERNATIONAL CAPITAL PARTNERS, INC.,
                                           PROFIT SHARING TRUST

                                           By:
                                               --------------------------------
                                           Name:
                                           Title:Prepared by MerrillDirect

Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

Exhibit 10.37

COLLABORATIVE
LICENSE AGREEMENT

Between

Cerus Corporation

And

Kirin Brewery Company, Limited

 

	
  TABLE OF CONTENTS
  
	 
  
	
  RECITALS
  
	 
  	 
  
	
  ARTICLE 1 – DEFINITIONS
  
	 
  	
  1.1
  	
  ACIT Technology
  
	 
  	
  1.2
  	
  Affiliate
  
	 
  	
  1.3
  	
  Controlled
  
	 
  	
  1.4
  	
  Cerus Improvement
  
	 
  	
  1.5
  	
  Cerus Know-How
  
	 
  	
  1.6
  	
  Cerus Patents
  
	 
  	
  1.7
  	
  Cerus Territory
  
	 
  	
  1.8
  	
  Compound
  
	 
  	
  1.9
  	
  Core ACIT Research
  and Development
  
	 
  	
  1.10
  	
  Development
  Committee
  
	 
  	
  1.11
  	
  Development Program
  
	 
  	
  1.12
  	
  Drug Approval
  Application
  
	 
  	
  1.13
  	
  Field
  
	 
  	
  1.14
  	
  Illumination Devices
  
	 
  	
  1.15
  	
  Information
  
	 
  	
  1.16
  	
  Kirin
  Improvement Patents
  
	 
  	
  1.17
  	
  Kirin Improvements
  
	 
  	
  1.18
  	
  Kirin Know-How
  
	 
  	
  1.19
  	
  Kirin Technology
  
	 
  	
  1.20
  	
  Kirin Territory
  
	 
  	
  1.21
  	
  Kits
  
	 
  	
  1.22
  	
  Manufacturing Agreement
  
	 
  	
  1.23
  	
  Net Revenue
  
	 
  	
  1.24
  	
  Patent
  
	 
  	
  1.25
  	
  Patent Costs
  
	 
  	
  1.26
  	
  Pivotal Study
  
	 
  	
  1.27
  	
  Product
  
	 
  	
  1.28
  	
  Reasonable Efforts
  
	 
  	
  1.29
  	
  Regulatory Approval
  
	 
  	
  1.30
  	
  Sublicensee
  
	 
  	
  1.31
  	
  Summary of Supply
  Terms
  
	 
  	
  1.32
  	
  S-59
  
	 
  	
  1.33
  	
  Third Party
  Royalties
  
	 
  	
  1.34
  	
  Third Party
  
	 
  	 
  
	
  ARTICLE 2 – LICENSES AND RELATED RIGHTS 
  
	 
  	
  2.1
  	
  Licenses Granted to Kirin
  
	 
  	
  2.2
  	
  Licenses Granted to Cerus
  
	 
  	
  2.3
  	
  Notice of
  Development for New Indications
  
	 
  	
  2.4
  	
  Cerus License to Third
  Parties
  
	 
  	
  2.5
  	
  Trademark Rights
  
	 
  	 
  	 
  
	
  ARTICLE 3 – MANAGEMENT
  
	 
  	
  3.1
  	
  The Development Committee
  
	 
  	
  3.2
  	
  Development Committee
  Meetings
  
	 
  	
  3.3
  	
  Decision-Making
  and Issue Resolution
  
	 
  	
  3.4
  	
  Other Research
  
	 
  	 
  	 
  
	
  ARTICLE 4 – RESEARCH AND DEVELOPMENT FUNDING
  
	 
  	
  4.1
  	
  Funding for Initial
  Indications
  
	 
  	
  4.2
  	
  Funding for New Indications
  
	 
  	
  4.3
  	
  Funding for Kirin Territory
  
	 
  	
  4.4
  	
  Cerus Funding
  
	 
  	
  4.5
  	
  Kirin Decision Not to
  Participate
  
	 
  	
  4.6
  	
  Core ACIT
  Research and Development Costs
  
	 
  	
  4.7
  	
  Development Efforts
  and Expenses
  
	 
  	
  4.8
  	
  Advance Payments
  
	 
  	
  4.9
  	
  Expenditures
  
	 
  	
  4.10
  	
  Reconciliation of
  Expenditures
  
	 
  	 
  	 
  
	
  ARTICLE
  5 – DEVELOPMENT AND MARKETING IN THE KIRIN TERRITORY
  
	 
  	
  5.1
  	
  Kirin Efforts
  
	 
  	
  5.2
  	
  Meetings Concerning
  Marketing
  
	 
  
	
  ARTICLE 6 – MILESTONE DEVELOPMENT PAYMENTS
  
	 
  	
  6.1
  	
  Milestone Development
  Payments
  
	 
  	
  6.2
  	
  Withholding Taxes
  
	 
  	
  6.3
  	
  Method of Payment
  
	 
  	
  6.4
  	
  Application
  of Milestone Development Payments
  
	 
  
	
  ARTICLE 7 – ROYALTIES
  
	 
  	
  7.1
  	
  Royalties on Sales of
  Products
  
	 
  	
  7.2
  	
  Payment of Royalties
  
	 
  	
  7.3
  	
  Royalty
  Structure and Marketing Strategy
  
	 
  	
  7.4
  	
  Withholding Taxes
  
	 
  	
  7.5
  	
  Third Party Royalties
  
	 
  
	
  ARTICLE 8 – CONFIDENTIALITY
  
	 
  	
  8.1
  	
  Confidentiality; Exceptions
  
	 
  	
  8.2
  	
  Authorized Disclosure
  
	 
  	
  8.3
  	
  Survival
  
	 
  	 
  	 
  
	
  ARTICLE 9 – INTELLECTUAL PROPERTY
  
	 
  	
  9.1
  	
  Ownership
  
	 
  	
  9.2
  	
  Prosecution
  and Maintenance of Patents by Cerus; Abandonment
  
	 
  	
  9.3
  	
  Prosecution
  and Maintenance of Patents by Cerus; Abandonment
  
	 
  	
  9.4
  	
  Defense and Settlement of
  Third Party Claims
  
	 
  	
  9.5
  	
  Enforcement of Patent Rights
  
	 
  	 
  	 
  
	
  ARTICLE 10 –
  REPRESENTATIONS AND WARRANTIES; UNDERTAKINGS CONCERNING SUPPLY
  
	 
  	
  10.1
  	
  Representations and
  Warranties
  
	 
  	
  10.2
  	
  Cerus Warranties and
  Undertakings
  
	 
  
	
  ARTICLE 11 – REPORTS,
  RECORDS AND MATERIAL
  
	 
  	
  11.1
  	
  Sharing
  of Information
  
	 
  	
  11.2
  	
  Records
  of Net Revenue
  
	 
  	
  11.3
  	
  Materials; Technical
  Support
  
	 
  	
  11.4
  	
  Publicity
  Review
  
	 
  	
  11.5
  	
  Publications
  
	 
  	
  11.6
  	
  Adverse
  Event Reporting
  
	 
  
	
  ARTICLE 12 – TERM
  AND TERMINATION
  
	 
  	
  12.1
  	
  Term
  
	 
  	
  12.2
  	
  Termination
  for Breach
  
	 
  	
  12.3
  	
  Surviving
  Rights
  
	 
  	
  12.4
  	
  Non-exclusive
  Licenses after Expiration
  
	 
  	
  12.5
  	
  Termination
  by Kirin Without Cause
  
	 
  	
  12.6
  	
  Termination
  by Cerus of Funding Without Cause
  
	 
  
	
  ARTICLE 13 –
  INDEMNIFICATION AND INSURANCE
  
	 
  	
  13.1
  	
  Indemnification in
  Kirin Territory
  
	 
  	
  13.2
  	
  Indemnification in
  Cerus Territory
  
	 
  	
  13.3
  	
  Indemnification Procedure
  
	 
  	
  13.4
  	
  Insurance
  
	 
  
	
  ARTICLE 14 –
  MISCELLANEOUS 
  
	 
  	
  14.1
  	
  Assignment
  
	 
  	
  14.2
  	
  Retained Rights
  
	 
  	
  14.3
  	
  Force Majeure
  
	 
  	
  14.4
  	
  Further
  Actions
  
	 
  	
  14.5
  	
  No
  Trademark Rights
  
	 
  	
  14.6
  	
  Notices
  
	 
  	
  14.7
  	
  Dispute
  Resolution
  
	 
  	
  14.8
  	
  Waiver
  
	 
  	
  14.9
  	
  Severability
  
	 
  	
  14.10
  	
  Ambiguities
  
	 
  	
  14.11
  	
  Entire
  Agreement
  
	 
  	
  14.12
  	
  Headings
  
						

 [ * ] = Certain
confidential information contained in this document, marked by brackets, has
been omitted and filed separately  with
the Securities and Exchange Commission pursuant to  24-B2 of the Securities Exchange Act of 1934, as amended.

	
  EXHIBIT A 
  	
  CERUS PATENTS
  
	
  EXHIBIT B 
  	
  KIRIN TERRITORY
  
	
  EXHIBIT C 
  	
  SUMMARY OF TERMS OF MANUFACTURING AND
  SUPPLY
  

COLLABORATIVE
LICENSE AGREEMENT

This Collaborative
License Agreement (the "Agreement") is made and entered into
effective as of December 31, 2000 (the "Effective Date") by and
between Cerus
Corporation, a Delaware corporation having its principal place of
business at 2411 Stanwell Drive, Concord, California, U.S.A.
("Cerus"), and Kirin Brewery Company, Limited
a corporation organized and existing under the laws of Japan having its
principal place of business at 10-1, Shinkawa 2-chome, Chuo-ku, Tokyo, Japan
("Kirin").  Cerus and Kirin may be referred to herein
collectively as the "Parties" or individually as a "Party."

RECITALS

	
  A.
  	
  Cerus has developed and owns certain proprietary
  ACIT Technology (as defined below), and Kirin possesses research, development
  and marketing capabilities for pharmaceutical and other medical products.
  
	
  B.
  	
  Kirin desires to obtain from Cerus a license to
  develop and commercialize, in Japan and certain other Asian and Oceanic
  countries, Products based on such technology.
  
	
  C.
  	
  Cerus and Kirin will enter into a Manufacturing
  Agreement consistent with the Summary of Supply Terms, which will establish
  the terms and conditions for the Parties' purchase and supply of Kits and
  Illumination Devices.
  

NOW, THEREFORE,
the Parties agree as follows:

ARTICLE 1

DEFINITIONS

The following
terms shall have the following meanings as used in this Agreement:

1.1          “ACIT
Technology”  means technology to
treat leukocytes to inhibit proliferation but preserve leukocyte function,
leukocytes so treated and methods of use of such leukocytes, including
Illumination Devices and Compounds used in such treatment, and including the
Cerus Know-How, the Cerus Improvements and the Cerus Patents, either
collectively or any part thereof.  For the purpose of such definition, the
term "preserve leukocyte function" means that the leukocytes continue
both to [ * ] and [ * ]. 
For the purpose of clarity, it is understood that Cerus is separately
pursuing programs for inactivation of pathogens; any inactivation or modulation
of the activity of leukocytes incidental to such pathogen inactivation shall be
considered outside the definition of ACIT Technology.

1.2          "Affiliate"  means, with respect to a particular Party, a person
,
corporation or other entity that, directly or indirectly, through one or more
intermediaries, controls, is controlled by or is under common control with such
Party. For the purposes of this definition, "control" means the
direct or indirect ownership by a Party of at least fifty percent (50%) of the
outstanding voting securities of the controlled entity; provided, that in any
country where the law does not permit foreign equity ownership of at least
fifty percent (50%), then with respect to corporations organized under such
country's laws, "control" shall mean the direct or indirect ownership
by a Party of outstanding voting securities of such corporation at the maximum
amount permitted by the law of such country.

1.3          "Controlled"  means, with respect to

a particular item, material, or intellectual property right, that a Party owns
or has a license under such item, material or intellectual property right and
has the ability to grant to the other Party access to and/or a license or
sublicense under such item, material or intellectual property right as provided
for herein without violating the terms of any agreement or other arrangement
with, or the rights of, any Third Party.

1.4          "Cerus Improvement"  means any improvement to ACIT
Technology in
the Field, including new applications of the ACIT Technology, that is made and
Controlled by Cerus during the term of the Development Program.

1.5          "Cerus Know-How"  means all
Information Controlled by Cerus during the term of the Development Program that
relates to ACIT Technology in the Field.

1.6          "Cerus Patents" means the
Patents and Patent applications Controlled by Cerus during the term of the
Agreement, that claim an invention in the Cerus Know-How or Cerus Improvements.
Such Patents existing as of the Effective Date are listed on Exhibit A, and
Cerus will use reasonable efforts to amend such Exhibit A from time to time to
reflect any changes.  Cerus warrants and represents to Kirin that Exhibit A is a complete and accurate list of all Cerus Patents as of the Effective
Date and that Cerus has the full right and authority to grant to Kirin the
licenses and/or sublicenses granted herein under all such Cerus Patents.

1.7          "Cerus Territory"  means all countries of
the world and all territories and possessions thereof, excluding all countries,
territories and possessions within the Kirin Territory.

1.8          "Compound" means, with
respect to a particular Product, any proprietary compound of Cerus,including without limitation
S-59, that is required for commercial manufacture and/or use of such Product.

1.9          “Core ACIT Research and Development”  is non-clinical research and development and
clinical development intended to support a Drug Approval Application with the
U.S. Food and Drug Administration (“FDA”).

1.10        "Development Committee"  shall have the meaning
set forth in Section 3.1.

1.11        "Development Program"  means, collectively, all of the projects to
develop Products to be carried out pursuant to this Agreement.

1.12        "Drug Approval Application" means an application for
Regulatory
Approval required before commercial sale or use of a Product for human therapy
or prophylaxis in a regulatory jurisdiction.

1.13        "Field"  means leukocytes for
human therapeutic or prophylactic use.

1.14        “Illumination Devices” means devices to emit light of a wavelength
appropriate to activate a Compound to cross-link with nucleic acid of
leukocytes.

1.15        "Information"  means any and
all information and data of any kind, including without limitation techniques,
inventions, practices, methods, knowledge, know-how, skill, experience, test
data (including pharmacological, toxicological and clinical test data),
analytical and quality control data, manufacturing data and descriptions,
compositions, assays, and information about marketing,
costs and sales.

1.16        "Kirin Improvement Patents"  means all Patents and
Patent applications Controlled by Kirin during the term of this Agreement that
claim an invention in the Kirin Improvements.

1.17        "Kirin Improvements"  means any improvement
to ACIT Technology in the Field, including new applications of the ACIT
Technology, that is made and Controlled by Kirin or its Affiliates during the
term of the Development Program.

1.18        "Kirin
Know-How"  means all
Information Controlled by or on behalf of Kirin or its Affiliates during the
term of the Development Program that relates to ACIT Technology in the Field.

1.19         "Kirin Technology" means the Kirin
Improvements, Kirin Know-How and Kirin Improvement Patents, either collectively
or any part thereof.

1.20        "Kirin Territory" means the countries listed in Exhibit B and their
possessions and dependencies.

1.21         “Kits” means Compounds and a set of disposable
 (expected to consist
of blood bags and tubing) which permit storage of Compound, mixture of Compound
with leukocytes and treatment of the leukocytes in connection with the ACIT
Technology.

1.22        “Manufacturing Agreement” A manufacturing and supply agreement to be
entered into between Kirin and Cerus consistent with the Summary of Terms of
Manufacturing and Supply set forth on Exhibit C to this Agreement, provided, however, that until a separate Manufacturing Agreement is
executed, the terms of Exhibit C will be binding upon the Parties.

1.23        "Net
Revenue"  means the total
revenue received by Kirin, and any Affiliate or Sublicensee of Kirin, for sale
or other disposition of a Product to a Third Party, less the following to the
extent actually incurred or allowed by Kirin or such Affiliate or Sublicensee
with respect to such sale or disposition: (i) discounts, including cash
discounts, or rebates, price reductions or allowances actually allowed or
granted at the time of invoice from the billed amount; (ii) credits or
allowances actually granted upon claims, rejections or returns of Products,
including recalls; (iii) freight, postage, shipping and insurance charges paid
for delivery of Product, to the extent billed separately and (iv) taxes, duties
or other governmental charges levied on or measured by the billing amount when
separately included in billing, as adjusted for rebates and refunds. In the
event that in any country in the Kirin Territory, the [ * ] or [
* ] companies, as the case may be, establish a [ * ] to Kirin, its Affiliates or
Sublicensees, for a [ * ] that
includes [ * ], but does not
establish a [ * ] itself, the Net
Revenue allocable to the Product will be a [
* ].  Such [ * ]
shall be [ * ] and shall take into
account the [ * ] of the Product
and the [ * ] of the Product in [ * ] where the Product is [ * ].  In addition, if Kirin charges
a customer a   [ * ] which includes the [ * ] and also of [ * ], the Net Revenue allocable to the
Product will be computed on the [ * ]
if the Product had been [ * ],
according to principles stated in the preceding sentence.  If Kirin sells any Product or Illumination Devices and Kits through a distributor or sales agent, Net Revenue
will be calculated based on the price charged to the end user for such Product
(rather than solely the revenue received by Kirin), subject to the deductions
in clauses (i) through (iv) above.  Kirin will require the distributor or
sales agent to provide such information to Kirin.

1.24        "Patent" means (i) a
valid and enforceable patent, including any extension, registration,
confirmation, reissue, re-examination or renewal thereof; and (ii) to the
extent valid and enforceable rights are granted by a governmental authority
thereunder, a patent application.

1.25        "Patent Costs"  means the fees and
expenses paid to outside legal counsel and other Third Parties, and filing and
maintenance expenses, incurred in connection with the establishment and
maintenance of rights under Patents applicable to the ACIT Technology including
the costs of patent interference proceedings.

1.26        "Pivotal
Study"  means that portion of a clinical development
program that provides assessment of safety and efficacy of a product in
patients, which is intended to gather the pivotal information to support the
marketing approval such product in a particular country. Any such clinical
development program shall be performed in accordance with the U.S.A. Federal
Food, Drug and Cosmetic Act and applicable regulations promulgated thereunder
(including without limitation 21 CFR Part 312), as amended from time to time,
or the comparable foreign laws and regulations in the applicable country.

1.27        "Product" means: (a) any
product comprising leukocytes that embody, use or are made, treated or modified
through use of the ACIT Technology; and/or (b) any service to a patient that
involves use of the ACIT Technology. 
Further, the Parties may agree in writing to amend and extend the
definition of Product as provided in Section [
* ].

1.28        "Reasonable Efforts"  shall
mean efforts and resources commonly used in the research-based pharmaceutical
industry for the research, development and commercialization of a product at a
similar stage in its product life taking into account the establishment of the
product in the marketplace, the competitiveness of the marketplace, the
proprietary position of the product, the regulatory structure involved, the
profitability of the product and other relevant factors.

1.29        "Regulatory Approval"  means any approvals,
licenses, registrations or authorizations of any federal, state or local
regulatory agency, department, bureau or other government entity, necessary for
the manufacture, use, storage, import, transport or sale of Products in a
regulatory jurisdiction.

1.30        "Sublicensee"  shall mean
any Third Party expressly licensed by Kirin to develop, make and sell one or more Products.  Sublicensees shall not include
distributors or sales agents that do no more than purchase and resell finished
Products on behalf of Kirin.

1.31        "Summary of Supply Terms"  means that certain Summary of Terms of
Manufacturing and Supply attached as Exhibit C to this Agreement.

1.32        “S-59”  means the compound whose
chemical structure is shown in a
letter dated January 18, 2001 from Howard G. Ervin of Cerus to Dr. Kinya Ohgami
of Kirin.

1.33        "Third Party Royalties"  means royalties
payable to a Third Party in respect of the sale of Products other than
royalties payable with respect to licenses entered into prior to the Effective
Date.

1.34         "Third
Party"  means any entity other
than Cerus or Kirin or an Affiliate of Cerus or Kirin.

ARTICLE 2

LICENSES AND RELATED RIGHTS

2.1          Licenses Granted to Kirin.

                (a)      Subject to the terms of this Agreement, Cerus hereby grants to
Kirin an exclusive license to practice the ACIT Technology to develop, use,
make, have made, sell and offer for sale Products for any indications in the
Field in the Kirin Territory; provided that the Products are prepared or made
using Kits supplied by Cerus pursuant to the Manufacturing Agreement or are
manufactured by or for Kirin pursuant to the manufacturing license provided for
in Section 2.1(e) of this Agreement.

                (b)      Kirin may grant sublicenses to its Affiliates under the
foregoing license for any permitted purpose without Cerus' prior written
approval. Kirin may grant sublicenses under such rights to Third Parties solely
for making, use or sale of Products in the Kirin Territory with Cerus' prior
written approval, which shall not be unreasonably withheld or delayed. 
Kirin may grant sublicenses to Third
Parties for development of Products in the Kirin Territory only upon the prior
approval of the Development Committee, which is acknowledged in writing by
Cerus.  Any such development will be in accordance with plans approved by
the Development Committee.  As a condition to such sublicense, Cerus may
require that the Sublicensee enter into an agreement in form and substance
satisfactory to Cerus to protect Cerus confidential information and provide for
rights in intellectual property consistent with this agreement. Any sublicense with a Third Party entered
into in the absence of Cerus' consent will be null and void.  Kirin will provide to Cerus a copy of any proposed sublicense agreement not
later than ten (10) business days prior to execution of such agreement, and
will provide to Cerus a copy of the final executed agreement promptly upon
execution.  Kirin will provide such proposed
sublicense agreement, and the final executed agreement, in English translation,
if the sublicense is not already in English. 
Prior to providing copies to Cerus of the proposed sublicense agreement
and final sublicense agreement, Kirin may, if it chooses, delete information
specifying the split of Product revenues between Kirin and the Sublicensee, it
being understood that royalties to Cerus will be computed on Net Revenues
received collectively by the Sublicensee and Kirin, irrespective of such
split.  Kirin will remain responsible for the payment of
royalties on the Net Revenues of any Sublicensee.

                (c)

Additionally,
Kirin and its Affiliates may conduct clinical development in the Cerus
Territory, of particular Products, so long as Kirin obtains Cerus' prior
written approval of the location and clinical study protocol of any such
clinical work or study of each such Product, such approval not to be
unreasonably withheld or delayed, and so long as such work is intended to
generate data to be used in obtaining Regulatory Approval of such Product.

                (d)      Subject to the terms of Section [ * ], and except as otherwise
provided in the Manufacturing Agreement, the license rights granted in
subsection (a) of this section are subject to the following express limitation
(and to all other obligations and limitations in the Agreement):

                           (i)          Kirin obtains no
license or rights to
practice any of the ACIT Technology to sell Illumination Devices, Compounds or Kits or any other devices or products for
use in the treatment of leukocytes, except as set forth in Section [ * ] in which Kirin [
* ]. 
In case Kirin [ * ], Kirin’s license in Section 2.1 (a) will
be [
* ]. Otherwise, Kirin may use Illumination
Devices and Kits only as part of preparing a Product or performing a service
comprising a Product.

                           (ii)         Kirin's license to develop
is a license
to develop in accordance with plans previously approved by the Development
Committee; provided that if there are regional issues requiring testing or
trials that concern only countries in the Kirin Territory, and which do not
have a potential effect outside the Kirin Territory, Kirin may undertake such
testing or trials without the plans being first approved by the Development
Committee.

                           (iii)        In
the event that Kirin elects not to participate in funding Cerus Core ACIT
Research and Development costs for a particular indication, as provided in
Section 4.5 of this Agreement, Kirin will not practice the license rights for
such particular indication until the Parties have renegotiated rights to that
indication, as provided in such Section 4.5.

                (e)      Kirin may obtain Kits and Illumination
Devices only under the terms of the Manufacturing Agreement.  Kirin
obtains no license or other rights to make or have made Illumination Devices,
Compounds or Kits, or
any other devices for use in the treatment of leukocytes, unless  (i) Cerus is unable to supply such item to
Kirin, or (ii) Cerus, pursuant to Section 10.2 of this Agreement, elects to
license Kirin to manufacture such items.  In such case Kirin's license in
Section 2.1 (a) will be expanded to include a license to make or have made the Illumination Devices,
Kits or Compounds that Cerus is unable to supply.
 The license to Cerus Patent PCT/US94/07185, referenced on Exhibit A, is
limited to a license to make or have made Compounds
in the event it is not supplied by Cerus.

2.2          Licenses Granted to
Cerus.

                (a)      Subject to the terms of this Agreement, Kirin
hereby grants to Cerus a perpetual exclusive royalty-free license in the Cerus
Territory, with the right to sublicense, under Kirin Improvements, the Kirin
Know-How and the Kirin Improvement Patents to develop, make, have made, use,
import and sell products in the Field.

                (b)      Kirin may from time to time disclose to Cerus, in Kirin’s sole
discretion,
other technologies Controlled by Kirin in the area of immune therapy or
prophylaxis that may be complementary to the ACIT technology, and in which
Cerus may have interest.  Kirin agrees that, at Cerus' request, Kirin will
discuss with Cerus possible licenses to use such other technology in the Cerus
Territory, and the royalties and other terms of any such license agreement will
be negotiated in good faith.

2.3          Notice of Development for New Indications.
  Upon reasonable request by Cerus, Kirin will
provide Cerus with Information regarding Kirin pre-clinical studies of the ACIT
Technology and the Products that are in Kirin clinical trials for new
indications..
Upon reasonable request by Kirin, Cerus will provide Kirin with Information
regarding Cerus pre-clinical studies of the ACIT Technology and the Products
that are in Cerus clinical trials for new indications.

2.4          Cerus License to Third Parties.  If Cerus licenses the ACIT Technology in the
Field to a Third Party (outside the Kirin Territory), Cerus will use its best
efforts to negotiate a license that permits Kirin to share and use pre-clinical
and clinical development data of such Third Party.

2.5          Trademark Rights.

                (a)      License
Grants.  Subject to the
limitations set forth below, Cerus grants to Kirin a non-exclusive,
royalty-free license, with the right to sublicense, to use any and all marks
Cerus adopts for use with the  Products
(the " Licensed Marks"), solely in connection with the promotion and
sale of Products in the Field in the Kirin Territory. Kirin shall not use
Licensed Marks in connection with any other products or activities without
prior written approval of Cerus.  The
mark “Cerus,” however, is excluded from this license.

                (b)      Form
of Use.   Kirin, its Affiliates and Sublicensees shall
use the Licensed Marks only in the form(s) approved in writing by Cerus and
shall include where appropriate the designations (R) and (TM) and a statement
that Licensed Marks are the trademarks of Cerus Corporation, and other
proprietary notices as reasonably required by Cerus from time-to-time. Kirin
agrees to comply with all applicable laws and regulations pertaining to the
proper use and designation of trademarks.

                (c)       Ownership of Licensed Marks

                           (i).         
Ownership. 
Kirin acknowledges that it has no interest in the other Licensed Marks
other than the license granted under this Agreement and that Cerus is, and will
continue to be, the sole and exclusive owner of all right, title and interest
in the Licensed Marks.

                           (ii).        No Contest.  Kirin
will not contest, oppose or challenge Cerus’ ownership of
its Licensed Marks. Kirin agrees that it will do nothing to impair Cerus’
ownership or rights in its Licensed Marks. In particular, Kirin will not
register or attempt to register Cerus’ Licensed Marks in any jurisdiction nor
oppose Cerus’ registration of its Licensed Marks, alone or with other words or
designs, in any jurisdiction. If Kirin uses, registers or applies to register a
licensed mark that violates its obligations under this section, Kirin agrees,
at Cerus’ request, to abandon the use of such mark and any application or
registration for such mark.

                           (iii).       Adverse Use.  Kirin shall
notify Cerus of any adverse use by a Third Party of
the Licensed Marks or of a mark or name confusingly similar to the Licensed
Marks of which Kirin becomes aware, and agrees to take no action with respect
thereto except with Cerus’ written authorization. Cerus may thereupon take such
action as it in its sole discretion deems advisable for the protection of its
rights in and to its Licensed Marks, including allowing Kirin to bring and
prosecute a claim against such Third Party at Kirin’s expense and for Kirin's
sole benefit. Kirin further agrees to provide full cooperation (at Cerus'
expense) with any legal or equitable action by Cerus to protect Cerus’ title
and interest in the Licensed Marks.

                (d)      Quality
Control.  The nature and quality of all goods sold by
Kirin, its Affiliates and Sublicensees in connection with Licensed Marks and
all advertising and promotional uses and all other related uses of Licensed
Marks by Kirin, its Affiliates and Sublicensees shall conform to Cerus' standards.
Kirin further agrees to provide samples of advertising and other promotional
material bearing the Licensed Marks to Cerus for approval at least thirty (30)
days before such materials are to be distributed, displayed or otherwise used.
Kirin, its Affiliates and Sublicensees will not distribute, display or
otherwise use such materials without Cerus' prior written approval, which
approval shall not be unreasonably withheld or delayed.

                (e)      Confusingly Similar and/or Combination Marks.  Kirin agrees that Kirin, its
Affiliates and Sublicensees will not adopt or use any other trademarks, words,
symbols, letters, designs or marks (i) in combination with Licensed Marks in a
manner that would create combination marks or (ii) that would be confusingly
similar to Licensed Marks, provided, however, that Kirin, its Affiliates and
Sublicensees may use Licensed Marks with other marks or names if such other
marks or names are sufficiently separated from Licensed Marks and sufficiently
distinctive to avoid the consumer impression that such other marks or their
owners are associated with Cerus.

ARTICLE 3

MANAGEMENT

3.1          The Development Committee.  Cerus and Kirin agree to for
m,as of the Effective Date, a committee to facilitate the research
and development of Products ("the Development Committee").  The
Development Committee shall comprise four (4) individuals, two (2) being Cerus
employees, appointed and replaced by Cerus at its discretion, and two (2) being
Kirin employees, appointed and replaced by Kirin at its discretion.  The
size and composition of the Development Committee may be changed by mutual
agreement of the Parties. The Parties shall form the Development Committee
within forty-five (45) days after the Effective Date.
 The Development Committee shall have the following authority and
obligations:

                (a)      To encourage and facilitate the ongoing cooperation of the
Parties in conducting the research and development of Products;

                (b)      To establish and implement specific plans to obtain Regulatory
Approval of Products and commercialize Products as soon as possible, and
otherwise accomplish the tasks and goals of the Parties as set forth in the
Agreement;

                (c)      To coordinate the communication, information exchange and
efforts of the Parties with respect to all matters under this Agreement;

                (d)      To discuss and resolve, if possible, any issues or disputes
that arise under the Agreement; and

                (e)      To review new indications to be addressed by the ACIT
Technology and budgets for such projects within the Development Program.

3.2          Development Committee
Meetings. 
The Development Committee shall act at meetings held regularly with all
members present, according to the following procedures:

                (a)      The Development Committee meetings shall take place at such
times and places as shall be determined by the Development Committee but no
less frequently than once per six (6) months; it is expected that the meetings
will alternate between appropriate offices of each Party, or will be held at
such other convenient locations as agreed;

                (b)      If requested by a Party, the Development Committee may conduct
a particular meeting by telephone or video conference or other acceptable
electronic means, provided that all Development Committee members attend such
meeting and can hear and communicate with all other members, and any decisions
made during such meeting are recorded in writing and confirmed by signature of
at least one of the Development Committee members from each of the Parties;

                (c)      A Party may bring a reasonable number of additional
representatives, in a non-voting capacity, to attend appropriate Development
Committee meetings, provided that such attendance is helpful to the Development
Committee carrying out its tasks and obligations;

                (d)      Prior to each meeting, the designated chair of the Development
Committee (which may vary during the term) shall circulate an agenda for the
meeting, and the Development Committee shall keep minutes reflecting matters
discussed and the actions taken at the meeting, a copy of which shall be
provided to each Party; and

                (e)      The Development Committee may act on a specific issue or matter
without a meeting if the Development Committee members all agree as to such
action and such agreement is set forth in a written consent signed by all the
members of the Development Committee.

3.3          Decision-Making and Issue Resolution.  All decisions of or actions taken by the
Development Committee shall be by unanimous approval of all the members of the
Development Committee or such subcommittee, and voting on any matters shall be
reflected in the minutes of the meeting at which the vote was taken. If the
Development Committee fails to reach unanimous agreement on an issue or matter
needing resolution, the matter shall be referred for good faith discussion and
resolution by the appropriate senior executive officer of each Party.

3.4           Other
Research. 
Kirin acknowledges and agrees that nothing in this Agreement shall
prevent or otherwise hinder Cerus from conducting, and Cerus shall retain full
rights to conduct, its own independent research and development work with
respect to ACIT Technology or any aspect thereof for any use or purpose outside
the Kirin Territory or any use or purpose outside the Field in the Kirin
Territory, and including conducting such research and development work with or
on behalf of Third Party partners.

ARTICLE 4

RESEARCH AND DEVELOPMENT FUNDING

4.1          Funding for Initial Indications.  Subject to the other provisions of this
Article, Kirin will fund [ * ]% of Cerus’ Core ACIT Research and
Development costs, commencing January 1, 2001, for Cerus’ ongoing and planned
haploidentical and unrelated donor stem cell transplant indications, provided
that Kirin’s responsibility for such funding shall be limited to a maximum of
U.S. $[
* ]
over [ *
] years.  It is understood
that Kirin’s contributions under this Section 4.1 and under Section 4.2 are in
addition to, and not reduced by, the milestone development payments under
Article 6 of this Agreement.

4.2          Funding for New Indications.  The Development Committee will review new indications
for the ACIT Technology program and the corresponding pre-clinical and clinical
expenses required to pursue those indications. 
Assuming that the Development Committee agrees to include a new clinical
indication in the Development Program, Kirin will fund [ * ]% of Cerus’ Core ACIT
Research and Development costs (subject to reasonable caps for Kirin
and for Cerus to be agreed upon before such costs are incurred) for such new indication.  If the
caps for Kirin and Cerus are reached before completion of the Core ACIT
Research and Development for such new indication, the parties will discuss how
to proceed for completion of such development.

4.3          Funding for Kirin Territory.  Kirin will fund 100% of the
research and development costs in the Kirin Territory required for Reasonable
Efforts to obtain Regulatory Approval of Products.  These expenses are independent of Kirin’s contributions to the
Core ACIT Research and Development activities and not subject to the limitations
on expenditure obligations set forth in Section 4.1, above.

4.4          Cerus Funding.  Cerus will fund 100% of its costs in the Cerus Territory, except
for the Core ACIT Research and Development cost.

4.5          Kirin Decision Not to Participate.  If Kirin decides not to participate in
funding Cerus’ Core ACIT Research and Development for a particular indication,
but wishes to retain commercialization rights to such indication, Kirin will so
notify Cerus in writing promptly following Kirin’s decision not to fund such
indication, and the parties will renegotiate rights to that indication in the
Kirin Territory.  If Kirin does wish to
retain rights to commercialize Products in the Kirin Territory for such
indication, Kirin will use Reasonable Efforts to obtain Regulatory Approval and
to market and sell the Products for such indication in the Kirin Territory.
 If Kirin does not wish to retain rights to commercialize Products for
such indication in the Kirin Territory, Kirin will execute and deliver such
documentation as Cerus may reasonably request, releasing Kirin's rights to the
ACIT Technology for such indication.

4.6          Core ACIT Research and
Development Costs. 
Cerus’ Core ACIT Research and Development costs will be considered to
include, in addition to any such costs funded directly by Cerus, any costs funded
by other Cerus collaborators in the ACIT program, including without limitation
the [ * ], and any funding for
research and development of the ACIT Technology from governmental or other
organizations.  All such costs will be
subject to the recordkeeping and disclosure requirements set forth in Section
4.9 below.

4.7        Development Efforts and Expenses.  Each of the Parties will maintain
scientific staff, laboratories, offices and other facilities necessary to carry
out the tasks and obligations assigned to it pursuant to this Agreement.
 Each party shall use Reasonable Efforts to conduct and complete such
tasks and obligations.

4.8          Advance Payments.  Prior to, or promptly following, the
Effective Date and each January 1 and July 1 during the term of the Development
Program, Cerus will submit to Kirin a projected estimate of Core ACIT Research
and Development costs to be incurred by Cerus during the six month period
commencing on such date.  Kirin will pay to Cerus an amount equal to [ * ]% of such costs reasonably projected
by Cerus to be incurred in such period within thirty (30) days
after Kirin receives invoice of Cerus’ projected estimate.

4.9          Expenditures. 
Cerus shall maintain detailed records which accurately identify Core
ACIT Research and Development Costs incurred and paid in connection with the
Development Program.  Such records shall
be open during reasonable business hours, for a period of three (3) years from
the creation of individual records, for examination at Kirin’s expense, and not more often than once
each year and upon not less than thirty (30) days advance notice, by a
certified public accountant selected by Kirin and acceptable to Cerus for the sole
purpose of verifying the correctness of calculations or payments made under
this Agreement.Cerus
shall submit this information to Kirin following the end of each semi-annual
period of the Agreement (ending June 30 and December 31).  Expenses internally generated because tasks
are performed by Cerus' own staff will be accounted for based upon asingle average hourly rate
agreed upon annually by the Parties; provided, however, that such expenses will
only be included among those shared by Kirin if they are attributable to
individual Cerus employees who each devote their working hours to Core ACIT Research and Development.

4.10        Reconciliation of Expenditures.  Unless otherwise agreed, the
Parties shall reconcile actual cash outlays and expenses for Core ACIT Research
and Development on a semi-annual basis within sixty (60) days after
each January 1 and July 1, such
that costs have been incurred in the proportion specified in Sections 4.1 and
4.2 of this Agreement.  If they are not
in such proportion, Cerus will make a cash payment to Kirin, or Kirin will make
a cash payment to Cerus, in order to achieve such proportion.  The payment shall be made in cash within
thirty (30) days after its receipt of an invoice based on the determination of the amount to be
reconciled.

ARTICLE 5

DEVELOPMENT AND MARKETING IN THE KIRIN TERRITORY

5.1          Kirin Efforts.  Kirin shall use Reasonable Efforts to develop and obtain
Regulatory Approval in the Kirin Territory for the Products and to obtain the
maximum reimbursement prices for the Products. Kirin shall pay all the
development and registration costs for all Products in the Kirin Territory.
Kirin shall use Reasonable Efforts to market and sell in the Kirin Territory
all Products for which Regulatory Approval in the Kirin Territory has been
obtained.

5.2           Meetings Concerning Marketing.  The Parties shall meet from time-to-time to
discuss and exchange marketing information and strategies in order to
optimize customer acceptance and effective promotion of the Product for each
approved indication in the Kirin Territory. 
Kirin will be responsible to make marketing and sales decisions using
reasonable business judgment, and to use its best efforts to maximize Net
Revenues in the interest of both parties.

ARTICLE 6

MILESTONE DEVELOPMENT PAYMENTS

6.1          Milestone Development
Payments.  Kirin shall pay Cerus milestone development payments
(which will be non-refundable) payable in accordance with the following
schedule:

	
  (a)
  
  	
  On
  January
  31, 2001:  One Million Dollars (U.S. $1,000,000);
  
	
  (b)
  	
  Upon
  [ * ]: 
  [ * ] Dollars (U.S. $[ *
  ])
  
	
  (c)
  	
  Upon
  [ * ]: 
  [ * ] Dollars (U.S. $[ *
  ])
  
	
  (d)
  	
  Upon
  [ * ]: [ * ] Dollars (U.S. $[ * ])
  
	
  (e)
  	
  Upon
  [ * ]: 
  [ * ] Dollars (U.S. $[ *
  ])
  
	
  (f)
  	
  Upon
  [ * ]: 
  [ * ] Dollars (U.S. $[ *
  ]) (payment to be made only upon the first occurrence of this
  condition)
  

6.2          Withholding Taxes.  The foregoing
milestone development payments are inclusive of such withholding taxes as are
finally and reasonably ascertained to be due and payable by Kirin on account of
Cerus.  Kirin will provide Cerus with
evidence of payment of such withholding tax so that Cerus may seek to claim foreign
tax credit in the United States.  If
Kirin receives a refund or rebate for taxes it has paid on behalf of Cerus,
Kirin shall promptly remit it to Cerus.

6.3          Method of
Payment.  Payment of the
milestone development payments shall be made by wire transfer to an account
designated by Cerus for such purpose within thirty (30) days after each milestone event described Section 6.1
has occurred.

6.4          Application of Milestone
Development Payments.  Without
limiting Kirin’s responsibility under Article 4 to pay [ * ]% of Core ACIT Research and
Development Costs, Cerus will apply the milestone development payments to pay
or reimburse Cerus’ expenditures in developing the ACIT Technology.

ARTICLE 7

ROYALTIES

7.1          Royalties
on Sales of Products.

                (a)      Subject to subsection (b) and Section 7.5 below, Kirin shall
pay Cerus royalties on sales of Products by or on behalf of Kirin or its
Affiliates or Sublicensees,  as follows:

	
  •  [ * ]
  percent ([ * ]%) on the first $[ * ] million of annual Net Revenue
  (aggregate of all countries in Kirin Territory); and
  
	
  •  [ * ]
  percent ([ * ]%) royalty on
  annual Net Revenue over   
  $[ * ] million (aggregate of
  all countries in Kirin Territory).
  

                The calendar year shall be used
for the purpose of determining annual Net Revenues.  The increase of royalty rate to [ * ]
percent ([
* ]%) shall not apply to China to the extent China continues to
impose an upper limit on royalties or other regulations (as referenced in
Section 7.1(c)) that make such royalty rate uneconomical.

                (b)      For each particular Product, Kirin shall pay the royalties
specified above, on a country by country basis, during the Term of this
Agreement.

                (c)      For
China or any other country in the Kirin Territory which imposes an upper limit
on royalty rate or other regulations, Cerus and Kirin will discuss the royalty rate and the other
terms and conditions
to reach an arrangement that is equitable to both parties.

7.2          Payment
of Royalties.  Royalty
obligations hereunder shall accrue at the time of sale of the applicable
Product, and all such royalties that have accrued during a particular calendar
quarter shall be paid quarterly within sixty (60) days after
the end of such calendar quarter. Such royalties shall be calculated on the
basis of Net Revenue in the local currency of each country, and converted into
U.S. Dollars and paid in U.S. Dollars by using the average currency exchange rate at each end of the month for the applicable calendar quarter for purchase
quoted by the Bank of Tokyo-Mitsubishi (or its
successor). Each royalty payment shall be accompanied by a statement of such
royalties showing the Net Revenue for the applicable royalty-bearing Products,
on a country-by-country and product-by-product basis and, in addition, a
statement indicating the total revenues and line item deductions from which the
Net Revenue was derived. Royalty payments shall be made by wire transfer to an
account designated by Cerus for such purpose.

7.3          Royalty Structure and Marketing
Strategy.  The terms of
this Agreement permit Kirin to market  and
sell Products to hospitals and other similar health-care provider organizations
as services or as products.  Kirin shall
not sell Illumination Devices or Kits to Third Parties, provided, however, that in the event that (i) Kirin [ * ] as provided in Section 1.27 in any
country in the Kirin Territory by certain [ *
] and/or (ii) the [ * ],
Kirin [ * ] in accordance with [ * ] to be agreed by the Parties. In such event, the Parties also shall agree on any needed [ * ] to
the [ * ] established for [ * ],
including appropriate amendments to the definitions of such terms under Article
1.  Any change to the current marketing
strategy, and any adjustment to the royalty calculation mechanism related
thereto, must be set forth in writing and signed by an authorized
representative of each Party.

7.4.         Withholding Taxes.  The foregoing royalty
payments are inclusive of such withholding taxes as are finally and reasonably
ascertained to be due and payable by Kirin on account of Cerus. Kirin will
provide Cerus evidence of payment of such withholding tax so that Cerus may
seek to claim foreign tax credit in the United States.  If Kirin receives a refund or rebate for
taxes it has paid on behalf of Cerus, Kirin shall promptly remit it to Cerus.

7.5.         Third Party Royalties.  In the event that
Kirin is required to obtain a license under a Third Party patent that covers or
claims the manufacture, use or sale of a Product in order to practice a Cerus
Patent in the field of allogeneic stem cell
transplantation in any country in the Kirin Territory, as permitted under the
licenses in Article 2, Kirin shall be entitled to deduct from amounts owing to
Cerus [ * ] of any royalties owing
to such Third Party based on the sale of Products in such country under such
license, subject to a maximum royalty reduction of [ * ] of the amounts that otherwise would be owed by Kirin
under Article 7 hereof.  Royalty
reduction, if any, in a field other than allogeneic stem cell transplantation
will be negotiated in good faith by both parties.  Kirin shall disclose the relevant portions of such license under
such Third Party patent to Cerus in English and the extent of any alleged
infringement.

ARTICLE 8

CONFIDENTIALITY

8.1          Confidentiality;
Exceptions.  Except to the
extent expressly authorized by this Agreement or otherwise agreed in writing,
the Parties agree that, for the term of this Agreement and for ten (10) years
thereafter, the receiving Party shall keep confidential and shall not publish
or otherwise disclose to a Third Party or use for any purpose other than as
provided for in this Agreement any Information and materials furnished to it by
the other Party pursuant to this Agreement (collectively, "Confidential
Information"), except to the extent that it can be established by the receiving
Party by competent proof that such Confidential Information:

                (a)      was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the other Party;

                (b)      was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the receiving Party;

                (c)      became generally available to the public
or otherwise part of the public domain after its disclosure, other than through
any act or omission of the receiving Party in breach of this Agreement;

                (d)      was disclosed to the receiving Party, other than under an
obligation of confidentiality, by a Third Party who had no obligation to the
disclosing Party not to disclose such information to others; or

                (e)      was independently developed by the receiving Party
without
reference to or reliance upon any information or materials disclosed by the disclosing Party.

8.2          Authorized
Disclosure.  Each Party may
disclose the other's Confidential Information to the extent such disclosure is
reasonably necessary in filing or prosecuting patent applications, prosecuting
or defending litigation, complying with applicable governmental regulations or
conducting preclinical or clinical trials, provided that if a Party is required
by law or regulation to make any such disclosure of the other Party's
Confidential Information it will, except where impracticable for necessary
disclosures, for example in the event of medical emergency, give reasonable
advance notice to the other Party of such disclosure requirement and, except to
the extent inappropriate in the case of patent applications, will use its best
efforts to secure confidential treatment of such Confidential Information
required to be disclosed.  Cerus may provide
information contained in royalty reports to its auditors and may report
payments received in accordance with normal practices.

8.3          Survival.  This Article 8 shall
survive the termination or expiration of this Agreement for a period of ten
(10) years.

ARTICLE 9

INTELLECTUAL PROPERTY

9.1          Ownership.  Each Party shall
solely own Patents for any inventions made solely by that Party's employees or
consultants in the course of performing any work under this Agreement. The law
of inventorship of the United States shall apply to any inventions, whether
made inside or outside the United States by either of the Parties.

9.2          Prosecution and Maintenance of
Patents by Cerus; Abandonment.  Cerus shall
have the responsibility to file, prosecute and maintain the Cerus Patents and
joint Patents relating to the ACIT Technology in the world and shall bear all
expenses associated therewith. All decisions regarding prosecution of the Cerus
Patents in the world will be at Cerus’ sole discretion and responsibility.
 Cerus agrees to keep Kirin informed of the course of patent prosecution
or other proceedings relating to the Cerus Patents in the Kirin Territory in
the Field.  In the event Cerus elects not to prosecute such Patent
application filed or to abandon such issued Patent in the Kirin Territory in
the Field, Cerus shall notify Kirin not less than two (2) months before any
relevant deadline, and thereafter Kirin shall have the right to pursue, at its
expense and sole discretion, prosecution of such Patent application or
maintenance of such issued Patentand in the event that Kirin pursue prosecution of such
Patent application or maintenance of such issued Patent, Cerus shall promptly
assign its rights therein to Kirin.

9.3          Prosecution
and Maintenance of Kirin Improvement Patents by Kirin; Abandonment.  Kirin shall have the responsibility to file,
prosecute and maintain the Kirin Improvement Patents in the
world and shall bear all expenses associated therewith. All decisions regarding
prosecution of the Kirin Improvement Patents in the
world will be at Kirin's sole discretion and responsibility.  Kirin agrees
to keep Cerus informed of the course of patent prosecution or other proceedings
relating to the Kirin Improvement Patents in the Cerus Territory in the Field.
 In the event Kirin elects not to prosecute such Patent application filed
or to abandon such issued Patent in the Cerus Territory in the Field, Kirin
shall notify Cerus not less than two (2) months before any relevant deadline,
and thereafter Cerus shall have the right to pursue, at its expense and sole discretion,
prosecution of such Patent application or maintenance of such issued Patent.
 In such event, Kirin shall promptly assign its rights therein to Cerus.

9.4          Defense
and Settlement of Third Party Claims. 
If a Third Party files a claim, suit or action
against a Party claiming that a Patent or other intellectual property right
owned by such Third Party is infringed by the development, use, marketing,
distribution or sale of a Product, and such claim, suit or action (a
"Claim") arises out of such Party's operation in the Field pursuant to this Agreement, the Party against whom
the Third Party has filed such Claim ("Defending Party") will have
the right to defend against any such Claim. The other Party will assist in the
defense of any such Claim as reasonably requested by the Defending Party and at
the Defending Party's expense and may retain separate counsel at its own
expense. The Defending Party shall not settle any such Claim without the prior
express written consent of the other Party, which consent shall not be
unreasonably withheld or delayed, if such settlement would impose on such other
Party the obligation to pay any damages or would adversely affect such Party's
rights.

9.5           Enforcement of Patent Rights

                (a)      If any Cerus Patent, Kirin Improvement Patent or joint patent
relating to ACIT Technology in the Field is infringed by a Third Party, the
Party to this Agreement first having knowledge of such infringement shall
promptly notify the other in writing. The notice shall set forth the facts of
such infringement in reasonable detail.

                (b)      Cerus shall have the right, but not the
obligation, to institute, prosecute and control any action or proceeding with
respect to infringement in the Cerus Territory of Cerus Patents,Kirin Improvement Patents and joint
patents relating to the ACIT Technology.

                (c)      Kirin
shall have the right, but not the obligation, to institute, prosecute and
control any action or proceeding with respect to infringement in the Kirin
Territory of Cerus Patents, Kirin
Improvement Patents and joint patents relating to ACIT Technology and patents
abandoned by Cerus pursuant to Section 9.2.

                (d)      If a Party given the right to enforce a Cerus
Patent or Kirin Improvement Patent pursuant to Section 9.5(b) or Section 9.5(c) fails to bring an action or
proceeding against a suspected infringer within a period of ninety (90) days
after having knowledge of such infringement in the Field, the other Party shall
have the right to bring and control an action against such infringer by counsel
of its own choice, and the non-enforcing Party shall have the right to be
represented in any such action by counsel of its own choice at its own expense.

                (e)      The Party controlling an action involving any infringement in
the Field shall consider in good faith the interests of the other Party in so
doing, and shall not settle or consent to an adverse judgment in any such
action which would have a material adverse effect on the rights or interests of
the other Party without the prior express written consent of such other Party,
which shall not be unreasonably withheld. If one Party brings any such action
or proceeding, the other Party agrees to be joined as a Party plaintiff if
necessary to prosecute the action and to give the first Party reasonable
assistance and authority to file and prosecute the suit. In each case relating
to infringement within the Field, each Party shall bear the costs of its
enforcement of the Patent rights discussed in this section and any amounts
received from Third Parties shall be equitably shared between the Parties in a
manner to be negotiated.

                (f)       The Parties shall consult regarding the institution,
prosecution and control of any action or proceeding with respect to
infringement outside the Field of any of the Kirin Improvement Patents. In the
absence of Agreement with respect to infringement outside the Field, Kirin may
proceed in such manner as the law permits.

ARTICLE 10

REPRESENTATIONS AND WARRANTIES;

UNDERTAKINGS CONCERNING SUPPLY

10.1        Representations
and Warranties.  Each of the Parties
hereby represents and warrants as follows:

                (a)      This Agreement is a legal and valid obligation binding upon
such Party and enforceable in accordance with its terms. The execution,
delivery and performance of the Agreement by such Party does not conflict with
any agreement, instrument or understanding, oral or written, to which it is a
Party or by which it is bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over
it.

                (b)      Such
Party has not, and during the term of the Agreement will not, grant any right
to any Third Party relating to its respective technology in the Field licensed
to the other Party hereunder that would conflict with such rights granted to
the other Party.

10.2        Cerus Warranties and Undertakings.  Cerus represents and warrants to
Kirin that Cerus owns the rights to manufacture Compounds, Kits and the
Illumination Devices,  and undertakes to
provide Kirin with (i) the Kits and the Illumination Devices as Kirin, its Affiliate
and permitted Sublicensees require to conduct clinical development of the
Product at cost of goods plus reasonable handling charge and (ii) Kirin’s, its
Affiliate and/or permitted Sublicensees’ commercial requirements of Compounds,
Kits and Illumination Devices in response to and in accordance with the terms set forth on Exhibit C to this Agreement,
which will be included in the Manufacturing Agreement.  It is agreed,
however, that with respect to Kirin's commercial requirements, Cerus may elect
to permit Kirin to manufacture Compounds, Kits and/or Illumination Devices, instead of
supplying them to Kirin.  If Cerus intends not to supply Compounds, Kits or
Illumination Devices, it will give Kirin notice of such decision reasonably in
advance of the time when Kirin will need such Compounds, Kits or
Illumination Devices, to permit Kirin to make arrangements in timely manner for
manufacturing. In such event, Cerus will continue to be obligated to provide Compounds to Kirin,
but will be relieved of its obligations to provide Kits (except for Compounds) or
Illumination Devices, according to Cerus’ election.

ARTICLE 11

REPORTS, RECORDS AND MATERIAL

11.1        Sharing of Information.  Commencing on
the Effective Date and continuing during the term of this Agreement, each Party
will make available and disclose to the other Party the Information Controlled
by such Party that reasonably relates to such other Party's activities under
this Agreement in the Field. In particular, Cerus will disclose to Kirin on a
regular basis the ACIT Technology and results of Core ACIT Research and Development, and provide
reasonable assistance to Kirin (at Kirin's request and expense) in transferring
such ACIT Technology for use in and commercializing Products in the Field in
the Kirin Territory. Cerus shall deliver to
Kirin within thirty (30) working days of the Effective Date a copy of documents
relating to the ACIT technology, including, but without limitation, IND,
clinical protocols and pre-clinicalor clinical results.  Similarly, Kirin
will disclose to Cerus on a regular basis the Kirin Technology and results of
Kirin research and development relating to ACIT Technology, and provide
reasonable assistance to Cerus (at Cerus' request and expense) in transferring
such Kirin Technology for use in and commercializing Products in the Field in
the Cerus Territory. In addition, both Parties will disclose to each other any
non-clinical and clinical regulatory information which relates to such other
Party's activities under this Agreement in the Field.

11.2        Records of Net Revenue.  Kirin will
maintain, and will require each sublicensee to maintain, complete and accurate
records of Net Revenue which are relevant to payments to be made under this
Agreement. Such records shall be open during reasonable business hours, for a
period of three (3) years from creation of individual records, for examination
at Cerus’ expense, and not more often than once each year and upon not less
than thirty (30) days advance notice, by a certified public accountant selected
by and acceptable to Kirin for the sole purpose of verifying for Cerus the
correctness of calculations or payments made under this Agreement.

11.3        Materials; Technical
Support.  The Parties intend to
maintain an open and extensive exchange of biological, chemical and other
tangible materials during the course of the Agreement.  Information
obtained by the other Party in the testing of such materials will be promptly
disclosed to the Party providing the sample, and all such Information will be
considered Confidential Information of the party supplying the proprietary
materials, to be protected under the restrictions of Article 8.  The Party supplying any such materials will
be entitled to recover its cost of goods from the party receiving the materials.
Any such materials supplied will be used solely for the uses authorized under
this Agreement.  Upon termination of this Agreement, any unused materials
will be returned to the Party who supplied them.  If Kirin requests
technical support from Cerus for development or commercialization of the
Products in the Kirin Territory (beyond the activities Cerus is conducting for
its own development and commercialization in the Cerus Territory), Cerus will
be entitled to receive reimbursement from Kirin for Cerus' costs of such
technical support on a time and materials basis.

11.4        Publicity Review.  If either Party
is required by law or regulation to make a public disclosure or announcement
concerning this Agreement or the subject matter thereof, such Party shall, to
the extent practicable, give reasonable prior advance notice of the proposed
text of such disclosure or announcement to the other Party for its review and
comment. The terms of this Agreement may also be disclosed to Third Parties
with the consent of the other Party, which consent shall not be unreasonably
withheld so long as such disclosure is made under a binder of confidentiality.

11.5        Publications.  Each Party agrees that it shall not
publish or present the
results of studies carried out pursuant to this Agreement without the
opportunity for prior review by the other Party.  Each Party shall provide to the other Party the opportunity to review any
proposed abstracts,
manuscripts or presentations (including information to be presented verbally)
which relate to the Field at least thirty (30) days prior to their intended
submission for publication, and each Party agrees, upon written request from the other Party, not to submit such abstract or manuscript for
publication or to make such presentation until the other Party is given a reasonable period of time to secure
patent protection for any material in such publication or presentation which it
believes is patentable.

11.6        Adverse Event Reporting.  In the event
that either Party, its Affiliates or Sublicensees obtains, directly or
indirectly, information and data on the side effects or toxicity of a Product
during the development, marketing and distribution of any of the Products
hereunder, such Party shall disclose, as soon as reasonably practicable, such
information and data to the other Party. Either Party, its Affiliates and
Sublicensees shall notify the other Party as soon as reasonably practicable of
any complaints or reports of adverse events associated with the Products which
are serious, new or unexpected events, or events with increased frequency. All
other adverse events associated with Products shall be reported by either Party
to the other Party in summary format at least quarterly. At the request of
either Party, the other Party shall cooperate in the investigation and respond
to any Product complaints which may relate to the role of the informed Party in
the development or manufacture of the Products. Each Party shall be responsible
for all reporting of adverse events to regulatory authorities in its respective
territory.

 

ARTICLE 12

TERM AND TERMINATION

12.1        Term.  This Agreement shall
commence on the Effective Date and, unless sooner terminated as provided
herein, shall continue in effect for each Product and on a country by country basis until the later
of the expiration of ten (10) years from the first commercial launch of such
Product in such country or the expiration of all Patents with claims covering
such Product or its manufacture, sale or use in such country.

12.2        Termination for Breach.  If either Party
materially breaches this Agreement at any time, which breach is not cured
within thirty (30) days of written notice thereof if such breach is caused by
the failure of a Party to meet its financial obligations under this Agreement,
or within ninety (90) days of written notice thereof for any other material
breach of this Agreement, from the non-breaching Party specifying in detail the
nature of the breach, the breaching Party's licenses granted in this Agreement
shall terminate and the non-breaching Party shall continue to have whatever
licenses it had at the time of such termination and on the terms of this
Agreement for such licenses, under the breaching Party's technology, Patents
and (if applicable) Licensed Marks to make, have made, use and sell Products it
already had developed or sold, in those countries in which it already had
developed or sold such Products.  The breaching Party will assist the
non-breaching Party in every proper way to effect the license granted above.
The breaching Party shall further deliver to the non-breaching Party such
relevant tangible materials embodying such technology, Patents and Licensed
Marks as may be necessary or useful to the exercise of the non-breaching Party
of the license hereunder.

12.3        Surviving Rights.  The obligations
and rights of the Parties under Section 2.2, Section 2.5(b)–(e), Article 8,
Section 9.1, Section 11.4, Section 11.5, Section 12.4, Sections
13.1-13.3, and Article 14 of this Agreement will survive termination.

12.4        Non-exclusive Licenses after Expiration.  Upon the
expiration of the Agreement under Section 12.1, Kirin shall retain a
non-exclusive, royalty-free license to use the ACIT Technology and Licensed
Marks to make, have made, use offer for sale and sell in the Field in the Kirin
Territory the Products  that Kirin was
selling as of the date of such expiration.

12.5        Termination
by Kirin Without Cause.  On or after
January 1, 2002, Kirin may terminate this Agreement and all of its rights and obligations hereunder except as otherwise
provided herein without cause upon on hundred eighty (180) days
prior written notice to Cerus.  At such time, all licenses granted to
Kirin under this Agreement shall terminate, and Kirin shall covenant not to use
any Information or materials of any kind related to, made or derived from the
ACIT Technology or Licensed Marks after such termination.  Kirin also
shall return to Cerus all Information and materials of any kind related to,
made or derived from the ACIT Technology or Licensed Marks upon such
termination.  Kirin's licenses to Cerus under this Agreement shall survive
any such termination.

12.6        Termination by Cerus of Funding.  On or
after January 1, 2002, Cerus may
discontinue funding of Core ACIT Research and Development in its entirety or for
particular indicationson hundred
eighty (180) days prior written notice to Kirin if Cerus determines that the ACIT Technology or
such particular indications, as the case may be, are not likely to be
technically or clinically viable or financially successful in the United
States.  In the
event that Cerus ceases such funding in its entirety, Kirin may nevertheless proceed with development of
Products and will retain its license rights thereto, provided that Kirin’s obligations of milestone development payment set
forth in Section 6.1(b), (c) and (e), and research and development funding
obligation set forth in Section 4.1 and 4.2 will be terminated, except for any
research and development funding obligation incurred, but not paid, prior to
the date of termination.  In the event that Cerus discontinues funding for any indication, but
continues funding for other indications, Kirin’s obligations of milestone
development payment set forth in Section 6.1(b), (c) and (e), and the research
and development funding obligation set forth in Section 4.1 and 4.2 will be
terminated solely for such discontinued indication, except for any research and
development funding obligation incurred, but not paid, prior to the date of
termination. In the event that Kirin obtains Regulatory Approval
of a Product in the Kirin Territory for any indication as to which Cerus has
previously ceased funding of Core ACIT Research and Development, the Parties
will renegotiate the milestone development
payments  other than mentioned in the
preceding sentence and royalty obligations of Kirin with respect to
Products for such indication in light of such circumstances.

ARTICLE 13

INDEMNIFICATION AND INSURANCE

13.1        Indemnification
in Kirin Territory.  Kirin shall indemnify, defend and hold
harmless Cerus [ * ] from and
against any and all liability, damage, loss, cost (including reasonable
attorneys' fees) and expense from any infringement, claim of bodily injury or
property damage arising in the Kirin Territory to the extent (a) relating to
the development, manufacture, use, distribution or sale of any Product by
Kirin, its Affiliates, Sublicensees, employees or agents or (b) due to the
negligence or willful misconduct of Kirin or its Affiliates, Sublicensees,
employees or agents.

13.2        Indemnification
in Cerus Territory.  Cerus shall indemnify
and hold Kirin harmless from and against any and all liability, damage, loss,
cost (including reasonable attorneys' fees) and expense from any infringement,
claim of bodily injury or property damage arising in the Cerus Territory to the
extent (a) relating to the development, manufacture, use, distribution or sale
of any Product by Cerus, its Affiliates, Sublicensees, employees or agents or
(b) due to the negligence or willful misconduct of Cerus or its Affiliates,
Sublicensees, employees or agents.

13.3        Indemnification
Procedure. Each Party’s obligations under Sections 13.1
and 13.2 are conditioned on the Indemnified Party’s (a) providing written
notice to Indemnifying Party of any claim, demand or action arising out of the
indemnified activities within thirty (30) days after Indemnified Party has
knowledge of such claim, demand or action; (b) permitting Indemnifying Party to
assume full responsibility to investigate, prepare for and defend against any
such claim or demand; (c) assisting Indemnifying Party, at Indemnified Party’s
reasonable expense, in the investigation of, preparation for and defense of any
such claim or demand; and (d) not compromising or settling such claim or demand
without Indemnifying Party’s written consent, which shall not be unreasonably
withheld.

13.4        Insurance.  Kirin will
maintain product liability insurance or self-insurance covering the clinical
trials and sale of Products in the Kirin Territory in amounts customary for
medical products in the Kirin Territory. 
Kirin will provide Cerus [ * ] with a
certificate of insurance evidencing such coverage.

ARTICLE 14

MISCELLANEOUS

14.1        Assignment.  Neither Party shall
assign any of its rights and obligations hereunder except (i) as incident to
the merger, consolidation, reorganization or acquisition of stock affecting
actual voting control or transfer of substantially all of the assets of the
assigning Party or (ii) to an Affiliate; provided, however, that in no event
shall either Party's rights and obligations hereunder be assigned without prior
written notice to the other Party.  In any case, neither Party may make an
assignment of its assets which renders it unable to perform its material
obligations hereunder.  This Agreement shall be binding upon and inure to
the benefit of the Parties hereto and their permitted successors and assigns.

14.2        Retained Rights.  Nothing in this
Agreement shall limit in any respect the right of either Party to conduct
research and development with respect to, and market products outside of, the
Field using such Party's Technology, but no license to use the other Party's
technology to do so is granted herein expressly or by implication.

14.3        Force Majeure.
 Neither Party shall lose any
rights hereunder or be liable to the other Party for damages or losses on
account of failure of performance (other than the payment of monies) by the
defaulting Party if the failure is occasioned by government action, war, fire,
explosion, flood, strike, lockout, embargo, act of God, or any other similar
cause beyond the control of the defaulting Party, provided that the Party
claiming force majeure has
exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, in no
event shall a Party be required to settle any labor dispute or disturbance.

14.4        Further Actions.  Each Party agrees to
execute, acknowledge and deliver such further instruments, and to do all such
other acts, as may be necessary or appropriate in order to carry out the
purposes and intent of this Agreement.

14.5        No Trademark Rights.  Except as
otherwise provided herein, no right, express or implied, is granted by the
Agreement to use in any manner the name "Cerus" or "Kirin"
or any other trade name or trademark of the other Party in connection with the
performance of the Agreement.

14.6        Notices.  All notices and other
communications hereunder shall be in writing and shall be deemed given if
delivered personally or by facsimile transmission (receipt verified), mailed by
registered or certified mail (return receipt requested), postage prepaid, or
sent by express courier service, to the Parties at the following addresses (or
at such other address for a Party as shall be specified by like notice;
provided, that notices of a change of address shall be effective only upon
receipt thereof):

If to Cerus, addressed to:

Cerus Corporation

2411 Stanwell Drive

Concord, CA 94520

Attention: Vice President, Legal Affairs

Telephone: +1 (925)
288-6116

Telecopy:  +1 (925)
288-0194

With copy to:

Cooley Godward LLP

Five Palo Alto Square, 4th Floor

Palo Alto, CA  94306

Attention:  Bob Jones

Telephone:  +1 (650)
843-5000

Telecopy:   +1 (650)
849-7400

If to Kirin, addressed to:

Kirin Brewery Company, Limited

26-1, Jingumae 6-chome

Shibuya-ku

Tokyo 150-8011, Japan

Attention: General Manager of Licensing

Pharmaceutical
Division

Telephone:  +81 (3)
5485-6206

Telecopy:   +81 (3) 3499-6152

14.7        Dispute Resolution.  If any dispute,
controversy or claim arises out of or in connection with this Agreement, the
Parties shall use reasonable efforts to settle it by friendly negotiation
within sixty (60) days of notice from one Party to the other of such dispute,
controversy or claim, before pursuing any other remedies available to them. If
either Party fails or refuses to participate in such negotiations, or if, in
any event, the dispute, controversy or claim is not resolved to the
satisfaction of both Parties within the sixty (60) day period, any such
dispute, controversy or claim shall be settled by arbitration. Any such
arbitration shall be conducted in accordance with the Japan-American Trade
Arbitration Agreement of September 16, 1952. The Parties agree that any such
arbitration shall be conducted in the English language in a location within the
United States selected by the Party that did not initiate such arbitration, and
the Agreement shall be governed by and construed in accordance with the laws of
the State of California and the United States of America. The arbitrators shall
include one independent, un-affiliated nominee selected by each Party and a
third neutral arbitrator selected by such nominees. The Parties agree that any
arbitration panel shall include members knowledgeable as to the evaluation of
biopharmaceutical technology. Judgment upon the award rendered may be entered in the
highest state or federal court or forum, state or federal, having jurisdiction;
provided, however, that the provisions of this Section 14.7 shall not apply to
any dispute or controversy as to which any treaty or law prohibits such
arbitration. The prevailing Party shall be entitled to reasonable attorney's
fees and costs to be fixed by the arbitrators.

14.8        Waiver.  Except as specifically
provided for herein, the waiver from time to time by either of the Parties of
any of their rights or their failure to exercise any remedy shall not operate
or be construed as a continuing waiver of same or of any other of such Party's
rights or remedies provided in this Agreement.

14.9        Severability.  If any term, covenant
or condition of this Agreement or the application thereof to any Party or
circumstance shall, to any extent, be held to be invalid or unenforceable, then
the remainder of this Agreement, or the application of such term, covenant or
condition to Parties or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant
or condition of this Agreement shall be valid and be enforced to the fullest
extent permitted by law.

14.10      Ambiguities.   Ambiguities, if any,
in this Agreement shall not be construed against any Party, irrespective of
which Party may be deemed to have authored the ambiguous provision.

14.11      Entire Agreement.   This Agreement
sets forth all the covenants, promises, agreements, warranties,
representations, conditions and understandings between the Parties hereto with
regard to the subject matter discussed herein and supersedes and terminates all
prior agreements and understanding between the Parties with regard to the
subject matter discussed herein.  There are no covenants, promises,
agreements, warranties, representations, conditions or understandings, either
oral or written, between the Parties with regard to the subject matter
discussed herein other than as set forth in this Agreement; provided that the
services of manufacturing and supply of products will be set forth in a
Manufacturing Agreement to be negotiated and executed by the Parties consistent
with the Summary of Supply Terms.No subsequent alteration, amendment, change or
addition to this Agreement shall be binding upon the Parties hereto unless
reduced to writing and signed by the respective authorized officers of the
Parties.

14.12      Headings.   The Section and
Paragraph headings contained herein are for the purposes of convenience only
and are not intended to define or limit the contents of the Section or
Paragraphs to which they apply.

                IN WITNESS WHEREOF, the Parties
have executed this Agreement in duplicate originals by their proper officers as
of the date and year first above written.

CERUS CORPORATION  
                   
 KIRIN BREWERY COMPANY, LIMITED

	
  By: /s/ Stephen Israel
  	
  By /s/  Koichiro Aramaki: 
  
	 
  	 
  
	
  Printed Name:  Stephen Israel
  	
  Printed Name:   Koichiro Aramaki
  
	 
  	 
  
	
  Title:   President & CEO
  	
  Title: President, Pharm. Div.
  
	 
  	 
  

EXHIBIT A

CERUS PATENTS

 

Cerus’
initial U.S. filing was 09/119,707 (PCT/US98/15067), which was also filed in the PCT and is
now pending in Australia, Japan and China, among other countries.  Cerus filed a continuation-in-part (CIP) in
the U.S., 09/238,355, and has intentionally abandoned the initial filing in the
U.S. in favor of this CIP case.  The CIP
includes all of the [ * ], plus a [ * ]. 
Cerus did not file this CIP in the PCT, as Cerus [ * ]. 
Cerus is continuing to [ * ].

Cerus
has licensed from [ * ] U.S.
Patent [ * ] issued [ * ], which license rights include U.S.
Patent Application [ * ].  The license rights in Article 2 of the
Agreement include a sublicense of rights to foreign counterparts of this patent
and application in the Kirin Territory. 
Regarding [ * ], a patent
has been issued in [ * ].  This case is in the national phase in [ * ], among other countries.

PCT/US94/07185 for S-59 composition of matter.

EXHIBIT B

KIRIN TERRITORY

 

	
  Afghanistan
  
	
  Australia
  
	
  Bangladesh
  
	
  Brunei
  
	
  Cambodia
  
	
  Indonesia
  
	
  Japan
  
	
  Laos
  
	
  Malaysia
  
	
  Mongolia
  
	
  Myanmar
  
	
  Nepal
  
	
  New
  Zealand
  
	
  North
  Korea
  
	
  Pakistan
  
	
  Peoples
  Republic of China (including  Hong
  Kong and Macao)
  
	
  Philippines
  
	
  Singapore
  
	
  South
  Korea
  
	
  Sri
  Lanka
  
	
  Taiwan
  
	
  Thailand
  
	
  Vietnam
  
	 
  

 

EXHIBIT C

SUMMARY OF TERMS OF MANUFACTURING AND SUPPLY

 

•               Cerus
owns rights of manufacturing Compounds, Kits and Illumination Devices, and is
responsible for supplying to Kirin Compounds, Kits 
and Illumination Devices for treatment of leukocytes, in cases that
(i)  Kirin markets and sells Products to
hospitals and other similar health-care provider organizations and (ii) that
Kirin sells [ * ] pursuant to
Section [ * ].

•               The
transfer price of the Kits is [ * ]
(such [ * ] not to exceed $[ * ] per Kit) plus a Kit [ * ] (computed on a
country-by-country basis) per unit of Product to end users received by Kirin,
its Affiliates, Sublicensees, distributors and sales agents. 
The transfer price of the Illumination Devices is [ * ]% of Cerus’ [ * ].    In case that Kirin sells [ * ], the transfer price calculation
mechanism will be [ * ], as
provided in Section [ * ] of the
Collaborative License Agreement.

•               Kirin
will remit the transfer price of the Illumination Devices within thirty (30) days after invoice on shipment of the
Illumination Devices to Kirin or its Affiliate or Sublicensee. Kirin will remit
the transfer price of the Kits not later than one hundred and fifty
(150) days after
shipment of the Kits to Kirin or its Affiliate or Sublicensee.

•               The Manufacturing Agreement will provide for
rolling forecasts of Kirin's needs for Illumination Devices and Kits.

•               The
Manufacturing Agreement will not require Cerus to supply Kits to Kirin at a
loss.

•               In the event Cerus is unable to supply
Illumination Devices, Kits or Compounds to Kirin, or Cerus elects to license
Kirin to manufacture such items, Cerus
grants Kirin a license to manufacture such items, in accordance with Sections
2.1(e) and 10.2 of the Collaborative License Agreement and the compensation to
Cerus will be appropriately reduced.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]